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Abstract 
Neural crest cells are a transient population of multipotent cells which arise at the border of 
the neural and non-neural ectoderm (known as the neural plate border) during neurulation. 
These cells migrate through the embryo and differentiate into a range of cell types so diverse 
that the neural crest is sometimes termed the fourth germ layer. Neural crest cell formation 
and differentiation is driven by a cascade of transcription factor activity at the neural plate 
border in response to the combinatorial action of several major signal transduction pathways, 
including canonical Wnt signalling. Canonical Wnt signalling culminates in the conversion of 
TCF transcription factors from repressors to activators and TCF consensus DNA binding sites 
are known as Wnt responsive elements (WREs). The zinc finger of the cerebellum (ZIC) proteins 
are a family of transcriptional regulators that promote neural crest cell specification in a 
variety of vertebrate organisms. The ZIC proteins, however, are known to bind TCF proteins 
and repress Wnt mediated transcription at WREs, implying a role in preventing neural crest cell 
differentiation. The work presented in this thesis resolves the apparent paradox of ZIC 
behaviour. Cell-based reporter assays demonstrate a bi-phasic response of ZIC proteins to Wnt 
signalling. In a low Wnt environment ZIC proteins repress transcription at WREs but this 
repression is lost in a high Wnt environment. Wnt signalling promotes post-translational 
modification of ZIC proteins, via SUMOylation at the highly conserved but hitherto functionally 
uncharacterised Zinc Finger N-terminally Conserved (ZF-NC) domain. SUMOylated ZIC proteins 
exhibit decreased TCF interaction and decreased inhibition at WREs. Simultaneously, 
SUMOylated ZIC proteins exhibit increased transactivation activity of an enhancer element 
known to drive expression of the neural crest specifier gene Foxd3 in the specified trunk neural 
crest cells. These in vitro findings have a direct in vivo correlate as a mouse strain in which ZIC5 
protein is refractory to SUMOylation exhibits decreased Foxd3 expression in trunk neural crest 
and decreased numbers of differentiated neural crest cells. Canonical Wnt signalling controls 
the activation of the ZIC proteins and impacts gene expression not only at classical WREs but 
also at ZIC responsive elements. Neural crest cell specification can therefore be restricted to 
the neural plate border despite a broad neurectodermal domain of ZIC expression. High 
concentration Wnt signals at the neural plate border will simultaneously convert ZIC and TCF 
proteins into transactivators, whereas in the future lateral neurectoderm repression at WREs 
will persist. 
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Chapter 1: Introduction 
The ZIC (zinc finger of the cerebellum) gene family consists of multifunctional transcriptional 
regulators that are part of the GLI superfamily. Members of this family have been identified 
based on homology in a range of species and in all cases are critical regulators of early 
development. In mammals mutation and deletion analysis has shown that correct function of 
these genes is critical for the correct formation of the central and peripheral nervous systems, 
muscle and skeleton as well as organisation of the Left-Right body axis and neural crest 
development (Ali et al., 2012). Despite a growing list of biological processes known to require 
ZIC function (Houtmeyers et al., 2013), there is very little known regarding the molecular 
control and functional consequence of ZIC protein activity (Ali et al., 2012). 
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1.1 ZIC Structure and expression 
1.1.1 Genomic arrangement 
While ZIC genes have been identified in a range of species, they vary in number from the single 
Drosophila pair-rule gene odd-paired (opa) to the seven zic genes identified in zebrafish, with a 
family of five genes found in human, mouse and Xenopus. The evolution of these genes from a 
single member to a larger family in vertebrates likely involved an initial tandem duplication 
prior to several genomic duplications (Aruga et al., 2006). The resulting arrangement has 
largely been retained in vertebrate ZICs, as such the majority of the genes are arranged in 
divergently transcribed gene pairs. For example, in humans a ZIC gene has been lost, thus ZIC1 
and 4 exist as divergently transcribed gene pairs on chromosome 3, as do ZIC2 and 5 on 
chromosome 13, with ZIC3 on the X chromosome the only genetic singleton (Figure 1.1a). The 
same pattern is seen in mouse (Figure 1.1b) and Xenopus, with zebrafish containing an extra 
gene pair (Figure 1.1c). Several other gene families critical for early development are retained 
in such clusters (e.g. Hox, Fox and Dlx gene clusters), which is thought to allow co-ordinated 
expressed through shared regulatory regions (Hannenhalli and Kaestner, 2009; Lemons and 
McGinnis, 2006). As in each case the ZIC pairs are separated by less than 10 Kb, it is likely these 
genomic arranged pairs also share regulatory regions. 
 
1.1.2 Zic expression 
The murine Zics can be divided into two groups based on embryonic expression, as expression 
of Zic2, Zic3 and Zic5 can be detected earlier in embryogenesis than Zic1 and Zic4. Zic2, Zic3 
and Zic5 expression can be detected immediately post-implantation and is maintained through 
gastrulation [days post coitum (dpc) – 8.0 dpc], whereas Zic1 and Zic4 expression begins later 
at the somite stage of development (8.5 dpc) (Figure 1.2) (Houtmeyers et al., 2013). Zic2, Zic3 
and Zic5 show largely overlapping expression domains during early embryogenesis, with 
expression initially found in the embryonic and extraembryonic ectoderm (Elms et al., 2004; 
Furushima et al., 2000). Some Zic2, Zic3 and Zic5 transcripts can be detected in the mesoderm 
during primitive streak formation, but Zic expression is limited to the neuroectoderm by early 
headfold stage (Elms et al., 2004; Furushima et al., 2000). As neurulation progresses Zic 
expression becomes restricted to the dorsal regions that represent the future site of neural 
crest production and dorsal neural production. By the stage Zic1 and Zic4 expression is 
detected at 8.5 dpc neural crest cell migration has begun and by 9.5 dpc expression of all 
members of the Zic family overlap, with transcripts detected in the dorsal spinal cord and 
cranial neural tube (Elms et al., 2004; Furushima et al., 2000; Gaston-Massuet et al., 2005; 
Inoue et al., 2004; Nagai et al., 1997). 
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Figure 1.1: Genomic arrangement of the ZICs. Depiction of the genomic arrangement of 
human, mouse and zebrafish ZICs, as shown in the Ensembl gene browser. The ZIC genes are 
largely arranged in divergently transcribed pairs, with one singleton in each species. Adapted 
from Houtmeyers et al., 2013. 
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Figure 1.2: Zic expression subclasses. The murine Zics divided into two subclasses based on 
early embryonic expression. Zic2, Zic3 and Zic5 transcripts can be detected at 7.5 dpc in the 
ectoderm and mesoderm, whereas Zic1 and Zic4 expression can not be detected at this stage. 
Lateral view of embryos show after whole mount in situ hybridization to Zic1-5. Adapted from 
Houtmeyers et al., 2013 with in situs by Kristen Barratt. 
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The nearly identical expression of the genomic ZIC pairs at this early stage of development 
supports the idea the gene pairs share regulatory regions. It should be noted that despite the 
large overlap in expression, there are some areas of unique Zic expression at this early stage of 
development. For example, both Zic2 and Zic3 are expressed uniquely in node at different 
stages of development, with Zic2 transiently expressed at mid-gastrulation (7.25 dpc) (Elms et 
al., 2004), whereas Zic3 is detected at slightly later stage (7.75 dpc) (Sutherland et al., 2013). 
 
1.1.3 Protein domains 
The defining feature of the ZICs is a zinc finger domain (ZFD), closely related to the ZFD of the 
GLI, GLIS and NKL protein families (Figure 1.3) (Houtmeyers et al., 2013). The ZFD of these 
protein families contain five highly conserved tandem C2H2 type zinc fingers, with the ZIC 
proteins distinguished by an atypical first finger which has 6 to 38 amino acids between the 
two cysteine residues rather than the normal 2 to 4 (Aruga et al., 2006). The atypical first zinc 
finger is highly conserved between mammalian ZIC1, ZIC2 and ZIC3, but shows more 
divergence for ZIC4 and ZIC5, which allows the ZICs to be classified into two subgroups 
(Houtmeyers et al., 2013). The ZFD is thought to have several functions including interacting 
with DNA (Badis et al., 2009; Lim et al., 2010), interacting with proteins (Koyabu et al., 2001; 
Pourebrahim et al., 2011) and possibly localising ZICs to the nucleus (Bedard et al., 2007; 
Hatayama et al., 2008).  
 
Outside the ZFD, the ZICs are more varied (Figure 1.3), however two domains show some 
conservation of sequence within the family. The first is the zinc finger N-terminally conserved 
(ZF-NC) domain, a small domain (14-21 amino acids) which as the name implies is located 
immediately adjacent to the ZFD. The ZF-NC domain is highly conserved and is present in all 
vertebrate and arthropod ZICs except for zebrafish zic6 which shows only partial conservation 
(Aruga et al., 2006; Keller and Chitnis, 2007), but the function of this region is currently 
unknown. The second region is the Zic-Odd paired conserved (ZOC) domain, which is a small 
region (9-10 amino acids) only found in a subset of the ZICs. In particular, this domain is found 
in mammalian ZIC1-3 and opa, but is absent from ZIC4 and ZIC5. The ZOC domain is thought to 
be necessary for certain protein-protein interactions, and in particular allows interaction with 
MDFI (MyoD Family Inhibitor, also called I-mfa) (Mizugishi et al., 2004). Aside from these 
conserved domains, several low complexity domains, including poly-alanine, histidine, proline 
and serine/glycine tracts are found within individual ZICs (Figure 1.3). Although the function of  
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Figure 1.3: Protein domains of the ZICs. The five human ZICs are shown. All human ZICs 
contain the highly conserved ZF-NC domain followed by five tandem C2H2 zinc fingers. ZIC1, 
ZIC2 and ZIC3 also share the ZOC domain. In addition, several low complexity regions are 
present (A = alanine tract, H = histidine tract, P = proline tract and S/G = serine/glycine tract). 
Figure adapted from Houtmeyers et al., 2013. 
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these domains in the ZICs is not well characterised, there is evidence that generally the 
number of protein binding partners is higher in proteins that contain low-complexity domains 
in the terminal regions (Coletta et al., 2010), suggesting these domains confer protein binding 
capabilities.  
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1.2 ZIC Function in Development and Disease 
In all species studied members of the ZIC gene family are crucial mediators of embryonic 
development. While it is thought that some functions of the ZICs must overlap due to the 
similarities in expression patterns and protein structure, in humans germline mutations of four 
of the five ZIC genes have so far been associated with different congenital defects, indicating 
the roles are not completely redundant. These and other mammalian ZIC associations are 
discussed below: 
 
1.2.1 ZIC1 and ZIC4 
In humans, deletion of ZIC1 and ZIC4 (which can occur in a single small interstitial deletion due 
to their tandem arrangement) is associated with Dandy-Walker Malformation (DWM) 
(Grinberg et al., 2004), a common congenital cerebellar malformation. This condition is 
distinguished by the region of the cerebellum between the two hemispheres, called the 
vermis, being small and rotated away from the brainstem, as well as by an enlargement of the 
posterior fossa which is the part of the intracranial cavity which contains the brainstem and 
cerebellum (Patel and Barkovich, 2002). ZIC1 and ZIC4 were linked to this congenital defect 
through mapping of interstitial deletions in human patients (Grinberg et al., 2004). Mouse 
studies have also shown that while targeted knockout of Zic1 cause cerebellar hypoplasia as 
well as folial mispatterning (Aruga et al., 1998) and knockout of Zic4 causes posterior 
cerebellar hypoplasia (Grinberg et al., 2004), mice must be heterozygous null for both these 
genes for DWM to occur, and even then it only occurs in 15% of cases (Grinberg et al., 2004).  
 
Currently it is unclear what role ZIC1 and ZIC4 have in preventing DWM, but it seems to be 
linked to regulating the granule cell progenitor (GCP) population of the cerebellum. Postnataly, 
the GCP population in the cerebellum greatly expands before these cells eventually 
differentiate to form the granule cell neurons, which are the most abundant neuron in the 
adult brain (Roussel and Hatten, 2011). The GCP expansion is believed to be largely driven by 
Sonic Hedgehog protein (SHH) secreted from the Purkinje cells (Corrales et al., 2006). 
Previously it has been hypothesised that ZIC1 and ZIC4 prevent early differentiation of the GCP 
population (Aruga et al., 2002; Grinberg and Millen, 2005), the loss of which leads to DWM. 
This idea is supported by the finding that mouse ZIC1 represses the expression of MATH1, a 
protein which promotes neuronal differentiation (Ebert et al., 2003). However, a recent study 
found no evidence of altered GCP differentiation in Zic1/4 null mice (Blank et al., 2011). 
Instead it was found that although Shh was expressed normally, in Zic1/4 null mice 
downstream targets of the Shh pathway showed decreased expression, suggesting that in the 
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absence of Zic1/4 the signal was not correctly transduced. The lack of signal transduction in 
turn leads to reduced GCP expansion without affecting time of differentiation and ultimately 
leads to reduced cerebellum size seen in DWM. As well as this role in Shh signalling, Zic1 and 
Zic4 were also shown to have a Shh-independent role in regulating cerebellar foliation, 
possibly through patterning of the Purkinje cells (Blank et al., 2011), suggesting these proteins 
act at multiple stages of brain formation. 
 
1.2.2 ZIC2 
In humans, mutations in ZIC2 are associated with holoprosencephaly (HPE), a common 
forebrain malformation. Mutation of mouse Zic2 causes a severe form of this condition, as well 
as neural tube and neural crest defects (Elms et al., 2003; Warr et al., 2008). HPE has been 
divided into two classes: ‘classical HPE’ in which the ventral forebrain is the worst affected 
region and ‘middle interhemispheric (MIH) HPE’, which affects the dorsal forebrain (Fernandes 
and Hebert, 2008). Classical HPE phenotypes vary in severity from alobar HPE, in which the 
separation of the two cerebral hemispheres is completely lost, to lobar HPE, in which two 
distinct hemispheres are formed, but other cerebral structures, such as the corpus callosum 
and the olfactory bulbs may be missing or reduced in size (Fernandes and Hebert, 2008; 
Krauss, 2007). Craniofacial phenotypes of classical HPE also vary, from cyclopia with an 
overlying proboscis in the most severe cases to the milder cases in which the only indication of 
HPE may be a single central incisor (Schachter and Krauss, 2008; Solomon et al., 2010). MIH is 
normally considered the milder form of HPE, with failure of the posterior frontal and parietal 
lobes to divide in the dorsal region, but often normal separation of the ventral regions 
(Fernandes and Hebert, 2008). 
 
While there are at least 13 genes for which mutation of or deletion has been associated with 
human HPE (Mercier et al., 2011), ZIC2 is the only gene to be associated with both classical and 
MIH HPE (Schachter and Krauss, 2008). Classical HPE is most commonly associated with 
defects in the Shh signalling pathway which promotes formation of the ventral regions, 
whereas mouse models suggest MIH HPE is caused by defects in the Bone Morphogenetic 
Protein (BMP) signalling pathway which promotes formation of the dorsal regions (Fernandes 
et al., 2007). Shh and BMP signalling are considered to have opposing roles in neural axis 
development (Fernandes and Hebert, 2008), raising the question: why would ZIC2 positively 
influence both a ventral and a dorsal promoting pathway? The current theory is that ZIC2 
mutations do not directly disrupt either of these pathways, but instead the HPE defects are a 
consequence of the loss of signalling structures within the embryo. Studies in the mouse show 
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that severe loss of Zic2 function results in the defects in the formation of the prechordal plate, 
from which the Shh signal is normally produced, suggesting that classical HPE is caused by the 
loss of this structure (Warr et al., 2008). On the other hand MIH HPE triggered by partial loss of 
ZIC2 is suggested to be caused by the loss of the roof-plate induction, from which BMP signal is 
normally produced (Cheng et al., 2006). Which of these conditions arises could be influenced 
by what other mutations are present within these pathways or may depend on which region of 
ZIC2 is mutated. 
 
1.2.3 ZIC3 
ZIC3 was the first gene in humans for which deletion or mutation was associated with 
heterotaxy (Gebbia et al., 1997; Ware et al., 2004), a condition in which the internal organs are 
distributed randomly with respect to the Left-Right axis but varies in severity and in milder 
cases is thought to include heart defects, such as defects in heart looping. Heterotaxy and 
heart defects are also seen in Zic3 null mice, as well as neural tube and skeletal defects 
(Purandare et al., 2002). It is thought that ZIC3 loss of function associated heterotaxy is due to 
problems with initial establishment of the Left-Right axis during gastrulation.  
 
Normally, the Left-Right axis is established via the action of the node cilia, which cause 
redistribution of the Transforming Growth Factor (TGF)-β-related ligand NODAL to the left side 
of the embryo. In Zic3 null mice, Nodal shows a random expression pattern with respect to the 
Left-Right axis (Purandare et al., 2002). Initially the random expression of Nodal postulated to 
be due to a Nodal enhancer known to be up-regulated in the presence of ZIC3 (Ware et al., 
2006a). More recently Cre recombinase based knockout of murine Zic3 has demonstrated that 
ZIC3 function is required before Nodal asymmetry. Specifically, comparison of node 
morphology using scanning electron microscopy indicated nodes of ZIC3 mutant mice were 
abnormal, with the cells showing smaller apical surfaces and shorter cilia than found in 
wildtype nodes (Sutherland et al., 2013). Such defects may prevent redistribution of NODAL 
and thus result in heterotaxy.  
 
In the mouse the role of Zic3 is not limited to establishing the Left-Right axis in early 
development. For example Zic3 was recently implicated in regulation of Gli3 in mouse 
developing limb buds, as loss of Zic3 gene rescues preaxial polydactyly caused by GLI3 
haploinsufficiency (Quinn et al., 2012). Another noteworthy role of ZIC3 is promoting 
maintenance of pluripotency in stem cells. The three genes OCT4, NANOG and SOX2 are 
known to be crucial transcriptional regulators for maintaining self-renewal and pluripotency in 
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embryonic stem cells (ESCs) (Chambers, 2004). These genes are all expressed in ESCs, but are 
quickly repressed when ESCs differentiate, a pattern which ZIC3 follows, suggesting a link 
between ZIC3 and the maintenance of pluripotency by OCT4, NANOG and SOX2 (Lim et al., 
2007). Furthermore, co-transfection of ZIC3 with the three pluripotency regulators OCT4, SOX2 
and KLF4 increases efficiency of reprogramming human fibroblast cells to form 
neuroprogenitor cells (Kumar et al., 2012) and murine MEFs to form iPS cells (Declercq et al., 
2013) compared to OCT4, SOX2 and KLF4 alone, suggesting ZIC3 enhances such 
reprogramming and therefore pluripotency. Given OCT4, NANOG and SOX2 have all been 
mapped to bind the promoter of ZIC3 in ESCs and that RNAi knockdown of ZIC3 in ESCs leads to 
loss of pluripotency, it has been suggested that ZIC3 is a downstream effecter of these 
pluripotency regulators (Lim et al., 2007). However recently ZIC3 has been shown to bind and 
activate the Nanog promoter, indicating a more complex relationship potentially including a 
regulatory loop (Lim et al., 2010). 
 
1.2.4 ZIC5 and overlapping roles of the ZIC family 
No strong links have been found between loss of the remaining ZIC gene, ZIC5, and congenital 
defects in humans, although a very small number of patients with DWM have been shown to 
have an interstitial deletion of both ZIC2 and ZIC5 (Ballarati et al., 2007). As the number of 
individuals with DWM that also develop hydrocephaly, a phenotype observed in ZIC5 null mice 
(Furushima et al., 2005; Inoue et al., 2004), has been estimated to be as high as 80%, it is 
possible there is a link between the mouse and human phenotypes.  
 
Lack of a definitive human phenotype should not be taken as a sign of a lack of importance for 
this gene during early development. In fact, studies of Zic5 knockout mouse lines are 
producing a growing list of conditions caused by loss of Zic5 function, the majority of which are 
shared with other members of the ZIC family. For example, neural crest defects are seen with 
loss of either Zic2 or Zic5 (Elms et al., 2003; Furushima et al., 2005; Inoue et al., 2004), neural 
tube defects such as exencephaly and spina bifida can be caused by loss of Zic2, Zic3 or Zic5 
(Elms et al., 2003; Inoue et al., 2004; Nagai et al., 2000; Purandare et al., 2002) and various 
skeletal defects have been associated with the individual loss of every mouse Zic gene except 
Zic4 (Aruga et al., 1999; Inoue et al., 2004; Nagai et al., 2000; Purandare et al., 2002). 
 
These shared phenotypes are a good illustration of the overlapping roles of the ZICs in early 
development. In fact, due to the close expression patterns (see Section 1.1.2), overlapping 
loss-of-function phenotypes and high levels of conservation within the family it has been 
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suggested that there are high levels of partial or full functional redundancy within the ZIC 
family (Houtmeyers et al., 2013). In such a model, whether the ZICs loss-of-function 
phenotypes are unique or conserved is at least partially dependent on the ZIC expression 
patterns. For example, Zic2, Zic3 and Zic5 are expressed in overlapping expression patterns 
during gastrulation (see Section 1.1.2). As the expression patterns of these three genes at this 
stage overlap in the dorsal ectoderm that is the site of the future neural tube, all are 
associated with defects in neural tube closure or neural crest development. However, there is 
also some variation in the expression patterns between family members at this developmental 
stage. In particular, Zic2 is the only member of the family expressed in the node at a particular 
stage of gastrulation and it is the loss of this area of unique expression that is thought to result 
in HPE in Zic2 mutants (Houtmeyers et al., 2013; Warr et al., 2008).  
 
1.2.5 The role of ZICs in neural crest specification 
Neural crest cells are a transient population of multipotent cells that arise at the boundary of 
the neural plate (which goes on to form the central nervous system) and non-neural ectoderm 
(which goes on to form the epidermis) during neural tube closure at a region termed the 
neural plate border (Figure 1.4a). These cells undergo an epithelial-to-mesenchymal transition 
and migrate through the developing embryo (Figure 1.4b-d), forming an amazing variety of cell 
types including neurons and glia of the peripheral nervous system, melanocytes, Schwann 
cells, cardiac cells and cells of the craniofacial skeleton (Stuhlmiller and García-Castro, 2012). 
Mis-regulation of the neural crest cell formation results in a diverse range of congenital defects 
collectively termed neurocristopathy (Bolande, 1997). The neural crest is also of particular 
interest as it can be used to model a range of critical developmental events including 
induction, pluripotency, cell fate restrictions, migration and differentiation (Stuhlmiller and 
García-Castro, 2012). In particular, the epithelial-to-mesenchymal transition and migration 
seen in neural crest is reminiscent of cancer metastasis (Maguire et al., 2015; Powell et al., 
2013). 
 
In non-mammalian species the formation of the neural crest cells is a multistep process 
beginning during gastrulation (Basch et al., 2006; Simões-Costa and Bronner, 2015). First, 
several of the major signalling pathways, including the BMP, Fibroblast Growth Factor (FGF) 
and Wnt signalling pathways, act together to induce expression of several genes at the border 
between the neural plate and non-neural ectoderm including Zic1, Msx1/2 and Pax3/7 (Hong 
and Saint-Jeannet, 2007; Monsoro-Burq et al., 2005; Sato et al., 2005). These genes are  
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Figure 1.4: Neural crest formation. (a-d) Diagrammatic cross sections through the mouse 
embryo during neurulation when the neural crest forms. a) During gastrulation a region 
between the neural ectoderm and the non-neural ectoderm is specified as neural plate border. 
b) As neural folds elevate the cells at the neural plate border are specified as neural crest cells. 
c) These cells acquire migratory properties and delaminate from the neural tube. d) By the 
time the neural tube is formed neural crest cell emigration is complete and the crest cells are 
migrating on either a dorsolateral pathway beneath the ectoderm or a ventrolateral pathway 
between the somites. e) Timeline for neural crest formation in mice. NPB: onset of neural plate 
border gene expression, NCS: onset of neural crest specifier expression, mig: migration of 
neural crest begins. Initiation of Zic1 and Zic4 expression is also shown. Panel (e) was adapted 
from Stuhlmiller and García-Castro, 2012.  
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collectively termed the ‘neural plate border genes’, though it should be noted that the 
expression of individual neural plate border genes often extends beyond this region (Groves 
and LaBonne, 2014). The neural plate border genes act in concert with the major signalling 
pathways to trigger expression of a second set of genes, termed the ‘neural crest specifiers’, 
which include Snail, AP2, Sox9 and Foxd3 (Betancur et al., 2010; Sauka-Spengler and Bronner-
Fraser, 2008). These genes are the first markers of neural crest cell fate and are believed to 
ultimately control neural crest cell formation and behaviour through regulating expression of 
neural crest effector genes (Milet and Monsoro-Burq, 2012; Stuhlmiller and García-Castro, 
2012). 
 
It is unclear whether the same gene regulatory network of proteins regulates mammalian 
neural crest. The conundrum in understanding mammalian neural crest specification and 
formation is that knockout of the genes known to be critical for these processes in other 
species do not cause the same phenotype in mammalian systems. The disparity between 
species is found at all levels of neural crest specification/formation including for inductive 
factors such as Wnt1, Wnt3a and Fgf8, neural plate border genes such as Zic1 and Pax3/7 and 
neural crest specifiers such as Foxd3 (Barriga et al., 2015). There have been several 
explanations proposed to explain the lack of phenotype conservation. The first is that different 
genes undertake these functions in mammals however this seems unlikely given the strong 
level of conservation in other species. The second is that there are timing issues with some of 
the tools used to study neural crest development. Many studies rely on conditional knockout 
using Cre enzyme recombination based technology to study the effect of loss of genes in a 
spatial-temporal manner. The CRE mouse line most widely used for these studies is Wnt1-Cre 
(Luo et al., 2006; Mead and Yutzey, 2012; Mori-Akiyama et al., 2003; Pryor et al., 2014; Teng et 
al., 2008) however this system has several potential flaws. In particular, as Wnt1 expression in 
other species begins after the initial induction of neural crest (Basch et al., 2006) and thus may 
not be particularly informative for the earliest stages of neural crest formation. One recent 
mouse study has made a significant advance in this regard; the study utilised Ap2a-Cre 
deletion of Tcf7l1 and showed that Wnt signalling is sufficient for mouse neural crest cell 
formation (Masek et al., 2016). Two factors enabled this conclusion: (i) the use of Ap2a-Cre, 
which is expressed earlier than Wnt1 and is specific for neural crest cell progenitors and (ii) it 
focused on a non-redundant pathway component, circumventing issues of whether the correct 
family member was investigated. 
 
The third possibility is that gene duplication has resulted in either redundancy in gene function 
or for different genes of the same family to undertake these roles in mammals. For example, in 
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several species, including Xenopus and chick, one member of the ZIC family, Zic1, is known to 
be a neural plate border gene. In Xenopus, Zic1 is believed to be of critical importance for 
formation of the neural crest, as co-expression of Zic1 with Pax3, another neural plate border 
gene, is sufficient to activate expression of neural crest specifiers including Snail and Foxd3 
(Milet et al., 2013; Plouhinec et al., 2014; Sato et al., 2005) and to cause an epithelial-to-
mesenchymal transition in Xenopus ectoderm explants (Milet et al., 2013). In chick, expression 
of Zic1 has been found to be critical for activation of an enhancer of the neural crest specifier 
gene Foxd3 (Simões-Costa et al., 2012). However, in mice Zic1 expression is not detected until 
after neural crest has been specified and migration has begun (Figure 1.4e) (Elms et al., 2004), 
thus this gene is unable to regulate initial neural crest development. Other members of the Zic 
family (Zic2, Zic3 and Zic5) are expressed at this early stage, and loss of either ZIC2 or ZIC5 
protein function results in depletion of neural crest (Elms et al., 2003; Inoue et al., 2004), 
suggesting these genes undertake the neural plate border gene role in mammalian species. 
Although not yet determined, it will be interesting to see if loss of multiple mammalian Zics at 
this stage further exacerbates the depletion of neural crest.  
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1.3 ZIC Function 
The unique and common phenotypes caused by loss of ZIC function discussed in the previous 
section give an insight into the critical role of ZIC during embryogenesis. In fact the phenotypes 
discussed represent only a subset of the abnormalities resulting from loss of ZIC function (for a 
more comprehensive list see Houtmeyers et al., 2013). One of the reasons that loss of ZIC 
function is associated with such a wide variety of phenotypes is that the ZIC family is thought 
to either regulate or act as down-stream mediators for several of the major signalling 
pathways. For example, the previous section mentioned that ZIC2 influences the formation of 
the prechordal plate, and thus is necessary for the correct stimulation of the Shh signalling 
pathway. However, the ZICs are also thought to have a direct role in this pathway, as they have 
been shown to interact with and influence members of the Gli family (Koyabu et al., 2001; 
Quinn et al., 2012), which are downstream mediators of the Shh signalling pathway 
(Villavicencio et al., 2000). Evidence is also emerging that the ZIC proteins directly influence 
transcription at Wnt responsive elements (WREs) (Fujimi et al., 2012; Pourebrahim et al., 2011) 
and Nodal responsive elements (NREs; Arkell and Tejpar, unpublished observation). 
 
1.3.1 Wnt signalling 
Wnt signalling refers to several pathways activated by secreted Wnt ligands. The best studied 
of these, and most relevant for ZIC function, is the canonical or Wnt/β-catenin signalling 
pathway. Correct regulation of Wnt/β-catenin signalling levels has long been considered 
critical for early embryogenesis, due to the dramatic double-head phenotype produced by 
ectopic activation of this pathway in Xenopus embryos (Funayama et al., 1995). Control of 
Wnt/β-catenin signalling activity is equally important during mammalian development, as 
indicated by the dramatic phenotypes caused by aberrant Wnt signalling in mice, such as the 
loss of all caudal structures below the forelimbs in embryos lacking the Wnt ligand WNT3A 
(Takada et al., 1994), or the loss of head structures in embryos lacking the Wnt repressor DKK1 
(Dickkopf) (Mukhopadhyay et al., 2001). Together these phenotypes indicate an important role 
for Wnt signalling in setting up the anterior-posterior axis in early embryos. In fact, by altering 
the activity of the Wnt/β-catenin signalling using conditional loss-of-function and gain-of-
function β-CATENIN mice, incorrect Wnt signalling has been shown to cause a myriad of issues 
during development and into adulthood, including defects in the development of the somites 
and limb buds early in development, as well as later issues in the development of the skin, 
teeth, bone, central nervous system and almost every organ (reviewed in Grigoryan et al., 
2008). In particular, gain of Wnt activity during early embryogenesis results in posterior axis 
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duplication and anterior truncations in mice (Fossat et al., 2011; Popperl et al., 1997; Zeng et 
al., 1997). 
 
The overall effect of Wnt signalling pathway activation is varied and tissue specific, but has 
been shown to both positively and negatively regulate cell proliferation, migration, fate 
specification, differentiation and apoptosis depending on context (Archbold et al., 2012; 
Grigoryan et al., 2008; Serio, 2014). A good illustration of this tissue specific nature of Wnt/β-
catenin signalling is in the regulation of pluripotency and self-renewal. Activation of Wnt/β-
catenin signalling has long been thought to promote pluripotency and self-renewal, 
particularly in stem cells (Nusse et al., 2008). In fact, the formation of some cancers is thought 
to result from up-regulation of Wnt/β-catenin signalling driving uncontrolled cell renewal 
(Holland et al., 2013). However, some recent reports have found up-regulation of Wnt 
signalling promotes differentiation, not self-renewal of particular stem cell lines (Davidson et 
al., 2012; Lian et al., 2012). The choice between self-renewal and differentiation is therefore 
cell line specific and has been suggested to be influenced by the other major signalling 
pathways (Holland et al., 2013) or could reflect multiple roles for Wnt in this process (Merrill et 
al., 2001). 
 
1.3.1.1 Wnt signalling components and mechanisms 
The canonical Wnt/β-catenin pathway performs these important regulatory roles by 
controlling the amount of β-CATENIN reaching the nucleus. Regardless of the state of the 
Wnt/β-catenin signalling pathway, β-CATENIN protein is constantly produced by cells. When 
the Wnt/β-catenin pathway is in the low Wnt state (Figure 1.5a), the amount of β-CATENIN is 
strongly depleted by activity of the β-CATENIN cytoplasmic degradation complex, consisting of 
the scaffolding proteins AXIN and adenomatous polyposis coli (APC). AXIN and APC promote 
phosphorylation of β-CATENIN through the action of casein kinase 1 (CK1) and glycogen 
synthase kinase 3 (GSK3), which targets β-CATENIN for ubiquitin dependent degradation via 
the ubiquitin ligase β-TrCP (Cadigan and Peifer, 2009; MacDonald et al., 2009). It is important 
to note that cytoplasmic β-CATENIN is never completely depleted, as the protein also has an 
important role in cadherin based cell-cell adhesion and as such the total loss of β-CATENIN 
would cause adhesion defects resulting in embryonic disintegration (Hierholzer and Kemler, 
2010). However, the consistent degradation of cytoplasmic β-CATENIN not involved in the 
cadherin based cell-cell adhesion prevents β-CATENIN from entering the nucleus. 
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Figure 1.5: The canonical Wnt signalling pathway. In both the low and high Wnt states, β-
CATENIN protein is continually produced. a) When cells are in the Low Wnt state, β-CATENIN 
protein is continually produced, but is bound by the β-CATENIN degradation complex which 
includes AXIN and APC. The complex is recognised by CKIα and GSK3 resulting in 
phosphorylation of β-CATENIN, leading to recognition by TrCP and degradation of β-CATENIN. 
As such, β-CATENIN does not enter the nucleus and transcription at WREs is repressed by 
TCF/TLE repression complexes. b) When the canonical Wnt signalling pathway is in the high 
Wnt state, Wnt ligands are recognised by the extracellular regions of the low density 
lipoprotein (LDL) receptor-related protein 5 or 6 (LRP5/6) and (Frizzled) Fz receptors, which 
results in phosphorylation of the intracellular segment of LRP and inhibition of the β-CATENIN 
degradation complex in a Disheveled (Dvl) dependent manner. As such the levels of 
cytoplasmic β-CATENIN increase and β-CATENIN enters the nucleus where it binds TCF to act 
as a co-activator. Excretion of Wnt ligand through Golgi after modification by Porcn is also 
shown. Adapted from (Arkell et al., 2013).  
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The Wnt/β-catenin pathway is switched into the high Wnt state by the extracellular presence 
of one of at least 19 secreted Wnt ligands (Figure 1.5b) (Kikuchi et al., 2011). It should be 
noted that certain secreted Wnt proteins, such as Wnt5a and Wnt11, switch on the other β-
CATENIN-independent Wnt pathways (such as planar cell polarity and Ca2+) (Kikuchi et al., 
2012) which will not be discussed here. When the extracellular Wnt protein comes in to 
contact with Frizzled (FZ) receptor and the LRP5/6 co-receptor on the surface of cells, a 
Wnt/FZ/LRP receptor complex is formed, resulting in phosphorylation of the intracellular 
portion of LRP5/6 and inhibition of the β-CATENIN degradation complex in a Dvl dependent 
manner (Cadigan and Peifer, 2009; Kim et al., 2013; MacDonald et al., 2009). As such, β-
CATENIN accumulates and moves into the nucleus. 
 
Once in the nucleus β-CATENIN activates transcription of Wnt target genes, without contacting 
DNA, through interaction with the T-Cell Factor (TCF)/ Lymphoid Enhancer-binding Factor 1 
(LEF1) family of transcription factors. In the absence of β-CATENIN the TCF/LEF1 transcription 
factors inhibit transcription of Wnt targets through interaction with the TLE/GROUCHO family 
of co-repressors, possibly involving recruitment of a histone deacetylase (HDAC) (Cadigan and 
Peifer, 2009). The nuclear accumulation of β-CATENIN results in the displacement of 
TLE/GROUCHO and the recruitment of β-CATENIN along with additional co-activators, such as 
BCL9 (B-cell CLL/lymphoma 9), the histone acetyltransferases CBP (CREB binding protein) and 
p300, to interact with TCF/LEF1, resulting in activation of Wnt target genes (Mosimann et al., 
2009). 
 
1.3.1.2 Negative regulation 
Due to the plethora of defects/issues that can be caused by increased or ectopic expression of 
Wnt/β-catenin signalling this pathway must be tightly controlled. In fact, loss of murine TCF7L1 
function results in an increase in Wnt/β-catenin signalling at gastrulation, indicating that in 
some contexts the main function of the TCF/LEF is to repress target Wnt genes (Merrill et al., 
2004). As such there are many different levels at which Wnt/β-catenin signalling can be 
inhibited. For example, at the extracellular level secreted proteins WIF (Wnt Inhibitory Factor) 
and SFRP (secreted frizzled-related protein) contain regions mimicking Wnt receptors and can 
therefore bind and modulate the activity/stability of the Wnt ligands (Bovolenta et al., 2008). 
Other secreted proteins such as WISE and DKK inhibit Wnt/β-catenin signalling by interacting 
with the LRP5/6 receptor and thereby disrupting formation of the Wnt/Fz/LRP receptor 
complex (Itasaki, 2003; Semënov et al., 2001). Wnt/β-catenin signalling antagonists have also 
been identified at the nuclear level. These proteins, which include CHIBBY and ICAT (Inhibitor 
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of β-CATENIN and TCF4), negatively regulate Wnt/β-catenin signalling in two ways: by 
disrupting the interaction of β-CATENIN with TCF and by promoting export of β-CATENIN from 
the nucleus (MacDonald et al., 2009). Although β-CATENIN degradation usually occurs in the 
cytoplasm, it has also been suggested that SOX9 and OCT3/4 can down-regulate Wnt/β-
catenin signalling levels by causing β-CATENIN nuclear degradation (Abu-Remaileh et al., 2010; 
Topol et al., 2009). 
 
1.3.1.3 ZIC based inhibition of Wnt/β-catenin signalling 
The Wnt pathway and the ZICs also show similar loss-of-function phenotypes, as posterior axis 
duplications have been observed in Zic3 null mouse embryos (Ware et al., 2006b), a phenotype 
which has previously been associated with increased/ectopic Wnt signalling (Popperl et al., 
1997; Zeng et al., 1997). The tail kink phenotype seen in adult Zic3 katun (Ka) heterozygous 
mice (Ahmed et al., 2013; Bogani et al., 2004) also phenocopies the tail kink seen in mice 
heterozygous for the gain of Wnt function Lrp6 allele gwazi (Bogani et al., 2004; Fossat et al., 
2011). Further evidence for a link between the ZICs and the canonical Wnt pathway came from 
the discovery of ZIC1 and β-CATENIN co-expression in tissue samples of patients with 
Dupuytren disease (Degreef et al., 2009). Recently two papers have independently confirmed 
that the ZICs can inhibit Wnt signalling using fish embryos, frog embryos and cell line based 
assays (Fujimi et al., 2012; Pourebrahim et al., 2011). Of particular importance, Pourebrahim et 
al. demonstrated that this repression occurs through interaction of ZIC2 with TCFs rather than 
direct DNA contact and therefore represents a co-factor role, raising the possibility that the 
ZICs are multifunctional proteins. 
 
1.3.2 Evidence of ZIC multifunction 
It was originally postulated that the ZIC proteins were transcription factors based on 
observations made from the Drosophila homologue odd-paired (opa). As the knockout 
phenotype indicated opa was a pair-rule gene (Benedyk et al., 1994), almost all of which are 
transcription factors, and opa contains five C2H2 zinc fingers (Cimbora and Sakonju, 1995), 
which are domains previously implicated in DNA-binding, it was initially assumed opa and thus 
the ZICs functioned as transcription factors. However there were inconsistencies with both 
these observations. While opa is phenotypically classed as a pair-rule gene, the other 
Drosophila pair-rule genes are expressed only in every second segment of the embryo, 
whereas opa is expressed throughout the middle 80% of the embryo (Benedyk et al., 1994), 
suggesting that opa only functions in the presence of particular other proteins, indicative of a 
role as a co-activator. Also, although C2H2 zinc fingers were originally associated with DNA 
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binding, more recently it has been found that in multi-finger proteins usually only a subset of 
the zinc fingers are involved in DNA binding, with the others involved in other interactions 
including protein-protein interactions (Brayer and Segal, 2008). In fact the ZICs were some of 
the first proteins shown to contain bi-functional C2H2 ZFD that could interact with both 
proteins and DNA (Merzdorf, 2007). The same functional conundrum appears in the 
mammalian ZIC family, but it is now believed that the ZICs can perform both the transcription 
factor and co-activator role. 
 
Evidence that the DNA-binding based transactivation ability of ZIC is critical for their function is 
strong, as a mutation has been shown to prevent the DNA binding of ZIC2 (ZIC2-C370S) (Brown 
et al., 2005), while not altering ZIC2 Wnt inhibition (Pourebrahim et al., 2011). Moreover, the 
equivalent mutation present in the Zic2 mouse point mutant Kumba (Ku) results in a severe 
HPE phenotype in Zic2Ku/Ku mice (Elms et al., 2003; Warr et al., 2008), suggesting the phenotype 
is caused by loss of transcription factor activity or by some other non-Wnt inhibition role. 
Confirmation of the importance of ZIC DNA-binding came with identification of a DNA motif 
bound by the ZIC3 ZFD using Universal protein binding microarray (Badis et al., 2009), which 
was also shown to be a true ZIC in vivo target by genome-wide chromatin immunoprecipitation 
experiments in mouse ESCs (Lim et al., 2010). The co-factor ability of the ZICs is equally 
important. Aside from the Wnt inhibition co-factor ability already discussed, the ZIC influence 
on the Shh signalling pathway is thought to rely on the ZICs hetero-dimerising with the GLI 
proteins and therefore represents a co-factor role (Koyabu et al., 2001; Zhu et al., 2008). 
Identification of regions required for each of these roles requires further fine scale mapping. 
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1.4 ZIC5-K393R: a ZIC5 Hypomorphic Allele 
Much of our understanding of mammalian ZIC function has come from mouse loss of function 
studies. While these models are of great use, it is critical to take into account the unusual pair-
wise arrangement of the ZIC genes when designing strategies to study Zic gene function via 
such in vivo manipulations. In particular, two issues arise when creating null or hypomorphic 
alleles through gene targeting via homologous recombination. First, the closely linked and 
highly conserved sequences present due to the pairwise arrangement of the ZICs can confound 
homologous recombination. For example a previous attempt to target ZIC2 via homologous 
recombination failed to create a complete null allele due to this issue (Nagai et al., 2000). 
During the mutation process, one of the recombination events took place in an unintended 
region of Zic2, thus instead of replacing the first exon of Zic2 the targeting vector was inserted 
backwards in an intron of Zic2 to create Zic2tm1Jaru. Although the mis-targeting of the 
mutational vector resulted in a failure to create the desired null, the insertion of the antisense 
selectable Neo marker into introns is known to cause splicing defects in other genes (Boison 
and Stoffel, 1994) due to the presence of cryptic splice slice (Carmeliet et al., 1996; Nagy et al., 
1998) which ultimately reduces transcript levels. The Zic2tm1Jaru line shows such a reduction in 
transcript levels and thus acts as a hypomorphic allele (Nagai et al., 2000), suggesting such 
splicing defects occur. The difficulty of targeting this region is reflected in the paucity of 
homologous recombination alleles.  
 
The second issue is that targeting vectors usually remove or otherwise alter non-coding 
regions of the targeted genes. As the point of such gene targeting is to disrupt gene function 
this is not normally a problem, but in the case of closely linked genes such non-coding regions 
can contain shared regulatory regions such as promoters, enhancers, insulators or non-coding 
RNA sequences which effect both the target and the adjacent gene. For example, in the 
process of creating Zic5tm1Jaru part of the 5’ UTR and intron were deleted (Inoue et al., 2004) 
which could contain shared regulatory regions for both Zic2 and Zic5. Even the Zictm1Sia opr 
allele in which the non-coding regions are not directly altered as the targeting vector was 
inserted into the CDS (Furushima et al., 2005) has had the spacing between non-coding regions 
changed which can alter regulation by these regions. For both alleles it is possible that any 
phenotypes seen may be caused by the mis-regulation of Zic2, in combination with the loss of 
Zic5. Such issues can be avoided by using point mutations for investigating ZIC function. 
 
Using point mutations to analyse protein function also enables fine mapping of protein 
function not possible with total loss of gene expression/function (Nguyen et al., 2011; Oliver 
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and Davies, 2012). For example, the Zic2Ku/Ku mice not only demonstrates the importance of 
correct ZIC2 function in preventing HPE and promoting neural crest formation, but as it 
represents a single amino acid change in the fourth zinc finger, it also emphasises the 
importance of the ZFD for these functions (Elms et al., 2003; Warr et al., 2008). As previously 
mentioned, further experiments have indicated that the Zic2Ku/Ku mutation prevents ZIC2 from 
binding DNA (Brown et al., 2005), but does not alter the ability of ZIC2 to act as a co-factor 
(Pourebrahim et al., 2011), suggesting that the Zic2Ku/Ku phenotypes, including HPE and neural 
crest defects, are due to the loss of ZIC transactivation rather than co-factor ability. Neither of 
these observations would be possible with total-loss of function alleles. 
 
1.4.1 The Zic5-K363R mouse model 
While loss-of-function point mutation alleles have been identified for two of the Zic genes 
expressed at gastrulation via phenotype driven screens (Ahmed et al., 2013; Bogani et al., 
2004; Elms et al., 2003; Nolan et al., 2000), none had been found for the remaining Zic 
expressed at this stage, Zic5. In order to identify such a point mutation, a gene driven screen 
was carried out on the ethylnitrosourea (ENU) mutagenesis DNA archive generated by the 
Mammalian Genetics Unit at Harwell in the UK (Figure 1.6) (Coghill et al., 2002). These archives 
were generated by treating male mice (of the BALB/c inbred strain) with ENU. The treatment 
introduces single base mutations into DNA of all cells including spermatagonial germ cells, 
which are thus heritable. Once treated with ENU the males were crossed with females of the 
C3H/HeH strain and the resulting F1 male progeny used to generate parallel sperm and DNA 
archives. For the gene driven screen 5000 samples from the DNA archives were scanned for 
mutations in the ZF-NC domain and ZFD of Zic5, resulting in the detection of mutations in five 
of these samples. One mutation identified was an adenine to guanine alteration that resulted 
in the lysine at amino acid 363 being substituted with an arginine (K363R mutation). 
 
The Zic5-K363R mutant line was recovered from the sperm archive using in vitro fertilisation of 
C3H/HeH eggs. As ENU is a very efficient mutagen the Zic5-K363R mice were backcrossed onto 
an inbred strain for several generations to segregate unlinked mutations. At the same time a 
previously generated targeted null allele of Zic5 (Furushima et al., 2005) was imported and 
backcrossed onto the same strain for comparison. Analysis showed mice heterozygous for 
either the Zic5-K363R point mutation or the Zic5 null allele showed white ventral spots (Table 
1.1, Figure 1.7a; unpublished observation, R. Arkell and R. Ali), with the rate of ventral spots 
higher in the Zic5 null heterozygotes. Such spots occur due to a reduction in melanocyte  
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Figure 1.6: Gene driven ENU mutagenesis screen. The BALB/C ENU treated males were 
crossed to females from the C3H/HeH strain and male progeny of this cross were used to 
generate parallel sperm and DNA archives. The DNAs were screened for mutations in the gene 
of interest. If mutations are identified, the corresponding sperm sample is used to recover the 
strain.   
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Figure 1.7: Zic5 mutant phenotypes. a) Ventral white belly spot. b) Hydrocephaly. 
 
 
 
Genotype Number of mice  
Zic5K363R/+ 2/73 (3%) 
Zic5+/- 16/123 (13%) 
Zic5K363R/- 6/21 (29%) 
Table 1.1: Frequency of ventral white belly spots in Zic5 heterozygous mutant mice.  
 
 
Genotype Number of mice  
Zic5K363R/+ 0/43 (0%) 
Zic5+/- 3/54 (5%) 
Zic5K363R/- 3/31 (10%) 
Table 1.2: Frequency of hydrocephaly in Zic5 heterozygous mutant mice. 
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number, which are one of the many cell types that differentiate from the multipotent neural 
crest; thus the ventral spots are indicative of a defect in the formation, migration and 
differentiation of neural crest (Kelsh et al., 2009). In addition, while the Zic5-K363R 
heterozygous mice did not show a second phenotype of hydrocephaly observed in the Zic5 null 
heterozygous, placing the two alleles in trans increased the rate this phenotype appeared 
(Table 1.2, Figure 1.7b; unpublished observation, R. Arkell and R. Ali). Together these 
observations indicate the Zic5-K363R point mutation produces a hypomorphic allele, rather 
than a complete loss of function. Further work using cell based assays to measure the ability of 
ZIC5 to activate transcription confirmed this finding (Figure 1.8, unpublished observation by H. 
Bellchambers prior to PhD). 
 
1.4.2 Why does a conservative mutation alter protein function? 
It may be expected that the K363R point mutation would not alter the function of ZIC5, as 
lysine and arginine are similar in size and charge and therefore the mutation represents a 
conservative substitution. However, the findings of a Zic5-K363R phenotype as well as the 
results of the cell based experiments clearly demonstrate a lysine is needed at that position for 
proper ZIC function. In addition, the lysine lies within the ZF-NC domain, which is almost 
perfectly conserved within a range of species (Figure 1.9) suggesting a critical role for the 
region. One explanation for the apparent importance of the lysine and surrounding amino 
acids would be if the lysine was undergoing a post-translational modification. Lysine residues 
are known to undergo a variety of modifications, including phosphorylation, SUMOylation, 
methylation, ubiquitination, acetylation and succinylation. It is therefore possible that the 
arginine substitution prevents one, or more, of these modifications and consequently 
interferes with ZIC5 function. Examination of the ZF-NC shows that the lysine of interest lies 
within a consensus SUMOylation site which, due to the conservation of the ZF-NC region, is 
found in all vertebrate ZICs. Thus the hypothesis underlying my project is that this lysine is 
SUMOylated, and that this post-translational modification is essential for the function of both 
ZIC5 and the other mammalian ZIC proteins. 
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Figure 1.8: The K393R mutation reduces the ability of the ZIC5 protein to activate the ApoE 
promoter. Human Embryonic Kidney (HEK) 293T cells were transfected with the ApoE-
luciferase construct and either V5-ZIC5-WT (wildtype), V5-ZIC5-K393R or the myc-His A empty 
vector (as a negative control). Mean activation level for each protein was calculated using log 
values.  The V5-ZIC5-K393R shows significantly lower levels of ApoE activation compared to V5-
ZIC5-WT. Error bars = Least Significant Difference (L.S.D.) [Analysis of variance (ANOVA)] 
calculated using four external repeats. * : p<0.05, two-way ANOVA. 
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Figure 1.9: Alignment of the ZF-NC of various species. All mammalian ZICs as well as Zics in 
many other species such as Drosophila and Xenopus contain the ZF-NC domain. In each case 
the lysine equivalent to K393 in human ZIC5 is conserved (blue box). 
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1.5 SUMOylation 
One of the most studied post-translational modifications is ubiquitination, which is commonly 
associated with protein degradation, but also has various other cell signalling functions. The 
ubiquitin modification differs from other well-known post-translation modifications, such as 
acetylation or phosphorylation, in that it involves the attachment of a small protein, rather 
than a small functional group, to a target protein. In fact, ubiquitin is just one example of a 
group of post-translational modifications where the modifier is a protein which includes ISG15, 
FUB1, FAT10 and NEDD8. Another modification of this kind is SUMOylation, which is the 
attachment of the SUMO (Small Ubiquitin-like MOdifier) protein, to target proteins. The SUMO 
modification can have a wide range of effects on target proteins, including altering target 
protein activity, localisation and stability (Geiss-Friedlander and Melchior, 2007; Lomelí and 
Vázquez, 2011). 
 
Since the identification of SUMO1 (Boddy et al., 1996; Shen et al., 1996), several other SUMO 
paralogs have been identified based on homology. SUMO proteins have been identified in all 
eukaryotic kingdoms, though the number of SUMO proteins found in a particular organism 
varies from the single SUMO protein found in yeast (Saccharomyces cerevisiae) and 
invertebrates such as Drosophila melanogaster and Caenorhabditis elegans (Melchior, 2000), 
to the eight SUMO proteins identified in the plant Arabidopsis thaliana (Kurepa et al., 2003). In 
both mice and humans four SUMO isoforms have been identified based on homology: SUMO1, 
SUMO2, SUMO3 and SUMO4. The biological significance of SUMO4 is unclear, as SUMO4 
protein has never been detected in vivo. Quantitative proteomics has suggested the targets of 
the other SUMO proteins at least partially overlap (Vertegaal et al., 2006), but their general 
behaviour differs: in COS-7 cells under normal cell conditions the majority of SUMO1 is 
conjugated to target substrates, whereas SUMO2 and SUMO3 exist largely as a free pool 
(Saitoh and Hinchey, 2000). However, the amount of conjugated SUMO2 and SUMO3 is greatly 
increased under heat shock and other stresses, suggesting these proteins may be primarily 
involved in stress responses (Golebiowski et al., 2009; Saitoh and Hinchey, 2000). While the 
four SUMO isoforms are believed to have distinct roles, they are able to compensate to some 
degree for loss of each other, as evidenced by the survival of Sumo1 null mice (Zhang et al., 
2008), whereas blockage of all SUMOylation within cells by interfering with the conjugation 
pathway leads to early embryonic death (Nacerddine et al., 2005). 
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1.5.1 SUMO attachment 
The pathway for the attachment of the SUMO protein to target proteins is analogous to the 
ubiquitin conjugation pathway, involving three steps and three types of enzyme (Gareau and 
Lima, 2010) (Figure 1.10). First, the SUMO protein is activated in an ATP dependent reaction to 
form a thioester bond with the E1 SUMO-activating enzyme, the heterodimer AOS1/UBA2. In 
the second step, the SUMO protein is transferred to the E2 conjugating enzyme. Unlike the 
ubiquitin conjugation pathway, there is only a single SUMOylation E2 conjugating enzyme, 
UBC9. For some proteins, such as RanGAP1 (Ran GTPase activating protein), UBC9 is able to 
directly recognise the SUMOylation sites, allowing the SUMO protein to be directly transferred 
to the target protein without additional enzymes. However the SUMOylation of most proteins 
requires an additional enzyme, one of several E3 ligating enzymes, which assists in transferring 
the SUMO protein to specific target proteins in the final step. These enzymes recognise the 
consensus SUMOylation motifs, which consist of a hydrophobic residue (Ψ), then a lysine (K), 
then any amino acid (x) and finally an acidic residue (E/D) or ΨKxE/D, though it should be 
noted that not every consensus SUMO site is SUMOylated. 
 
1.5.2 Regulation by SUMOylation 
SUMO conjugation alters activity of target substrates through one of three non-exclusive 
consequences: first the SUMO moiety can mask an interaction surface, second attachment of 
the SUMO moiety along with a secondary non-covalent interaction alters the 3D structure of 
the target protein to disrupt binding sites or third attachment of SUMO creates binding sites 
due to interacting proteins containing SUMO interaction motifs or other SUMO-binding 
modules (Figure 1.11). Through these consequences of SUMO attachment, SUMO conjugation 
can result in a range of functional changes. For example to be able to function as a 
transcription factor a protein must be stably expressed, localised to the nucleus/specific gene 
promoters, interact with DNA and interact with other protein co-regulators. Examples exist of 
SUMO conjugation altering each of these abilities, often simultaneously. 
 
1.5.2.1 Stability 
In some cases SUMOylation is thought to alter protein stability through competition with other 
post-translational modifications for target lysines. For example, HeLa cell based studies 
utilising translation and proteasome inhibitors have demonstrated ubiquitin and SUMO2/3 
target the same lysine of serine hydroxymethyltransferase 1 (SHMT1), with opposing affects: 
ubiquitination promotes nuclear export and increases stability, whereas SUMOylation  
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Figure 1.10: SUMO conjugation pathway. First, unconjugated SUMO protein is activated in an 
ATP dependent reaction to form a thioester bond with the E1 SUMO-activating enzyme, the 
heterodimer Aos1/Uba2. In the second step, the SUMO protein is transferred to the E2 
conjugating enzyme, UBC9. In the third step the SUMO protein is transferred to specific target 
proteins with the aid of an E3 ligase. The modification can be reversed by actions of several 
SUMO proteases, which frees the SUMO protein for attachment to other targets. 
  
32 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Consequences of SUMOylation. At the molecular level SUMOylation can have 
several consequences. The attachment of SUMO may a) block access to a region near the 
conjugation site interactions, thereby preventing an interaction, b) alter the 3D structure of 
the protein to temporarily disrupts a binding region and thus the activity of a protein or c) 
promote interaction with a SIM containing protein. L-ABS: low-affinity binding site. Adapted 
from (Wilkinson and Henley, 2010). 
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promotes nuclear degradation (Anderson et al., 2012). It should be noted that in other cases 
ubiquitin and SUMO target the same lysine without directly competing. For example analysis 
of phosphorylation incompetent and permanently phosphorylated forms of IκBα demonstrated 
the choice of ubiquitination or SUMOylation can be determined by a third modification 
phosphorylation (Ulrich, 2005). For other proteins, such as promyelocytic leukemia protein 
(PML), SUMO and ubiquitin cooperate to influence protein fate, with formation of SUMO2/3 
chains acting as a signal for the subsequent ubiquitination leading to proteasome mediated 
degradation (reviewed in (Geoffroy and Hay, 2009) and (Sriramachandran and Dohmen, 
2014)). In other cases comparison of wildtype and SUMOylation incompetent forms of protein 
in cell based assays have shown SUMOylation can protect against ubiquitin mediated 
degradation without the modifications competing for the same lysine (Klenk et al., 2006). 
Thus, SUMOylation can potentially both positively and negatively influence protein stability. 
 
1.5.2.2 Protein-protein interactions 
The most common consequence of SUMOylation is to promote the formation of SUMO 
dependent protein-protein interactions (Figure 1.11c). SUMO dependent protein-protein 
interactions occur due to the non-SUMOylated proteins containing SUMO interacting motifs 
(SIMs) consisting of short stretches of branched hydrophobic residues, which act as low affinity 
binding sites for the SUMO moieties (Hecker et al., 2006; Song et al., 2004). As there are 
thousands of SUMOylated proteins the SIMs often cooperates with a second low affinity 
binding site to confer specificity. For example the DNA helicase Srs2 contains two closely 
spaced interaction motifs, one a SIM, the other a low affinity binding site for interaction with 
proliferating cell nuclear antigen (PCNA). Both interaction motifs are required for interaction of 
Srs2 with SUMOylated PCNA (Papouli et al., 2005; Pfander et al., 2005).  
 
Conjugation of SUMO often promotes binding of transcriptional co-repressors, frequently 
HDACs (Gill, 2005). For example SUMOylation of p300 and Elk-1 causes the recruitment of 
HDAC (Girdwood et al., 2003; Yang and Sharrocks, 2004), which modifies chromatin state 
leading to transcriptional repression. Other co-repressors which bind to SUMOylated proteins 
have also been identified, including Daxx (Shih et al., 2007). While transcriptional repression 
seems to be the more common outcome of SUMOylation of transcription factors, there are 
cases where the opposite occurs. For example, co-immunoprecipitation and luciferase reporter 
experiments in HEK293 cells illustrated that SUMOylation of TCF7L2 enhances its binding of 
the co-activator β-CATENIN, causing transcription activation of Wnt target genes (Shitashige et 
al., 2008). There are also examples of SUMOylation acting to block protein-protein interaction 
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sites, the end result of which is transcriptional activation; for example SUMOylation of the 
transcriptional repressor Dnmt3a disrupts its interaction with HDAC1 and HDAC2, thus 
resulting in an overall activation of transcription (Ling et al., 2004). 
 
1.5.2.3 Localisation change 
For several proteins SUMOylation is associated with a change in subcellular localisation. In 
many cases, such as for LEF1, the modification causes localisation away from active sites of the 
transcription to the PML bodies (Sachdev et al., 2001). As this localisation change prevents 
proteins from accessing DNA, it would cause a repression of function for transcription factors. 
Once a protein has been relocated to the PML bodies due to the SUMO modification, it may 
remain sequestered in the PML bodies even if it loses the SUMO modification. Thus a large 
amount of a protein can be relocated even if only a small amount is ever SUMOylated at one 
time. However, a recent paper has suggested a different purpose of relocation to the PML 
bodies. In the case of FOXL2, recruitment to the PML bodies is believed to induce a secondary 
phosphorylation modification (Georges et al., 2011). The phosphorylation modification 
remains after the FOXL2 protein is deSUMOylated, causing a long term enhancement of 
transcriptional ability. Changes to the localisation of a protein via SUMOylation can therefore 
both positively and negatively affect the function of transcriptional regulators. 
 
1.5.2.4 DNA binding change 
One of the best understood examples of SUMOylation affecting DNA binding is SUMOylation 
of the DNA proof reading enzyme Thymine-DNA Glycosylase (TDG). TDG is one of the few 
identified cases where conjugating SUMO regulates protein activity by affecting 3D protein 
structure (Figure 1.11b). After TDG detects and removes a mismatch it creates an abasic site to 
which the enzyme binds so tightly that it is effectively trapped, however it also becomes a 
strong target for SUMOylation (Hardeland et al., 2002). In addition to the covalent bond that 
forms with attachment of SUMO, TDG also has regions capable of forming non-covalent 
interactions with SUMO. By examining the crystal structure of SUMO conjugated TDG, it was 
found that when TDG forms both covalent and non-covalent bonds with the same SUMO 
moiety, it alters the 3D structure of TDG so that an α-helix secondary structure protrudes into 
the region interacting with DNA, causing TDG to be released into the nucleoplasm (Baba et al., 
2005; Hardeland et al., 2002). The protein is then quickly deSUMOylated, which allows TDG to 
continue its proofreading function. As the protein is only SUMOylated when trapped on the 
DNA, only a small amount of TDG is SUMOylated at any one time, even though the 
modification is essential for proper TDG enzyme function.  
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1.6 Pathways linked to both ZIC and SUMOylation 
SUMOylation is a widespread modification and as such is involved in regulation of many 
cellular processes, including transcriptional regulation, cell cycle regulation, DNA repair, 
chromatin organisation and nuclear transport. In fact SUMOylation is absolutely critical for 
embryonic viability in mammals, as demonstrated by death of mouse embryos in the early 
post-implantation stage when total SUMOylation is lost by targeting the single E2 conjugating 
enzyme (Nacerddine et al., 2005). SUMOylation has several critical roles during embryonic 
development, including regulating photoreceptor development, neural crest and inner ear 
specification, cardiac development and axis formation (for a recent review on these and other 
known roles of SUMOylation in development, see Lomelí and Vazquez, 2011). Here, we will 
focus on three roles linked to both ZIC and SUMOylation: neural crest formation, Wnt 
inhibition and pluripotency. 
 
1.6.1 Neural crest formation 
Several proteins known to influence neural crest development have been found to be 
SUMOylated, however the response to the modification is complex. For example the two 
neural crest specifiers Sox9 and Sox10 are both known to be SUMOylated (Taylor and Labonne, 
2005). Initially it was found that injection of SUMOylation incompetent sox9 into Xenopus 
embryos was more efficient than injection of wildtype sox9 at inducing neural crest formation 
based on higher expression of neural crest markers including sox10 and increased number of 
ectopic melanocytes (Taylor and Labonne, 2005). In addition the SUMOylation incompetent 
forms of Sox9 and Sox10, but not wildtype forms, were able to activate both endogenous 
expression of the neural crest effector gene dopachrome tautomerase (dct), which is critical 
for formation of the neural crest melanocyte lineage, and a dct promoter based reporter in 
Xenopus embryos and human melanoma cells when introduced into cells with microphthalmia-
associated transcription factor (Mitf), a specifier of the neural crest melanocyte lineage (Lee et 
al., 2012). Together these findings suggest that SUMOylation interferes with the neural crest 
specifier activities of the Sox9 and Sox10 proteins. However, a recent paper reported the 
opposite, as co-expression of SUMOylation incompetent SOX9 in chick with the neural crest 
specifier SNAIL induced less neural crest cell delamination than co-expression of wildtype SOX9 
with SNAIL (Liu et al., 2013). Whether the difference in these studies is due to the difference in 
model species used (Xenopus vs chick), or a difference in the reporter/assays used to assess 
neural crest formation is not clear. 
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Further studies suggest SUMOylation has an overall positive influence on neural crest 
development. In particular in situ hybridisation and immunofluorescence experiments have 
illustrated that both mRNA transcripts and protein levels of the SUMO E2 ligase UBC9, which is 
essential for SUMO conjugation, are enriched in the neural folds of chick where the future 
neural crest cells are located (Luan et al., 2013), although the same enrichment is not seen in 
mouse embryos ((Costa et al., 2011) and Arkell Laboratory, unpublished observation), 
suggesting there are species differences. Furthermore, knockdown of UBC9 in this region in 
chick using morpholinos reduces expression of several neural crest specifiers including SNAIL2, 
SOX9 and FOXD3 as detected by in situ hybridisation, without altering expression of neural 
plate border genes (Luan et al., 2013). SUMOylation has also been found to directly positively 
regulate some neural plate border genes and neural crest specifiers. For example, loss of 
SUMOylation has been shown to negatively affect the ability of the neural plate border gene 
PAX7 to induce expression of neural crest specifiers such as SNAIL2, SOX9 and FOXD3 in a chick 
neural tube based morpholino rescue assay (Luan et al., 2013). It should be noted that while 
the experiments described here suggest SUMOylation is important for neural crest formation 
in chick, little is known about SUMOylation in mouse neural crest specification.  
 
1.6.2 Wnt inhibition 
Several key proteins in the canonical Wnt/β-catenin signalling pathway, including AXIN, GSK3β, 
LEF1, TCF7L2, TBL1 and TBLR1 have been found to be SUMOylated (Figure 1.12) (Gao et al., 
2014). With the exception of SUMOylation of LEF1, which has been shown to negatively 
regulate activation of the canonical Wnt/β-catenin signalling TOPflash reporter in Human 
Embryonic Kidney (HEK) 293 cells (Sachdev et al., 2001), most studies have found a positive 
relationship between SUMOylation and Wnt/β-catenin signalling. Rather than focus on 
particular SUMOylation substrates, many of these studies have focused on general cell 
SUMOylation. For example, Huang et al. (2015) showed that interfering with total cell 
SUMOylation in RPMI-8226 and NCI-H929 myeloma cells using SUMO1 siRNA reduces 
activation of the canonical Wnt/β-catenin signalling reporter TOPflash, as well as lowering the 
transcript levels of several Wnt targets as measured by quantitative realtime Polymerase Chain 
Reaction (PCR), implying SUMOylation positively regulates canonical Wnt/β-catenin signalling 
(Huang et al., 2015). The idea that SUMOylation in general positively regulates this pathway is 
also supported by the finding that multiple deSUMOylating enzymes, including Axam (Axin-
associating molecule) and Xenopus sentrin-specific protease 1 (XSENP1), have been found to 
rescue axis defects in Xenopus caused by ectopic β-catenin or dvl expression when injected 
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Figure 1.12: Involvement of SUMOylation in the canonical Wnt signalling pathway. Several 
components of the Wnt signalling are targeted by the post-translational modification 
SUMOylation. a) Several SUMO proteases including SENP and Axam are thought to promote 
the Low Wnt state in which β-CATENIN is degraded and WREs are repressed by TCF/TLE 
repression complexes. b) SUMOylation is thought to promote the high Wnt state in which the 
β-CATENIN degradation complex is inhibited in a Disheveled (Dvl) dependent manner which 
allows β-CATENIN to enter the nucleus where it binds TCF to act as a co-activator. Several key 
proteins in the canonical Wnt/β-catenin signalling pathway, including AXIN, GSK3β, β-
CATENIN, LEF1, TCF7L2, TBL1 and TBLR1 have been found to be SUMOylated, however in most 
cases the consequences of the modification are not known. In the case of TBL1/TBLR1, 
SUMOylation causes disassociation from the transcriptional inhibitors HDAC3 and NCoR/SMRT 
and promotes interaction with β-CATENIN, in effect acting as a switch turning these proteins 
from inhibitors to activators of canonical Wnt/β-catenin signalling.  
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into Xenopus embryos (Kadoya et al., 2002; Yukita et al., 2004), an ability associated with Wnt 
inhibitors. In addition, dorsal injection of XSENP1 into Xenopus leads to the Wnt inhibition 
associated phenotype of head defects and reduced expression of the Wnt target xnr3 (Yukita 
et al., 2004). Both these observations indicate loss of SUMOylation promotes transcriptional 
repression at WREs, suggesting SUMOylation must be stimulated for Wnt activation. 
 
One known case of SUMOylation directly positively regulating particular proteins of the 
canonical Wnt/β-catenin signalling pathway is the SUMOylation of TBL1 and TBLR1. Originally, 
these proteins were found to form a repression complex through interaction with the 
transcriptional inhibitors HDAC3 and NCoR/SMRT (Yoon et al., 2003). However, SUMOylation 
of TBL1 and TBLR1 was shown to disassociate these proteins from the transcriptional 
inhibitors, and instead promote association with β-CATENIN, in effect acting as a switch 
turning these proteins from inhibitors to activators of canonical Wnt/β-catenin signalling (Choi 
et al., 2011). As these findings were made using cell-based assays, the in vivo relevance is 
unknown. Intriguingly, canonical Wnt/β-catenin signalling itself appears to drive SUMOylation 
of TBL1 and TBLR1 (Choi et al., 2011). Other proteins, such as SOX9, have also been shown to 
be SUMOylated in response to canonical Wnt/β-catenin signalling (Liu et al., 2013), suggesting 
that up regulation of SUMOylation is an important mechanism by which canonical Wnt/β-
catenin signalling alters protein function. 
 
1.6.3 Pluripotency 
Although SUMOylation has been reported to increase the activity of certain pluripotency 
regulators including OCT4 (Wei et al., 2007), recent evidence suggests that in general 
pluripotency is negatively regulated by protein SUMOylation. For example, SUMOylation of 
several pluripotency regulators including SOX2 and KLF4 has been found to negatively affect 
both transcriptional activation of these proteins and the ability of these proteins to generate 
induced pluripotent stem (iPS) cells (Tahmasebi et al., 2013; Tsuruzoe et al., 2006; Wu et al., 
2012). Moreover decreasing levels of either SUMO1 or the E2 SUMOylation conjugating 
enzyme UBC9 in F9EC cells using short hairpin RNA (shRNA) increases endogenous expression 
of Nanog, a key positive regulator of pluripotency (Wu et al., 2012). It should be noted, 
however, that some SUMOylation is necessary for ESCs survival as shRNA knockdown of UBC9 
results in apoptosis of ESCs (Tahmasebi et al., 2014). Such a result underscores the general 
importance of SUMOylation as a widespread modification critical for normal cellular function, 
but proffers no specificity. Overall there is a lack of in vivo information about regulation of 
pluripotency by SUMOylation.  
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1.7 Scope of this thesis 
The SUMO modification potentially represents a novel mechanism for regulating ZIC function, 
by altering ZIC activity without affecting ZIC gene expression. Given the importance of correct 
ZIC function, as illustrated by the diverse phenotypes produced when ZIC function is lost, the 
main aims of this project are to determine if the ZICs are a true target for the SUMO 
modification and if so assess how this modification alters ZICs behaviour. Specifically, this 
thesis aims to: 
 
1. Generate wildtype and mutant ZIC expression constructs. 
2. Generate an assay to analyse ZIC based inhibition of Wnt signalling. 
3. Identify potential and actual sites of SUMOylation within the ZIC family members and 
identify the force driving this SUMOylation. 
4. Determine if SUMOylation alters the activity of the ZICs, including promotion of neural 
crest specification and Wnt inhibition. 
5. Investigate the underlying basis for any change in ZIC activity due to SUMOylation. 
 
 
 

41 
Chapter 2: Methods and Materials 
2.1 Plasmids 
2.1.1 Plasmid Vectors 
1. pENTR3C: Entry vector used for Gateway Cloning (Invitrogen). Contains multiple 
cloning site (MCS) surrounding the negative selection gene ccdB, all of which is 
bordered by two attL sites for LR recombination based cloning (see Section 2.2.4.6). 
2. V5-DEST: pcDNA3.1/nV5-DEST (Invitrogen) Destination vector used for Gateway 
Cloning (Invitrogen). Contains the cytomegalovirus (CMV) promoter upstream of a V5 
epitope tag followed by two attR sites surrounding a ccdB gene for LR recombination 
based cloning (see Section 2.2.4.6). In mammalian cells expresses a V5 tag fused to N-
terminus of sequence inserted between attR sites.  
3. EmGFP-DEST: Vivid colors™ pcDNA™ 6.2/N-EmGFP-DEST (Invitrogen). Destination 
vector used for Gateway Cloning. Contains CMV promoter upstream of an Emerald 
Green Fluorescent Protein [EmGFP; modified version of GFP (Green Fluorescent 
Protein) optimised for expression in mammalian cells] tag followed by two attR sites 
surrounding a ccdB gene for LR recombination based cloning (see Section 2.2.4.6). In 
mammalian cells expresses EmGFP tag fused to N-terminus of sequence inserted 
between attR sites. 
4. EGFP-C1: Mammalian expression vector (Clontech). Contains CMV promoter upstream 
of an Enhanced Green Fluorescent Protein (EGFP; modified GFP optimised for brighter 
fluorescence and higher expression in mammalian cells) followed by a MCS. 
5. pGL4.20: pGL4.20[luc2/Puro] reporter vector (Promega). Contains MCS upstream of 
luciferase reporter gene luc2 (codon optimised for expression in mammalian cell lines). 
The backbone has been engineered to reduce undesired non-specific transcription 
factor binding. 
6. V1-ORF: Destination vector used for Gateway Cloning. Contains the CMV promoter 
upstream of part of the Venus Coding Sequence (CDS), coding for the N-terminal 158 
amino acids of the Venus fluorescent molecule (termed V1) tag followed by two attR 
sites surrounding a ccdB gene for LR recombination based cloning (see Section 2.2.4.6). 
A gift from Darren Saunders, (Garvan Institute of Medical Research, Australia) 
7. V2-ORF: Destination vector used for Gateway Cloning. Contains the CMV promoter 
upstream of part of the Venus CDS, coding for the C-terminal 81 amino acids of the 
Venus fluorescent molecule (termed V2) tag followed by two attR sites surrounding a 
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ccdB gene for LR recombination based cloning (see Section 2.2.4.6). A gift from Darren 
Saunders, (Garvan Institute of Medical Research, Australia) 
 
2.1.2 Expression constructs gifted from other Laboratories 
1. pcDNA-ZIC1: Mammalian expression construct containing human ZIC1. A gift from 
Kathleen Millen (Seattle Children’s Research Institute, USA). 
2. pcDNA-ZIC4: Mammalian expression construct containing human ZIC4. A gift from 
Kathleen Millen (Seattle Children’s Research Institute, USA). 
3. YFP-SUMO1: Originally pEYFP-SUMO1 (Harder et al., 2004). Mammalian expression 
construct containing Yellow Fluorescent Protein (YFP) fused to human SUMO1. A gift 
from Dr Heidi McBride (McGill University, Canada) and Dr Rodolfo Zunino (Ottawa 
University, USA). 
4. ΔN89-β-CATENIN: Originally pCAN-β-CATENIN-ΔN89 (Munemitsu et al., 1996). 
Mammalian expression construct containing human β-CATENIN CDS for which the 
sequence coding for the first 89 amino acids have been deleted. As the deleted region 
includes the phosphorylation sites necessary for degradation via the cytoplasmic β-
CATENIN degradation complex, the protein is described as stabilized. A gift from 
Sabine Tejpar (Department of Oncology, Katholieke Universiteit Leuven, Belgium). 
5. V5-β-CATENIN: β-CAT-V5 (Usami et al., 2003). Mammalian expression construct 
containing the full length human β-CATENIN CDS downstream of a CMV promoter. A 
gift from Yoshitaka Sekido (Aichi Cancer Center Research Institute, Japan). 
6. pFLAG-CMV-TCF7L2: Originally pFLAG-CMV-TCF4 (Idogawa et al., 2005). Mammalian 
expression construct containing human TCF7L2. A gift from Sabine Tejpar (Department 
of Oncology, Katholieke Universiteit Leuven, Belgium). 
7. pSG5-HA-hUBC9: Mammalian expression construct containing wildtype human UBC9 
N-terminally tagged with HA (Chang et al., 2007). A gift from Shih-Ming Huang 
(National Defense Medical Center, Taiwan). 
8. pFLAG-UBC9-C93S: Mammalian expression construct containing FLAG tagged mouse 
UBC9 with the C93S mutation that causes the expressed protein to act as a dominant 
negative inhibitor of SUMOylation (Poukka et al., 1999). A gift from Olli Janne 
(University of Helsinki, Finland). 
9. STAT1-UBC9: Mammalian expression construct containing the UBC9 CDS C-terminally 
fused to the STAT1 CDS (with the stop codon removed) (Jakobs et al., 2007b). For 
testing the UBC9 fusion directed SUMOylation (UFDS) system (see Chapter 5). A gift 
from Rainer Niedenthal (Hannover Medical School, Germany). 
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10. pgalK: Plasmid containing the galK gene for PCR amplification needed for 
recombineering based cloning. A gift from Robert Saint (University of Melbourne, 
Australia). 
11. pCherry-C1: Mammalian expression construct containing the fluorescent Cherry 
protein. Used for transfection control for Bimolecular Fluorescence Complementation 
(BiFC) experiments. A gift from Alpha Yap, (University of Queensland, Australia). 
12. V2-Ubiquitin: Mammalian expression construct containing the CMV promoter 
upstream of C-terminal portion of the Venus fluorescent molecule fused to the 
wildtype Ubiquitin CDS. Used for BiFC protein interaction experiments. A gift from 
Darren Saunders, (Garvan Institute of Medical Research, Australia). 
 
2.1.3 Expression constructs generated within the Arkell Laboratory 
1. P[acman]-ZIC5: Human ZIC5 CDS in the P[acman] vector for recombineering based 
cloning. Constructed by M. Zavortink. 
2. pENTR3C-ZIC5-WT, pENTR3C-ZIC5-K393R and pENTR3C-ZIC5-K522R: pENTR3C entry 
vector containing the human ZIC5 CDS (wildtype or mutant indicated) inserted in the 
MCS. attL sites are flanking the ZIC CDS for LR based cloning. Constructed by R. Ali and 
M. Zavortink. 
3. V5-ZIC5-WT, V5-ZIC5-K393R and V5-ZIC5-K522R: Mammalian expression constructs 
containing V5 tagged human ZIC5 CDS (wildtype or mutant indicated) downstream of a 
CMV promoter. Constructed by R. Ali and M. Zavortink. 
4. pENTR3C-UBC9-ZIC5-WT, pENTR3C-UBC9-ZIC5-K393R and pENTR3C-UBC9-ZIC5-
K522R: pENTR3C entry vector containing the human UBC9 CDS (with the stop codon 
removed) upstream of the human ZIC5 CDS (wildtype or mutant indicated) inserted in 
the MCS. attL sites are flanking the ZIC CDS for LR based cloning. Constructed by R. Ali 
and H. Bellchambers. 
5. V5-UBC9-ZIC5-WT, V5-UBC9-ZIC5-K393R and V5-UBC9-ZIC5-K522R: Mammalian 
expression constructs containing V5 tagged UBC9 (with the stop codon removed) 
fused to human ZIC5 CDS (wildtype or mutant indicated) downstream of a CMV 
promoter. Constructed by R. Ali and H. Bellchambers. 
6. pENTR3C-ZIC3-WT, pENTR3C-ZIC3-K248R, pENTR3C-ZIC3-E249X and pENTR3C-ZIC3-
K359R: pENTR3C entry vector containing the human ZIC5 CDS (wildtype or mutant 
indicated) inserted in the MCS. attL sites are flanking the ZIC CDS for LR based cloning. 
Constructed by R. Ali and J. Ahmed. 
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7. V5-ZIC3-WT, V5-ZIC3-K248R, V5-ZIC3-E249X and V5-ZIC3-K359R: Mammalian 
expression constructs containing V5 tagged human ZIC5 CDS (wildtype or mutant 
indicated) downstream of a CMV promoter. Constructed by R. Ali. 
8. pENTR3C-ZIC2-WT: pENTR3C entry vector containing the human ZIC2 wildtype CDS 
inserted in the MCS. attL sites are flanking the ZIC CDS for LR based cloning. 
Constructed by J. Ahmed. 
9. V5-ZIC2-WT: Mammalian expression construct containing V5 tagged human ZIC5 
wildtype CDS downstream of a CMV promoter. Constructed by R. Ali. 
10. pENTR3C-ZIC1-C339S, pENTR3C-ZIC2-C370S, pENTR3C-ZIC3-C365S and pENTR3C-ZIC4-
C241S: pENTR3C entry vector containing the human ZIC CDS with a point mutation 
altering the second cysteine of the fourth zinc finger to a serine inserted in the MCS. 
The cysteine to serine change should prevent DNA binding by the ZICs. Constructed by 
K. Barratt and J. Ahmed. 
11. V5-ZIC1-C339S, V5-ZIC2-C370S, V5-ZIC3-C365S and V5-ZIC4-C241S: Mammalian 
expression construct containing V5 tagged human ZIC CDS with a point mutation 
altering the second Cysteine of the fourth zinc finger to a Serine downstream of a CMV 
promoter. The Cysteine to Serine change should prevent DNA binding by the ZICs. 
Constructed by K. Barratt, K. Diamand and J. Ahmed. 
 
2.1.4 Reporter Constructs 
1. cfos-TOPflash: Contains the four tandem optimised TCF binding sites upstream of the 
cfos minimal promoter followed by the luciferase reporter gene. Used to measure 
levels of Wnt/β-catenin signalling activation. A gift from Sabine Tejpar (Department of 
Oncology, Katholieke Universiteit Leuven, Belgium). 
2. cfos-FOPflash: Contains the four tandem mutated TCF binding sites upstream of the 
cfos minimal promoter followed by the luciferase reporter gene. Used as a control for 
the cfos-TOPflash plasmid. A gift from Sabine Tejpar (Department of Oncology, 
Katholieke Universiteit Leuven, Belgium). 
3. TK-TOPflash: Also called TOPFLASH (UPSTATE). Contains the six tandem optimised TCF 
binding sites upstream of the Thymidine Kinase (TK) minimal promoter followed by the 
luciferase reporter gene. Used to measure levels of Wnt/β-catenin signalling 
activation. Note that the construct was originally described as containing three 
tandem TCF binding sites, but sequencing showed this to be incorrect. 
4. TK-FOPflash: Also called FOPFLASH (UPSTATE). Contains the six tandem mutated TCF 
binding sites upstream of the TK minimal promoter followed by the luciferase reporter 
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gene. Used as a control for the TK-TOPflash plasmid. Note that the construct was 
originally described as containing three tandem TCF binding sites, but sequencing 
showed this to be incorrect. 
5. pXp-ApoE (-189/+1): Contains the ApoE promoter upstream of the luciferase reporter 
gene. The promoter region is known to be activated by the ZICs (Salero et al., 2001). A 
gift from Francisco Zafra (Univeridad Autónoma de Madrid, Spain). 
6. pGL4.20-ApoE (-189/+1): Contains the ApoE promoter from pXp-ApoE (-189/+1) 
upstream of the luciferase reporter gene in the pGL4.20 backbone. Constructed by J. 
Ahmed. 
7. pGL4.20-ApoE (-188/-169): Contains a small fragment of the ApoE promoter thought 
to be a target of ZIC binding (see Salero et al., 2001) upstream of the luciferase 
reporter gene in the pGL4.20 backbone.  Constructed by J. Ahmed. 
8. pGL4.20-ApoE (-143/124): Contains a small fragment of the ApoE promoter thought to 
be a target of ZIC binding (see Salero et al., 2001) upstream of the luciferase reporter 
gene in the pGL4.20 backbone.  Constructed by J. Ahmed. 
9. pGL4.20-β-globin-Z3M2 (-189/+1): ZIC reporter construct. Contains six tandem copies 
of a consensus ZIC3 DNA binding motif upstream of the β-globin minimal promoter 
followed by the luciferase reporter gene. Constructed by J. Ahmed. 
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2.2 Molecular Cloning 
2.2.1 Buffer and Solutions 
Luria Broth (LB) media: 25 g/L DifcoTM LB broth, Miller; Bacto 
LB Agar: 40 g/L DifcoTM LB agar, Miller; Bacto 
Lysis Solution: 50 mM tris(hydroxymethyl)aminomethane (Tris)-HCl (Sigma) pH 8.5, 1 mM 
EDTA (ethylenediaminetetraacetic acid; Ajax Chemicals), 5% Tween 20 (Sigma) and 0.4 
mg/mL of Proteinase K (Roche) 
M9 salts: 0.6% (w/v) Na2HPO4 (Mereck), 0.3% KH2PO4 (Ajax Chemicals), 0.1% NH4Cl (Ajax 
Chemicals) and 0.05% NaCl (Mereck) in MilliQ water 
Minimal Agar: 15 g/L bacto-agar (Difco), 20% v/v 5 x M63 media (10 g/L (NH4)2SO4 (Chem 
Supply), 68 g/L KH2PO4, 2.5 mg/L FeSO4•7H2O (Ajax Chemicals) with the pH adjusted to 7 with 
KOH (Ajax Chemicals), 1 mg/L biotin (Sigma-Aldrich), and 45 mg/L leucine (Sigma) 
Loading Dye: 4x: 20% glycerol (Merck), 19.2% 0.5 M Na2EDTA (Sigma-Aldrich) and 0.001% 
bromophenol blue (Sigma) 
 
2.2.2 DNA transformation and isolation 
2.2.2.1 Bacteria Transformation 
DNA was transformed into bacteria by either heat shock or electroporation. DNA from In-
fusion reactions was heat shocked into Fusion Blue Competent cells (Clontech) as described in 
the manufacturer’s instructions. In all other cases DNA was electroporated into cells. 
 
To electroporate the DNA, 50 - 100 µg of plasmid DNA or 1 µL of DNA from a precipitated 
ligation or LR reaction was added to ice cold electrocompetent cells (DH5α or Epi300 cells). 
Cells were then transferred to an ice cold cuvette and shocked using a BioRad Escherichia coli 
(E. coli) Pulser (BioRad) at 2.5 KV. 300 µL of LB (Luria-Bertani) broth media was then 
immediately added, and the cells were incubated at 37 oC for one hour with shaking to allow 
the bacteria to recover and start expressing the antibiotic resistance gene. Once recovered, 
either 150 µL of cells (if the DNA was from a ligation reaction) or 20 µL of cells were plated on 
LB Agar with 0.1 mg/mL of the appropriate antibiotic, and incubated for 16 hours at 37 oC. 
Electroporation of SW102 cells followed the same general protocol, but with modified 
incubation temperatures and times (Table 2.1 and Section 3.2.2.1 for details). 
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Bacteria Strain Amount Incubation 
Temperature 
Purpose 
DH5α 20 µL 37 oC Used for routine cloning 
SW102 50 µL 32 oC Used for inducing homologous 
recombination during recombineering  
Epi 300  50 µL 37 oC Used to change P[acman] into a high 
copy number plasmid via the addition 
of arabinose 
 
 
Table 2.1: Bacteria strains used for cloning. Amount refers to the amount of cells used for 
electroporation.  
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2.2.2.2 DNA isolation 
Plasmid DNA was isolated using two different methods depending on the amount DNA 
required. To check for successful cloning (which usually requires less the 2 µg of DNA), plasmid 
DNA was isolated from a 2 – 3 mL overnight culture with appropriate antibiotics using the High 
Pure Plasmid Isolation kit (Roche). If more than 1 µg was required, or if the DNA was needed at 
a higher concentration or purity, plasmid DNA was isolated from a 100 – 200 mL overnight 
culture with appropriate antibiotics using the Plasmid Filter Maxiprep kit (Invitrogen) or the 
Nucleobond Xtra Midiprep kit (Scientifix). In both cases DNA was resuspended in ddH2O 
instead of the supplied buffer. 
 
2.2.2.3 Genomic DNA isolation 
To obtain low quality DNA for PCR of genomic DNA, HEK293T cells were lysed. Briefly, 
approximately 5 µL of pelleted cells were added to 50 µL of lysis solution (50 mM Tris-HCl 
pH8.8, 1 mM EDTA and 5% Tween 20) and 2 µL of Proteinase K (10 mg/mL). The lysis solution 
containing the cells was incubated at 1 hour for 55 oC, followed by incubation at 95 oC for 10 
minutes to denature the Proteinase K. 
 
2.2.3 PCR based methods and analysis 
2.2.3.1 PCR based DNA amplification 
DNA fragments for cloning or sequencing were amplified using PCR. PCR products were 
amplified from approximately 40 ng of plasmid DNA or 20 ng of PCR fragments using 0.8 µg 
each of two oligonucleotides (primers, listed in Appendix 1) and a commercial PCR buffer at 
1X. Three commercial buffers were used, ImmoMix (Bioline), ReddyMix (ABgene) and 
ReddyMixKCl (ABgene). In some cases 5% dimethyl sulfoxide (DMSO) was also included in the 
reaction. Once prepared, the reaction mixture was cycled through the PCR amplification 
program (Table 2.2) using an Eppendorf Mastercycler PCR machine. Success of the PCR was 
analysed via gel electrophoresis. 
 
2.2.3.2 Bacterial Colony Screening  
In order to analysis whether ligation reactions had produced the desired constructs, colony 
PCRs were performed on the resulting bacterial colonies. Each colony to be analysed was 
picked from the agar plate using a sterile pipette tip and resuspended in 20 μL. A PCR reaction 
mixture was prepared as described in the previous section, but 5 μL of the bacteria in  
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Purpose Temperature Time  
Initial denaturation 94 oC 14 minutes  
Denature 95 oC 30 seconds  
Repeated for 
30 cycles 
Anneal various 30 seconds 
Extend 72 oC 30 seconds 
Final extension 72 oC 7 minutes  
Stop 4 oC Hold  
 
 
Table 2.2: PCR program. Annealing temperatures are listed as melting temperatures (Tm) with 
primers in Appendix 1. 
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water replaced the DNA as template. Once prepared, the reaction mixture was treated as a 
normal PCR reaction. The remaining bacteria resuspended in water was kept at 4 oC until 
analysis was complete, at which point the bacteria shown by the colony PCR to contain the 
desired clone was used to spike an overnight LB culture. 
 
2.2.3.3 DNA Sequencing 
200-300 ng of plasmid DNA or 3-20 ng of PCR product was sequenced using 3 pmol primer 
(varied depending on target, listed in Appendix 1) and 1 µL of Big Dye Terminating mixture in 
Sequencing Buffer (final concentration 70 mM Tris-HCL and 1.75 mM MgCl2). The reaction was 
cycled through the sequencing program shown in Table 2.3 using an Eppendorf Mastercycler 
PCR machine.  
 
Once the program was completed, the reaction was precipitated to remove any excess dye 
and nucleotides. To precipitate the reactions, 2 μL of 125 mM EDTA (Ajax Chemicals) at pH 8.0, 
3 μL of 3 M NaOAc (BHD) at pH 5.2 and 50 μL of 100% ethanol were added to each reaction 
with mixing. The reaction was then incubated at room temperature for 15 minutes and then 
centrifuged for 10 minutes at 21,000 g and 4 oC. After the spin was finished, the supernatant 
was removed and replaced with 250 μL of 70% ethanol to wash the DNA. The reaction was 
again centrifuged for 10 minutes at 21,000 g and 4 oC, after which the supernatant was 
discarded and the reaction was air dried to remove any remaining ethanol. Once dry, the 
samples were submitted to the Biomolecular Resource Facility (BRF; John Curtin School of 
Medical Research) to be analysed using their ABI 3730 sequencer (Applied Biosystems). The 
resulting sequences were analysed using the Geneious software (version 5.5.9; Biomatters). 
 
2.2.3.4 Agarose gel electrophoresis 
After DNA was digested using restriction enzymes or amplified using PCR, the size of the 
resulting bands was visualised using agarose gel electrophoresis. Agarose gels were made by 
dissolving Ultrapure Agarose (Life Technologies) in TBE buffer (0.1 M Tris-HCl, 0.09 M Boric 
acid and 0.001 M EDTA; Amersco). Once dissolved and cooled slightly, RedSafeTM Nucleic Acid 
Staining Solution (Intron Biotechnology) was added at a 1:20,000 dilution to allow visualisation 
of the DNA and the gel was allowed to set within a mould.  
 
To prepare the DNA for gel electrophoresis, 1 µL of 4X loading dye (see section 2.2.1) was 
added for every 4 µL of sample and with pipetting or vortexing to mix. The samples were then  
 
51 
 
 
 
 
 
 
 
 
 
 
 
Purpose Temperature Time  
Initial denaturation 94 oC 5 minutes  
Denature 95 oC 10 seconds  
Repeated for 
30 cycles 
Anneal 50 oC 5 seconds 
Extend 72 oC 4 minutes 
End 4 oC Hold  
 
 
Table 2.3: Sequencing program. 
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loaded into separate wells of the agarose gel. In an adjacent well, 0.6 µg of 1 Kb Plus DNA 
ladder (Invitrogen) was loaded into the gel to indicate band sizes. Once all the samples and the 
ladder had been loaded, a voltage of 5-6 Vcm-1 was applied to the gel for 25-50 minutes to 
separate the DNA fragments. The gel was then photographed by a Gel Doc XR (Bio-Rad), which 
exposes the gel to a UV light source so that the DNA fragments are visible.  
 
2.2.4 Ligation and Recombination based methods 
2.2.4.1 Restriction enzyme digests 
DNA was digested with restriction enzymes for analysis of plasmids and as part of cloning 
procedures. For analysis of plasmids, ≈ 500 ng of plasmid was added to 0.5 µL (5-10 U) of the 
appropriate restriction enzyme (Table 2.4), 2 µL of the appropriate New England Biolabs (NEB) 
buffer (10X conc, see Table 2.4), 2 µL of Bovine Serum Albumin (BSA; 10X conc), with enough 
AnalaR water to give a total volume of 20 µL, followed by incubation at 37 oC (except for BstEII, 
which was incubated at 60 oC) for 2 hours. 
 
For cloning, 2-10 µg of DNA was added to 1-2 µL (10-40 Units) of the appropriate restriction 
enzyme (Table 2.4), 5 µL of the appropriate NEB buffer (10x conc, see Table 2.4), 5 µL of BSA 
(10X conc, NEB), with enough AnalaR water to give a total volume of 50 µL. This digest mixture 
was then incubated at 37 oC for 2-4 hours. After this time the digest mixture was transferred to 
65 oC for 30 minutes to inactivate the restriction enzymes. 
 
2.2.4.2 Purification 
PCR fragments and digested plasmids were purified using the Nucleospin® Extract II purification 
kit following the manufacturer’s instructions. PCR fragments amplified for sequencing were 
purified using the Agencourt AMPure PCR purification system following the manufacturer’s 
instructions. 
 
To precipitate ligation reactions, 5 μL yeast tRNA (at 1 μg/μL), 12.5 μL of ammonium acetate 
(at 7.5 M) and 70 μL absolute ethanol (at -20 oC) were added to the reaction, which was 
vortexed thoroughly to mix. The reaction was immediately centrifuged for 20 minutes at room 
temperature and 16,000 g. The supernatant was then discarded and replaced with 500 μL of 
70% ethanol (at -20 oC). The reaction was then centrifuged for 2 minutes at room temperature 
and 16,000 g, after which the supernatant was discarded, with any remaining ethanol allowed 
to air dry off. Once dry the pellet was resuspended in 5 μL of AnalaR water. 
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Enzyme Target site Concentration NEBuffer 
ApaLI G/TGCAC 10,000 units/mL NEB4 
BamHI G/GATCC 20,000 units/mL NEB3 (in DD with Xho1) 
BglII A/GATCT 10,000 units/mL NEB3 (in double digest with 
Xho1) 
BstEII G/GTNACC 10,000 units/mL NEB4 (in DD with SacI) 
EcoRI G/AATTC 20,000 units/mL EcoR1 
HincII GTY/RAC 10,000 units/mL NEB3 
HindIII A/AGCTT 10,000 units/mL NEB2 
KpnI GGTAC/C 10,000 units/mL NEB1 Alone   
NEB1 (in DD with SacI) 
NEB2 (in DD with HindIII) 
NotI GC/GGCCGC 10,000 units/mL NEB3 
PstI CTGCA/G 20,000 units/mL NEB3 
NEB2 (in DD with StuI) 
SacI GAGCT/C 20,000 units/mL NEB1 (in DD with KpnI) 
NEB1 (in DD with XhoI) 
StuI AGG/CCT 10,000 units/mL NEB2 (in DD with PstI) 
NEB1 (in DD with SacI) 
XhoI C/TCGAG 20,000 units/mL NEB3 (in DD with BamHI) 
Xma1 C/CCGGG 10,000 units/mL NEB4 
 
 
Table 2.4: Restriction enzymes used to digest DNA. All enzymes were sourced from New 
England Biolabs. A unit is the amount of enzyme needed to completely digest 1 μg of DNA in 
one hour. DD = double digest. 
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2.2.4.3 In-Fusion Cloning 
In-Fusion cloning is a method of directionally cloning DNA fragments into any vector. It takes 
advantage of a proprietary enzyme that seamlessly fuses DNA fragments which contain at least 
15 bp of overlap at their ends. In order to directionally insert the ZIC2 PCR fragment into the 
pENTR3C vector the In-Fusion® HD Cloning kit (Clontech) was used, following the 
manufacturer’s instructions. Briefly, 100 ng of EcoRI digested pENTR3C was combined with 87 
ng of the gel purified ZIC2 PCR fragment, 2 μL of 5 x In-Fusion HD enzyme Premix and enough 
ddH2O to give a total of 10 μL. Reaction mix was incubated at 60 oC for 15 minutes before 
transferring to ice. The reaction was then transformed into competent bacteria cells via heat 
shock. 
 
2.2.4.4 Antarctic phosphatase treatment 
In most cases, DNA was inserted into vectors via ligation reactions. Vectors were prepared for 
ligation by digestion with the appropriate restriction enzymes (as described above), followed 
by Antarctic Phosphatase treatment to dephosphorylate the DNA and thus prevent unwanted 
re-ligation. To dephosphorylate the DNA, 4 µL of Antarctic phosphatase (5000 Units/mL; New 
England Biolabs), and 6 µL of Antarctic Phosphatase buffer (10x; New England Biolabs) were 
added to the heat inactivated restriction digest (containing 5-10 µg DNA). If the restriction 
digest contained less DNA (i.e. 1-2 µg of DNA), only 2 µL of Antarctic phosphatase was added, 
with 2 µL of AnalaR water added to make the volume up to 60 µL. Once prepared, the reaction 
was incubated at 37 oC for 35 minutes to ensure the DNA was completely dephosphorylated, 
followed by a 65 oC incubation for 35 minutes to inactivate the phosphatase. 
 
2.2.4.5 Ligation Reaction 
Once the dephosphorylated vectors were purified, the DNA fragments were inserted into the 
vectors using T4 DNA ligase (New England Biolabs).  
 
For the ligation reaction 100 ng of vector, 2 µL ligation buffer, 0.5 µL of ligase were added to 
enough insert DNA to form a either a 1:2, or 1:5 vector to insert Molar ratio, with enough 
water added to bring the total volume up to 20 µL. To test dephosphorylation of the backbone 
fragment the same reaction was prepared without insert DNA added and to test the level of 
digestion the same reaction was prepared without ligase. The reaction mixtures were then 
incubated at room temperature (22 oC) for 30 minutes. The mixtures were then either 
transformed into heat-shock bacteria, or purified (as described above) and electrotransformed 
into DH5α bacteria. 
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2.2.4.6 Gateway LR recombination based cloning 
DNA sequences were transferred from entry vector into destination expression vectors using 
LR Gateway reactions. BP and LR reactions are used by bacteriophage lambda phage to insert 
and excise DNA sequences into/from bacterial chromosomes. For cloning purposes, the LR 
reaction can be triggered in vitro by adding bacteriophage lambda recombination proteins and 
the E. coli-encoded protein Integration Host Factor. The reaction catalyses recombination 
between plasmids containing attL sites (in this case the entry vectors) and plasmids containing 
attR sites (in this case the destination vectors), thus the sequence between attL sites is 
transferred between the attR sites. The desired plasmid is selected by a combination of 
antibiotic resistance and the negative selection of the original Destination vector based on the 
presence of the lethal ccdB gene (Figure 2.1). 
 
DNA sequences were transferred from the pENTR3C entry vector into various destination 
vectors using the Gateway LR Clonase II Enzyme mix (Invitrogen), following the manufacturer’s 
instructions. 
 
2.2.5 Recombineering 
2.2.5.1 Annealing fragments 
The oligonucleotide pairs needed for galK mutagenesis and Wnt reporter generation (listed in 
Appendix 1) were annealed by diluting 10 μg of each oligonucleotide in a total of 100 μL TE 
Buffer, then boiling the diluted oligonucleotides after which the temperature was slowly 
dropped to room temperature using an Eppendorf Mastercycler PCR machines. Specifically, 
the PCR machine heated the mixture to 95 oC for 5 minutes to denature any secondary 
structures, and then slowly cool the mixture at the rate of 1 oC every minute until the mixture 
reached 25 oC. After annealing, the oligonucleotides were precipitated to remove the TE buffer 
salts by adding 10 μL of 3M NaOAc (Ajax Chemicals) and 250 μL of 100% ethanol (with 
pipetting to mix) and incubating at room temperature for 10 minutes. After the incubation, the 
oligonucleotides were centrifuged at 18,000 g and 4oC for 10 minutes, and the supernatant 
discarded. The annealed oligonucleotides were then washed by adding 250 μL of 70% ethanol, 
followed by a second spin at 18,000 g and 4oC for 10 minutes after which the supernatant was 
again discarded. The annealed oligonucleotides were resuspended in 50 μL AnalaR water to 
give a concentration of approximately 400 ng/μL (in the case of the oligonucleotides for galK 
recombineering) or 100 μL AnalaR water to give a concentration of approximately 200 ng/μL.  
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Figure 2.1: Gateway LR recombination based cloning. Gateway cloning uses site-specific 
recombination to transfer DNA sequences between vectors. The ‘Entry’ plasmid contains the 
region to be transferred (in this case ZIC2 CDS) flanked by attL1 and attL2 sites and a 
Kanamycin resistance CDS (KnR). The ‘Destination’ plasmid contains the ccdB gene flanked by 
attR1 and attR2 sites an ampicillin resistance CDS (AmpR). The LR Clonase Enzyme triggers a 
recombination event between the attL and attR sites, to transfer the region of interest into the 
‘Destination’ plasmid (to create the desired Expression plasmid), but also create a by-product. 
The resulted plasmids are transformed into DH5α bacteria, in which the by-product and 
original Destination plasmid are non-viable due to lethality of the ccdB gene. In addition, the 
DH5α bacteria are plated onto media containing Ampicillin on which the Entry clone is non-
viable. As such, only the bacteria containing the desired expression plasmid survive. 
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2.2.5.2 Preparing cells for electroporation 
For successful recombineering cells containing the plasmid of interest must first be prepared 
for electroporation and induced for recombineering via heat shock. For efficient 
electroporation, cells need to be harvested in the while undergoing growth. To acquire such 
bacterial cells a LB culture was inoculated with 1/50 of the volume of an overnight culture of 
cells, which was incubated at 32 oC until the OD600 reached 0.4 - 0.6. The culture was then 
divided into two flasks, one of which was incubated at 42 oC for exactly 15 minutes (the 
induced culture), and the other was left at 32 oC (the uninduced culture). After this time both 
cultures were placed on an ice bath for a minimum of 5 minutes. The cells were then pelleted 
via centrifugation at 2060 g and 0 oC for 10 minutes, after which the supernatant was 
discarded. The pellet was then washed by resuspending in 10 mL ice-cold sterile milliQ water 
or 10% glycerol and centrifuged at 2060 g and 0 oC for 10 minutes, after which the supernatant 
was again discarded. This wash step was repeated 3-4 times. After the final supernatant was 
discarded, the pellet was resuspended in the remaining liquid (about 100 μL). 
 
2.2.5.3 galK mutagenesis 
galK recombineering was used in one case to introduce a single base pair mutation into ZIC5.  
Cells containing the plasmid to be mutated were prepared for electroporation. After cells had 
been prepared, 50 µL of the cells were electroporated with 1 µL of the galK (approximately 
200 ng) gene, which had been amplified using PCR to contain 49 bp of homology on either end 
corresponding with the 49 bp to either side of the base to be mutated (see section 3.2.2.1). 
 
After the cells had recovered in 1 mL LB broth for 1 hour, they were washed to remove the LB 
broth by spinning the culture at 16,000 g for 15 seconds, then discarding the supernatant. The 
pellet was resuspended in 1 mL M9 salts and then centrifuged at 16,000 g for 15 seconds, after 
which the supernatant was discarded. This step was repeated a total of three times to remove 
all traces of LB broth. After the final spin, the cells were resuspended in 1 mL M9 salts, and 100 
µL of serial dilutions (100 μL of culture, 10 μL culture in 90 μl M9 salts and 1 μL culture in 99 μl 
M9 salts) of the induced culture and 100 μL of the uninduced culture were plated on minimal 
plates, with galactose and ampicillin [0.2% w/v galactose (Ajax Chemicals), 25 μg/mL 
ampicillin] and incubated at 32 oC for 4 days. Following this incubation, 3 colonies from these 
plates were streaked onto MacConkey agar plates (4% w/v MacConkey agar base, 1% w/v 
galactose, 25 μg/mL ampicillin) which were incubated at 32 oC for 2 days.  
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One bacterial colony which turned red on the MacConkey agar plate (indicating successful 
recombination) was then used to inoculate a 5 mL LB overnight culture from which cells were 
prepared for electroporation. The cells were then electroporated with 1 µL of a 99 bp 
annealed fragment containing the desired mutation surrounded by the same 49 bp homology 
regions. After the electroporation the bacteria were recovered in 10 mL LB for 4.5 hours. 1 mL 
of this culture was transferred to an eppendorf tube, and washed in M9 salts as above. 
Following the final re-suspension in 1 mL of M9 salts, 100 µL of serial dilutions (100 μL of 
culture, 10 μL culture in 90 μL M9 salts and 1 μL culture in 99 μL M9 salts) of the induced 
culture and 100 μL of the uninduced culture was plated on minimal plates with deoxygalactose 
and ampicillin [0.2% v/w deoxygalactose (Aldrich) and 0.2% glycerol (Mereck)] and incubated 
at 32 oC for 4 days. 
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2.3 Cell Culture 
2.3.1 Cell line and general cell maintenance 
For all cell based studies HEK293T cells were used (ATCC). The HEK293T cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) 
fetal bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen) and 0.1 mM non-essential 
amino acid solution (Invitrogen) (herein called DMEM with adds), on sterile tissue culture 
treated plasticware (Sigma-Aldrich). The cells were kept at 37 oC and 5% CO2 in a humidified 
incubator. 
 
To passage cells: media was discarded from the cells, which were first washed with Phosphate 
Buffered Saline (PBS) (140mM NaCl, 3mM KCl, 10mM phosphate buffer pH 7.4; Amersco). 
After the PBS was discarded, the cells were gently removed from the growth surface by 
addition of 0.5 g/L trypsin (Invitrogen; diluted in PBS) and incubation at 37 oC for five minutes. 
The supplemented DMEM was then added to inactivate the trypsin, and the entire cell/DMEM 
solution was repeatedly pipetted to homogenise the solution. The desired amount of cells was 
then transferred to fresh supplemented DMEM in new tissue culture treated plasticware. 
 
2.3.2 Transfection  
Cells were transfected at 60-90% confluency with LipofectamineTM 2000 (Invitrogen) according 
to the manufacturer’s protocol. Briefly, for a 12 well plate, 1.5-1.6 µg of the DNA to be 
transfected was diluted in 100 µL of DMEM without adds and 4 µg of LipofectamineTM 2000 
was diluted in 100 µL of DMEM without adds. The dilutions were then incubated at room 
temperature for 5 minutes. The LipofectamineTM 2000 dilution was then added to the DNA 
dilution which was then incubated at room temperature for 20 minutes. During this time the 
media on the cells that were to be transfected was replaced with fresh DMEM with adds. Once 
the incubation was complete, the lipofectamine/DNA mixture was added drop-wise to the 
cells, which were then gently rocked to mix and returned to the incubator. For larger or 
smaller dishes, the same protocol was used, but the amount of DNA, DMEM and 
LipofectamineTM 2000 was varied depending on the size of the dish (see Table 2.5 for 
amounts).  
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Dish type DMEM amount LipofectamineTM 
2000 amount 
DNA amount 
96 well plate 25 µL 0.5 µL 0.6 µL 
12 well plate 100 µL 4 µL 1.5-1.6 µg total 
6 well plate / 35mm 
dish 
250 µL 10 µL 4-4.5 µg total 
6 well plate (IF only) 125 µL 5 µL 2 µg total 
6 cm dish 500 µL 20 µL 8 µg total 
10 cm dish 1.5 mL 60 µL 24 µg total 
 
 
Table 2.5: Transfection amounts based on plate size. Amounts of DMEM, Lipofectamine™ 
2000 and DNA were varied based on size of tissue culture dish and thus the amount of cell. 6-
well plate is equivalent to 35 mm dish. 
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2.3.3 BIO treatment 
Wnt/β-catenin signalling levels of HEK293T cells was up-regulated by treatment with the 
GSK3β inhibitor (2’Z,3’E)-6-Bromoindirubin-3’-oxime (BIO). Cells were plated in 10 cm dishes 
and transfected with ZIC and SUMO expression constructs at 70-80% confluency, 6 hours after 
which the cells were replated into 2x10 cm dishes. 24 hours after transfection media was 
removed and replaced with either ‘untreated media’ (0.5% DMSO diluted in DMEM with adds) 
or ‘BIO treated media’ (5 μM BIO, 0.5% DMSO diluted in DMEM with adds), which was 
incubated for a further 24 hours before cells were processed and the resulting lysates 
analysed.  
 
2.3.4 Immunofluorescence 
Cells grown on coverslips (no.1 thickness, ProSciTech) in 6 well plates were transfected as 
described in Section 2.3.2. 24 hours after transfection, the media was removed from cells and 
replaced with 2 mL of 4% paraformaldehyde (PFA; ProSciTech) for 30 min to fix the cells. The 
cells were then washed 3 times with 2 mL of 1x PBS to remove any remaining PFA. After 
washing, the cells were incubated with 2 mL of 0.25% Triton X-100 (Sigma-Aldrich) in 1x PBS 
for 5 minutes to permeabilise the cells, then washed again three times with 2 mL of PBS. The 
cells were then incubated in 5% (w/v) skim milk (Diploma) in PBS either at room temp for 1 
hour or overnight at 4 oC to block any non-specific antibody reactions. 
 
Once blocked, cells were transferred to a humidifying chamber and  incubated with mouse 
anti-V5 (Invitrogen, at 1:200 dilution) and rabbit anti-Lamin B1 (Abcam, at 1:1000 dilution) 
antibodies diluted in 5% skim milk (w/v) (Diploma) in PBS for 1 hour at room temp. The cells 
were then washed 6 times with PBS before incubating for 1 hour at room temp with Alexa 
Fluor 594 anti-mouse (Molecular Probes; Invitrogen, at 1:500 dilution) and Alexa Fluor 488 
anti-rabbit (Molecular Probes; Invitrogen, at 1: 500 dilution) diluted in 5% (w/v) skim milk in 
PBS. The cells were then washed 6 times with PBS, before the coverslips were mounted onto 
glass slides with 2.4 mM n-propyl gallate [NPG, (Sigma) in a 1:1 solution of glycerol and PBS]. 
 
Cells were viewed and photographed using a DeltaVision Elite fluorescence microscope.  
 
2.3.4.1 Nuclear/cytoplasmic quantification 
Nuclear and cytoplasmic localisation of ZIC protein was quantified using the image processing 
software ImageJ. For each cell showing ZIC expression, the nucleus was traced based on the 
expression of LAMIN B1 and the average A594 fluorescence was calculated by ImageJ. The 
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cytoplasm of the same cell was then selected/traced and the average A594 fluorescence was 
calculated. The background average A594 expression was measure in three different sections 
of the image. These values were all exported in Excel, where the average background 
fluorescence was then subtracted from the nuclear and cytoplasmic fluorescence values and 
these adjusted values were used to calculate what percentage of the total protein was in the 
nucleus and the cytoplasm. 
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2.4 Cell Lysis and Western Blotting 
2.4.1 Nuclear/Cytoplasmic extraction 
Protein was extracted from cells and fractionated using the NE-PER Nuclear and Cytoplasmic 
Reagents (Pierce), following the manufacturer’s instructions, but altering the volumes. Briefly, 
(volumes are for a 35 mm dish) media was removed from cells and replaced with 100 µL of ice 
cold CER I buffer, with Protease Inhibitor (cOmplete, EDTA-free Protease Inhibitor, Roche) and 
Phosphatase Inhibitor (PhosStop Phosphatase Inhibitor Cocktail, Roche) added at final 
concentrations of 1X. Cells were gently scrapped to detach from the growth surface and the 
cell and CERI mixture was transferred to a 1.5 mL tube on ice, which was vortexed thoroughly 
and incubated for 10 minutes on ice. After the incubation, 5.5 µL CER II was added and cells 
were again vortexed followed by incubation on ice for one minute and a second vortex. Cells 
were then pelleted by centrifugation at 18,000 g for 15 minutes at 4 oC, with the resulting 
supernatant which represented the cytoplasmic fraction of the cells transferred to a new 1.5 
mL tube. To the pellet, 50 µL of NER, containing Protease Inhibitor and Phosphatase Inhibitor 
again added at a final concentration of 1X, was added and the cells were resuspended by 
vortexing thoroughly. The samples were then incubated on ice for 40 minutes, with vortexing 
every 10 minutes to mix. The samples were then pelleted by centrifugation at 18,000 g, for 25 
minutes at 4 oC and the resulting supernatant, which represented the nuclear fragment, was 
transferred to a new 1.5 mL tube. The cytoplasmic and nuclear fragments were then either 
used immediately or stored at -20 oC or -80 oC 
 
The amounts of lysis buffer used were varied with the size of the dish/amount of cells lysed. 
For 6 cm dishes 500 µL CER I, 27.5 µL CER II and 70 µL of NER was used. For 10 cm dishes 500 
µL CER I, 27.5 µL CER II and 500 µL of NER was used. Experiments to detect SUMOylated forms 
of proteins (see Chapter 5) also included Iodoacetamide (IAA; Roche) at final concentration of 
1 mM and N-Ethylmaleimide (NEM; Roche) used at final concentration of 0.1 mM in the CER I 
and NER buffers, which interfere with the deSUMOylation process and therefore stabilise the 
SUMOylated form (Jaffray and Hay, 2006; Suzuki et al., 1999).  
 
2.4.2 Sodium Dodecyl Sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein from cell lysates was separated by molecular weight (MW) on an acrylamide gel. 
Polyacrylamide 7% - 12% gels were made following the recipe in Table 2.6, and then while still  
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 7% gel 8% gel 10% gel 12% gel 
40% Acryl:Bisacryl (37.5:1) 
(Sigma-Aldrich) 
4.40 mL 5.00 mL 6.25 mL 7.5 mL 
1.5 M Tris pH8.8 (Merck) 6.25 mL 6.25 mL 6.25 mL 6.25 mL 
10% SDS (Roche) 0.25 mL 0.25 mL 0.25 mL 0.25 mL 
ddH20 13.85 mL 13.25 mL 12 mL 10.75 mL 
APS (Sigma-Aldrich) 0.125 mL 0.125 mL 0.125 mL 0.125 mL 
TEMED (Sigma-Aldrich) 0.0125 mL 0.0125 mL 0.0125 mL 0.0125 mL 
 
Table 2.6: Recipe for ‘running’ portion of polyacrylamide gel. Volumes are for two gels of 1.5 
mm thickness. 
 
 
 
 
 
 3.75% stacking gel 
40% Acryl:Bisacryl (37.5:1) 
(Sigma-Aldrich) 
0.94 mL 
1.5 M Tris pH8.8 (Merck) 6.25 mL 
10% SDS (Roche) 0.10 mL 
ddH20 6.36 mL 
APS (Sigma-Aldrich) 0.10 mL 
TEMED (Sigma-Aldrich) 0.01 mL 
 
Table 2.7: Recipe for ‘stacking’ section gel. Volumes are for two gels of 1.5 mm thickness. 
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liquid were cast in the Mini PROTEAN® casting apparatus (Bio-Rad), overlaid with hydrated 
butanol (Sigma-Aldrich) and left at room temperature to polymerise for 1 hour. After this time 
the butanol was removed and the gels were overlaid with a 3.75% stacking gel (recipe in Table 
2.7) (into which a comb was inserted to create wells for loading) which was again left to 
polymerise for 1 hour. 
 
To prepare the protein samples for SDS-PAGE, DTT (dithiothreitol; Sigma-Aldrich, at 20X) and 
NuPAGE LDS Sample Buffer (Invitrogen, at 4X) were added to the cell lysates to give a final 
concentration of 50 mM and 1X respectively. The samples were then heated at 90 oC for 5 
minutes to denature the proteins. 
 
Once the gel were fully polymerised and the samples were ready, the gels were placed into a 
BIORAD Mini PROTEAN® Tetra Cell apparatus which was then filled with 1X SDS-PAGE Running 
Buffer (192 mM Glycine, 24.9 mM TRIS base and 3.47 mM SDS). 5-30 µL of each sample were 
loaded into the separate wells of the gel. Alongside these samples, either 8 µL of PageRuler 
Prestained Protein Ladder (Fermentas) or 15 µL of Spectra Multicolour High Range Protein 
Ladder (Fermentas) to visual the protein separation during gel running and to determine 
approximate size of proteins after western blotting. Once loading was complete, 100 V was 
applied to the gel for 1.5-2.5 hours to separate the proteins, using the separation of the 
Protein Ladder as a guide for running time. Once the gel was run to an appropriate extent, the 
protein was transferred onto a membrane using wet transfer. 
 
2.4.3 Wet Transfer 
Once running was complete, the gel was removed from the tank and the stacking portion of 
the gel discarded. The gel was then placed on a piece of polyvinylidene difluoride (PVDF) 
membrane which were together sandwiched between four pieces of blotting paper (3 mm 
chromatography paper Whatman®) and two sponges, within a gel holder cassette. The 
assembly was completed while the gel and other components were submerged in 1x Towbin’s 
Buffer (190 mM Glycine, 24 mM Tris base and 20% methanol), to allow the gel to equilibrate 
and to reduce air bubbles. The gel holder cassette (containing the gel, PVDF, blotting paper 
and sponges) was transferred to a mini Trans-Blot Module (Bio-Rad) within a gel tank filled 
with 1X Towbin’s Buffer, and 15 V was applied overnight (16 hours) or 90 V was applied for 2 
hours to transfer the protein to the PVDF membrane. During this time the tank was 
surrounded by ice to minimise heating. 
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2.4.4 Western blotting 
Once transfer was complete the, PDVF membrane (to which the protein is now bound) was 
removed from the transfer apparatus and washed twice with MilliQ. The membrane was then 
blocked by covering with blocking buffer [5% skim milk (Diploma), 0.02% Tween 20 in PBS 
except for the GFP antibody, for which the PBS was replaced with TBS (Tris-Buffered Saline; 
50mM Tris, 150mM NaCl, pH7.5)] for at least 1 hour with agitation. After blocking, the 
membrane was exposed to a primary antibody (Table 2.8) diluted in 3 mL of the blocking 
buffer for 2 to 2.5 hours. The membrane was then washed with blocking buffer 6 times, with 
each wash lasting 5-10 minutes. The membrane was then exposed to the appropriate Horse 
Radish Peroxidase (HRP) conjugated secondary antibody (Table 2.9) diluted in 3 mL of the 
blocking buffer for 1-1.5 hours before washing with 0.02% Tween in PBS for 6 times with each 
wash lasting 5-10 minutes. 
 
Once the antibody incubations were complete the membrane was exposed to the SuperSignal 
West Pico Chemiluminescent Substrate (Pierce) for 5 minutes in darkness. The SuperSignal 
West Pico Chemiluminescent Substrate contains a substrate upon which the HRP tag of the 
secondary antibody can act to produce a Chemiluminescent signal, which is detected by X-ray 
film. Once the incubation was complete, the membrane was immediately exposed to X-ray film 
(CL-Xposure™ Film; Thermo Scientific or Amersham Hyperfilm MP; GE Healthcare Ltd.) for 5 
seconds to overnight (incubation time depended on the experiment and antibody used). Once 
exposed for the appropriate amount of time, the film developed by submersion in Multigrade 
Paper Developer solution (Ilford) for about 2 minutes, then fixed by submersion in Rapid Fixer 
solution. 
 
2.4.4.1 Relative protein Quantification 
The relative amount of SUMOylated ZIC protein with and without BIO treatment was 
quantified from western blots using the image processing software ImageJ. For each blot the 
amount of both SUMOylated ZIC and Tata Binding Protein (TBP) was measured by selecting 
lanes and using the ‘plot lane’ function. The relative SUMOylated ZIC levels were then 
calculated for each lane using Excel. 
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Target Protein Company/ Cat no. Species Dilution used 
β-CATENIN Santa Cruz, sc-1496 Goat, polyclonal 1/500 
FLAG Sigma, F1804 Mouse, monoclonal 1/1000 
GFP Cell Signalling, #2555 Rabbit, polyclonal 1/1500, TBS 
LAMIN B1 Abcam, ab16048 Rabbit, polyclonal 1/1500 
Tata binding protein (TBP) Abcam, ab818 Mouse, monoclonal 1/2000 
TCF7L2 Abcam, ab32873 Mouse, monoclonal 1/1000 
β-TUBULIN Abcam, ab7792 Mouse, monoclonal 1/1000 
UBC9 BD biosciences, 610748 Mouse, monoclonal 1/1000 
V5 Invitrogen, R960-25 Mouse, monoclonal 1/3000 
ZIC5 ANU Rabbit, polyclonal 1/500 
 
Table 2.8: Primary antibodies used for western blotting. 
 
 
 
 
 
Target Species Company/ Cat no. Species Dilution used 
Mouse Invitrogen, 616520 Rabbit 1/5000 
Goat Invitrogen, 811620 Rabbit 1/2500 
Rabbit Abacus ALS, J1711035152 Donkey 1/5000 
Mouse Invitrogen, A21203 Donkey 1/500 
Rabbit Invitrogen, A21206 Donkey 1/500 
 
Table 2.9: Secondary antibodies used for western blotting. 
  
68 
2.5 Reporter Assays 
2.5.1 Luciferase 
Cells that were plated in 12 well plates or 6 well plates were transfected at 70-80% confluency 
with reporter vector and with expression vector as described in Section 4.2.1 (amounts varied 
with experiment, see below for details). 5.5 hours after transfection, the cells of each well 
were dissociated from the growth surface be replacing the media with 0.5 g/L trypsin, and 
incubating the cells at 37 oC for 5 minutes. The trypsin was neutralised by addition of DMEM 
with adds, and the cells were replated into 3 wells of a 96 well white plate (Costar), at 
approximately 50% confluency. The remaining cells were replated into 6 well plates for 
western blot analysis. 24 hours after transfection the amount luciferase protein present within 
the cells was assayed by replacing the media in the 96-well plate with 100 μL of ONE-Glo 
Luciferase agent (Promega) diluted to 50% with no adds DMEM. The ONE-Glo Luciferase agent 
contains 5’-Fluoroluciferin, which is reduced by luciferase to form oxyfluoroluciferase with 
luminescence as a by-product. The intensity of luminescence produce was measured by the 
Promega Glomax luminometer, or the TECAN Infinite M1000 Pro. Where pooled data is 
shown, data represents at least three independent repeats. 
 
The following amounts/combinations of DNA were used for the luciferase assays: 
• ZIC5; ApoE reporter (in 96 well plates): 0.33 µg V5-ZIC5/ DEST, 0.3 µg pXP2-ApoE reporter. 
• ZIC5; ApoE reporter (in 12 well plates): 0.8 µg V5-ZIC5-WT, V5-ZIC5K393R or DEST, 0.8 µg 
pXP2-ApoE reporter. Also see Section 4.2.1.2. 
• ZIC5; Foxd3 reporter (in 12 well plates): 3 µg V5-ZIC5 (or DEST), 1 µg reporter, 0.5 µg DN-
UBC9 (or DEST). 
• ZIC5; Wnt inhibition (in 12 well plates): 2 µg V5-ZIC5 (or DEST), 1 µg reporter, 1 µg V5-β-
CATENIN and 0.5 µg DN-UBC9 (or DEST). 
• ZIC1 and ZIC4; Foxd3 reporter (in 12 well plates): 0.8 µg V5-ZIC (or DEST) and 0.8 µg 
pGL4.20-β-globin-Foxd3 reporter. 
• ZIC2 and ZIC3; Foxd3 reporter (in 12 well plates): 0.8 µg V5-ZIC (or DEST), 0.8 µg pGL4.20-
β-globin-Foxd3 reporter, 0.4 µg DN-UBC9 (or DEST). 
• ZIC1-3; Z3M2 reporter (in 12 well plates): 0.8 µg V5-ZIC (or DEST), 0.8 µg pGL4.20-β-globin-
Z3M2 reporter, 0.4 µg DN-UBC9 (or DEST). 
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• ZIC1-4 Wnt inhibition (in 6 well plates): 1 µg V5-ZIC, 1.5 µg pGL4.20-β-globin-TCFx3 
reporter, 1.5 µg β-CATENIN (ΔN89 or V5) and 0.5 µg DN-UBC9 (or DEST). 
 
2.5.2 BiFC protein-protein interaction assays 
Cells were transfected in 12 well plates with 0.8 µg V2-TCF7L2 and either 0.8 µg V1-ORF, 0.8 µg 
V1-ZIC-WT or 0.8 µg mutant V1-ZIC or in 6 well plates for the competition assays with the DNA 
combinations listed in Table 2.10. 24 hours after transfection, the cells of each well were 
dissociated from the growth surface be replacing the media with 0.5 g/L trypsin, and 
incubating the cells at 37 oC for 5 minutes. The trypsin was neutralised by addition of DMEM 
with adds, and the cells were replated into 3 wells of a 96 well white plate (Costar), at 
approximately 50% confluency, with the remainder replated in 6 well plates. 48 hours after 
transfection DMEM was removed from cells and replaced by PBS immediately prior to reading 
the plate with the Tecan Infinite M1000Pro. The fluorescence was measured with the 
excitation wavelength of 515 nm and the emission wavelength of 528 nm. Multiple reads 
(taken in a 4 by 4 square to give a total of 16 reads) were taken and averaged for each well to 
account for any difference in cell density within the wells. 
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 V2-TCF V1-ORF V1-ZIC-WT V5-ZIC-WT V5-DEST 
Background 1 µg 1 µg 0 µg 0 µg 2 µg 
No competition 1 µg 0 µg 1 µg 0 µg 2 µg 
0.5 µg competition 1 µg 0 µg 1 µg 0.5 µg 1.5 µg 
1 µg competition 1 µg 0 µg 1 µg 1 µg 1 µg 
2 µg competition 1 µg 0 µg 1 µg 2 µg 0 µg 
 
Table 2.10: Amount of DNA used in BiFC competition assay. 
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2.6 Embryo Hybridisation 
2.6.1 Mouse strains and Embryo collection 
The Zic5-K363R and the Zic5tm1Sia (Zic5 Null) (Furushima et al., 2005) strains of Zic5 were 
maintained on C57BL/6 background, in a cycle of 12 hours light then 12 hours dark beginning 
at 6 A.M. Embryos were dissected from the uterus and decidua in 10% (v/v) fetal bovine serum 
(Invitrogen) in PBS (Amersco) at 8.5 days dpc.  
 
2.6.2 Genotyping 
Ear biopsies were used to genotype adult mice and a fragment of the extra ectoplacental cone 
was used to genotype embryos. To each ear samples 50 µL of lysis solution (50 mM Tris-HCl 
pH8.8, 1 mM EDTA and 5% Tween 20) and 2 µL of Proteinase K (10 mg/mL) were added, 
whereas to the embryo samples 10 µL of lysis solution and 2 µL of Proteinase K were added. 
Samples were digested at 55 oC for 1 hour, followed by incubation at 95 oC for 10 minutes to 
inactivate the Proteinase K. 
 
The Zic5 Null lines were genotyped using previous described High Resolution Melt Analysis 
(HRMA) assay (Thomsen et al., 2012). The Zic5-K363R was genotyped using Allelic 
Discrimination. Briefly, 50 ng of DNA was amplified using the primers 5’-GGC CTT CCT GCG CTA 
CAT G-3’ and 5’-GGT CCA GCC ACT TGC AGA TG-3’, probes (wild-type): 5’ VIC – TCC CGC TTG 
ATT GG and (mutant): 5’ FAM – CTC CCG CCT GAT T and Platinum® Quantitative PCR SuperMix-
UDG w/ROX  (Life Technologies). The products were amplified and analysed on an ABI StepOne 
PCR machine. 
 
2.6.3 Riboprobe synthesis 
Plasmid pT7T3D-Foxd3 was linearized at the 5’ end of the Foxd3 fragment using HindIII 
restriction enzyme and gel purified. Antisense RNA probes were transcribed from 1 µg of 
linearized plasmid using T7 RNA polymerase (Roche) and labelled with Digoxygenin Labelling 
Mix (Roche) following the manufacturer’s instruction. After synthesis the remaining DNA was 
removed by digestion with 20 U of DNase I (RNase free, Roche), which was stopped by 
addition of EDTA (at final concentration of 16 mM). 
 
The probe was purified by precipitation. Briefly, LiCl (final concentration of 0.36 M) and 2.5 
volumes ethanol were added to RNA and precipitated at -20 oC overnight. The RNA was 
pelleted by centrifugation at 21,000 g at 4 oC for 20 minutes and the supernatant discarded, 
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followed by a 70% ethanol wash. The precipitated RNA was then resuspended in 100 µL of 
AnalaR H2O. To check the probe synthesis was successful 3 µL of resuspended probe was 
analysed by gel electrophoresis. Probes were stored at -20 oC. 
 
Whole Mount In Situ Hybridisation (WMISH) to Foxd3 was performed as previously described 
(Elms et al., 2003). After WMISH, embryos were post-fixed in 4% PFA and taken through a 
glycerol series to 100% glycerol. Embryos were photographed after using a Nikon SMZ 
Stereomicroscope and DS-Ril camera. 
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2.7 Analysis 
2.7.1 Bioinformatics Analysis 
Analysis of ZIC protein sequence for potential SUMOylation sites was performed using three 
programs: SUMOsp (Xue et al., 2006), SUMOplot Prediction (Abgent) and SUMOhydro (Chen et 
al., 2012). The region of the Foxd3 enhancer which was conserved between mouse and other 
species was identified using the Evolutionary Conserved Regions (ECR) browser (Ovcharenko et 
al., 2004). Potential protein binding sites within the conserved region of the Foxd3 enhancer 
were identified using the rVISTA comparative tool (Loots and Ovcharenko, 2004). 
 
2.7.2 Statistical Analysis 
For Luciferase and BiFC assays the Standard Deviation (S.D.) of the internal repeats of the 
representative experiment was calculated using Microsoft Excel. Pooled data was analysed 
using Genstat software to perform an analysis of variance (ANOVA) on a minimum of three 
external repeats and to calculate the Standard Error of the Mean (S.E.M.) of the means. For 
the Immunofluorescence nuclear/cytoplasmic quantification Genstat software was used 
perform an ANOVA on a minimum of two external repeats. For the quantification of 
SUMOylated ZIC +/- BIO treatment, Genstat software was used to perform a student’s T-test 
on a minimum of three external repeats. p values are shown in corresponding figure legends. 
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Chapter 3: Generating expression and reporter 
constructs for analysing the ZICs 
3.1 Introduction 
As there is variation in protein function between species, performing cell based assays with 
human ZIC expression constructs, rather than those of other species, would be the most 
relevant for understanding ZIC function to prevent human congenital defects during early 
development. While several studies have previously investigated ZIC function, many have not 
used human ZIC expression constructs. For example, some have used in vivo models which do 
not require ZIC expression plasmids (Blank et al., 2011; Elms et al., 2003) whereas others have 
focused on the ZICs of other species, such as mouse (Lim et al., 2010; Mizugishi et al., 2001) or 
Xenopus (Sato et al., 2005). Due to these and other factors, few plasmids were initially 
available for studying human ZIC function. As such, a large amount of this project was spent 
creating expression constructs, both for the human ZICs and for proteins such as TCF7L2 with 
which the ZICs are thought to interact (Pourebrahim et al., 2011). Various point mutations also 
needed to be introduced into these expression constructs, which due to the high GC content 
and length of the ZICs was not a straightforward process. In addition, several new roles of the 
ZICs have recently come to light, such as a role in repressing Wnt/β signalling (Fujimi et al., 
2012; Pourebrahim et al., 2011) and in activating an enhancer of the neural crest specifier 
Foxd3 during neural crest development (Simões-Costa et al., 2012), which have required 
generation of various new reporter constructs to better understand these roles.  
 
The large number of new constructs needed to complete this project has resulted in molecular 
cloning taking up a large portion of this PhD. As such, the following Chapter is dedicated solely 
to describing the generation of these various constructs (a list of all constructs created for this 
Chapter can be found in Appendix 2). 
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3.2 Results 
3.2.1 Generation of wildtype Entry constructs 
3.2.1.1 Generation of ZIC1 and ZIC4 pENTR3C constructs 
As described previously, the ZIC family in humans consists of five members. When this project 
began, other members of the Arkell Laboratory had already generated expression constructs 
containing cDNAs for ZIC2, ZIC3 and ZIC5 (described in Ahmed et al, 2013), but not for 
remaining members of the family, ZIC1 and ZIC4. In order to investigate the function of all five 
members of the family, constructs containing human ZIC1 and ZIC4 cDNA, called pcDNA-ZIC1 
and pcDNA-ZIC4 were obtained from Kathleen Millen. However, upon receiving and 
sequencing these plasmids it was realised that the ZIC4 construct was missing a 212 bp 
fragment of the N-terminal sequence (Figure 3.1), which falls over two exons. In order to 
obtain the full length gene, a plan was devised to reconstruct full length ZIC4 by amplifying the 
missing region from human genomic DNA. 
 
To recreate the fragment missing from the ZIC4 construct, the coding sequence of the two 
exons was PCR amplified off genomic DNA of HEK293T cells as two separate fragments, one of 
which is 89 bp (fragment A), the other 242 bp (fragment B; which also include some overlap 
with the section of cDNA found in the pcDNA-ZIC4 plasmid) (Figure 3.2a). The primers used in 
these PCRs were designed so that in addition to the 18-21 bp of homology to the ZIC4 genomic 
DNA sequence needed for the PCR, the 5’ ends of the primers both contained 9 bp of 
homology to the adjacent fragment, allowing the fragments to be joined via an overlap 
extension PCR (Heckman and Pease, 2007) to create fragment AB (see Figure 3.2b). To 
determine if the overlap extension PCR was successful, the resulting fragment was first 
confirmed to be the correct size via agarose gel electrophoresis (Figure 3.2b) and then 
sequenced. The remainder of ZIC4 was PCR amplified from pcDNA-ZIC4 (dubbed fragment C, 
Figure 3.2c), which was analysed via agarose gel electrophoresis and sequenced to confirm the 
correct fragment had been amplified. The primers used to amplify Fragment AB and Fragment 
C were designed so that the resulting fragments contained 18 bp of overlap, thus an overlap 
extension PCR could again be performed to join the fragments and consequently recreate full 
length ZIC4 (Figure 3.2d). The resulting full length fragment was analysed by agarose gel 
electrophoresis and sequenced to confirm the fragments had been seamlessly joined. 
 
At the same time the ZIC1 CDS was PCR amplified from pcDNA-ZIC1, analysed by agarose gel 
electrophoresis (Figure 3.3a) and sequenced to confirm no mutations were present. For both  
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Figure 3.1: Sequencing of pcDNA-ZIC4 demonstrates that a region of ZIC4 is missing from the 
plasmid. A sequencing read of pcDNA-ZIC4 is aligned with wildtype ZIC4 CDS. The sequencing 
read shows perfect alignment from 212 bp onwards of the ZIC4 CDS demonstrating that the 
sequencing was successful and that part of the ZIC4 was present. However, although the 
sequencing primer used was positioned within the vector background and thus should cover 
the entirety of ZIC4, the first section of the sequence read was shorter than expected, and 
showed little alignment to the ZIC4 CDS, suggesting a portion of the sequence was missing. 
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Figure 3.2: ZIC4 overlap extension PCR. a) Amplification of two exons of ZIC4. (i) 
Demonstration of the position of the two fragments amplified from human genomic DNA. 
Exon 2 (amplified to form fragment A) is shown in blue and Exon 3 (partially amplified to form 
fragment B) is shown in red. Note that the primers used to amplify these fragments were 
designed so that each of these fragments contains a small overlap with the other fragment. (ii) 
Gel electrophoresis analysis using a 2% agarose gel of the fragment A PCRs using three 
different buffers. ReddyMixKCl and ReddyMix buffers both showed a band consistent with the 
expected size of 98 bp (89 bp of intron 1 and 9 bp of homology to fragment B). (iii) Gel 
electrophoresis analysis using a 2% agarose gel of the fragment B PCRs using three different 
buffers. All buffers showed a band consistent with the excepted size of 251 bp (242 bp of 
intron 2 and 9 bp of homology to fragment A), although the ReddyMixKCl and ReddyMix 
buffers also showed several non-specific bands. b) Use of overlap extension PCR to join 
together the two exon fragments. (i) Diagram of overlap extension PCRs used to seamlessly 
join the two fragments. The overlap in sequence allows the two fragments to be joined in a 
PCR. (ii) Gel electrophoresis analysis using a 2% agarose gel of the overlap extension PCR using 
two different buffers. Both buffers tested showed a band consistent with expected size of 331 
bp. c) Amplification of remainder of ZIC4. (i) Remainder of ZIC4 (fragment C, shown in purple) 
was PCR amplified so that the fragment contained a small overlap in sequence with Fragment 
B. (ii) Gel electrophoresis analysis using a 1% agarose gel of the fragment C PCR testing three 
different buffers. All buffers showed a band consistent with the excepted size of 725 bp. d) 
Final overlap extension PCR to recreate full length ZIC4. (i) Diagram of overlap extension PCRs 
used to amplify the two fragments to recreate full length ZIC4. The overlap in sequence allows 
the two fragments to be joined in a PCR. (ii) Gel electrophoresis analysis using a 1% agarose gel 
of the overlap extension PCR using two different buffers. Both buffers tested showed a band 
consistent with expected size of 1030 bp. L = Ladder. 
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Figure 3.3: Generation of pENTR3C-ZIC1-WT and ZIC4-WT. a) PCR Amplification of ZIC1. Gel 
electrophoresis analysis using a 1% agarose gel of PCRs using two different buffers to amplify 
full length ZIC1. Both buffers tested showed a band consistent with expected size of 1376 bp. 
b) Illustration of In-Fusion cloning system. The In-Fusion system relies on regions of homology 
shared between the ends of the desired insert and the vector allowing incorporation of the 
insert sequence into the vector via recombination. c) Diagnostic digests of potential pENTR3C-
ZIC1-WT plasmids. Potential pENTR3C-ZIC1-WT plasmids were digested with the restriction 
enzyme EcoRI and the resulting fragments analysed by gel electrophoresis using a 1% agarose 
gel to determine size. Uncut plasmid samples were run on the same gel as a comparison. All 
plasmids showed bands consistent with the expected sizes of 1350 bp and 2296 bp. d) 
Diagnostic digests of potential pENTR3C-ZIC4-WT plasmids. Potential pENTR3C-ZIC4-WT 
plasmids were digested with the restriction enzyme EcoRI and the resulting fragments 
analysed by gel electrophoresis using a 1% agarose gel to determine size. Uncut plasmid 
samples were run on the same gel as a comparison. All plasmids, with the exception of plasmid 
three, showed bands consistent with the expected sizes of 1013 bp and 2296 bp if pENTR3C-
ZIC4-WT was correctly formed. For both (c) and (d) UC = Uncut, D = digested with EcoRI, L = 
Ladder. 
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ZIC1 and ZIC4, the primers used to amplify the full length genes contained an additional 15 bp 
at the 5’ end which consisted of homology to the pENTR3C vector, which allowed the full 
length ZIC1 and ZIC4 cDNAs to be inserted into the pENTR3C vector via the In-Fusion cloning 
system (Figure 3.3b and Section 2.2.4.3). The In-Fusion reaction generated 15 potential 
pENTR3C-ZIC1-WT and 30 potential pENTR3C-ZIC4-WT colonies, with no background detected. 
Eight pENTR3C-ZIC1-WT colonies and ten pENTR3C-ZIC4-WT colonies were mini-prepped and 
diagnostic digests were completed with the restriction enzyme EcoRI, which were analysed 
using agarose gel electrophoresis (Figure 3.3c and d). All but one of the DNA samples showed 
bands consistent with the expected 1350 bp and 2296 bp in the case of ZIC1 or 1013 bp and 
2296 in the case of ZIC4, indicating the In-Fusion reaction had correctly inserted the fragments. 
Sequencing was used to identify one pENTR3C-ZIC1-WT clone and one pENTR3C-ZIC4-WT clone 
with no unwanted side mutation, which were used for all downstream reactions. 
 
3.2.1.2 Generation of pENTR3C-TCF7L2 
During the completion of this thesis one member of the ZIC family, ZIC2, was reported to 
interact with the transcription factor TCF7L2 to inhibit Wnt/β-catenin signalling (Pourebrahim 
et al., 2011). As the ability of the ZICs to inhibit Wnt signalling was of particular interest to this 
project, it was decided a TCF7L2 expression construct was essential to better understand the 
ZIC based inhibition of Wnt/β-catenin signalling. Towards this end the pFLAG-CMV-TCF7L2 
(called pFLAG-CMV-TCF4 in Pourebrahim et al., 2011) expression plasmid was acquired from 
Sabine Tejpar. The TCF7L2 cDNA was PCR amplified from the pFLAG-CMV-TCF7L2, analysed by 
gel electrophoresis and sequenced, before insertion into the KpnI/EcoRI digested entry vector 
pENTR3C via a ligation reaction. Although the ligation produced some background, there was a 
greater than five-fold increase in the number of colonies on the ligation plate than the control 
plate. Four potential colonies were prepped and digested with KpnI/EcoRI to confirm the 
desired insert was present. As the diagnostic digests indicated all clones had the desired insert, 
sequencing was used to identify one pENTR3C-TCF7L2 clone with no side mutations which was 
used for further cloning. 
 
3.2.2 Mutagenesis 
As outlined in Chapter 5 all five members of the ZIC family contain high probability 
SUMOylation sites. To determine which of these sites undergo the modification lysine (K) to 
arginine (R) mutations needed to be introduced into these sites (for further explanation see 
Chapter 5). Some of these mutations were generated by other members of the Arkell 
Laboratory, either through overlap extension mutagenesis (in the case of ZIC5-K393R), 
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recombination (ZIC5-K522) or using a commercial site directed mutagenesis kit (in case of ZIC3-
K248R and ZIC3-K359R). However the majority of ZIC mutagenesis was completed as part of 
this thesis. As it has proved difficult in the past to mutate the ZIC CDSs using commercial kit 
based site directed mutagenesis (due to the length and high GC content of these genes), 
various PCR based methods, and in one case recombineering, were used to mutate these sites, 
as well as to introduce other mutations required for completion of this thesis. 
 
3.2.2.1 Generation of ZIC5-K4R 
Past attempts to introduce point mutations into ZIC5 using PCR based methods has always 
proven difficult, presumably due to the high GC content of ZIC5. As such, galK mutagenesis was 
used to introduce the Adenine to Guanine mutation that was needed to produce the ZIC5-K4R 
mutation.  
 
galK mutagenesis is a form of recombineering that relies on two properties of the SW102 
strain of bacteria: (1) the strain has genes that promote homologous recombineering and (2) 
the bacteria has been modified so that it can be selected either for the presence or the 
absence of the galK gene within plasmids. The first step is to introduce regions of homology 
onto the ends of the galK gene which correspond to the regions on either side of the base that 
is being mutated. The resulting fragment is introduced into bacteria which already contain the 
wildtype construct, which results in the bacteria attempting to ‘repair’ the linear galK fragment 
using homologous recombination. As a side effect of this ‘repair’, the DNA sequence between 
the two regions of homology on either end of the galK gene (in this case the base being 
mutated) is replaced with the galK (Figure 3.4a). Once the bacteria have undergone selection 
for this galK gene, a fragment containing the desired mutation with the same regions of 
homology mentioned above is introduced into the bacteria. The bacteria will once again 
attempt to ‘repair’ the fragment using homologous recombination, resulting in the desired 
mutation replacing the galK gene, thus generating the desired mutant construct (Figure 3.4b).  
 
To complete the first step of the ZIC5 mutagenesis, primers were designed to amplify the galK 
gene. In addition to 20-24 bp homology to galK, the forward primer also containing homology 
to the 48 bp upstream of the Adenine being mutated in P[acman]-ZIC5, and the reverse 
containing homology to the 48 bp downstream of the Adenine. Thus the PCR incorporated the 
appropriate regions of ZIC homology to the ends of galK. The resulting galK_K4 fragment was 
consistent with the expected 1231 bp fragment when analysed with gel electrophoresis. Once  
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Figure 3.4: Using galK recombination to introduce mutations. a) Homology (shown in blue) 
between the regions added to the ends of the galK gene and regions surrounding the base of 
interest allows the base of interest to be replaced with the galK gene (shown in black) via 
homologous recombination. The presence of the galK gene within the plasmid allows the 
bacteria which have successfully undergone this change to be selected for. b) Once the galK 
containing plasmid has been produced, the same regions of homology allow the galK gene to 
be replaced by the desired mutation, again via homologous recombination, recreating the 
original construct, but with the desired mutation (indicated by the star). The absence of the 
galK can be used to select plasmids which have successfully undergone this change. 
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the fragment was purified, the galK_K4 fragment was transformed into SW102 bacteria that 
contained the P[acman]-ZIC5 construct and that had been induced for homologous 
recombineering, as well as uninduced SW102 bacteria to estimated background. The two 
transformations were then plated onto minimal media plates with galactose as a carbon 
source. Theoretically only the bacteria that have undergone homologous recombination and 
therefore contain the galK gene will be able to digest the galactose on these plates and 
survive. However, after four and a half days there were about the same number of colonies on 
the control uninduced plate as the induced plate. That said, several of the colonies on the 
induced plate were much larger than any colonies on the uninduced plate, so two of these 
larger colonies, and one colony from the uninduced plate, were streaked onto MacConkey 
agar plates to check for the presence of the galK gene. While the uninduced colony appeared 
white, the induced colonies appeared pink due to the bacteria digesting galactose and in doing 
so producing an acidic by-product. The galK gene was therefore present. 
 
In order to replace the galK gene with the desired mutation, two complementary 
oligonucleotides were designed and then annealed to generate a K4R fragment. These 
oligonucleotides consisted of the desired mutation surrounded by the same regions of 
homology described for the galK primers. The K4R fragment was transformed into cells from 
the previous step (i.e. that contain the galK replacement) that had been induced for 
homologous recombination as well as an uninduced control. The transformations were both 
plated onto minimal media with deoxy-galactose, which should be toxic to bacteria still 
containing the galK gene. There were approximately equal numbers of small colonies on both 
the induced and the control plate; however once again there were two larger colonies on the 
induced plate. These colonies were mini-prepped and the resulting DNA dubbed P[acman]-
ZIC5R0A and P[acman]-ZIC5R0B. To acquire enough DNA for sequencing, P[acman]-ZIC5R0A 
and P[acman]-ZIC5R0B were transformed into Epi300 bacteria, which can be induced with 
arabinose to cause the P[acman] vector to act as a high copy number plasmid, and re-mini-
prepped.  
 
Attempts to sequence the plasmid failed, likely due to the large size of the P[acman] vector (13 
Kb). As such, both the ZIC5R0A and ZIC5R0B fragments were isolated from their relevant 
plasmids by digestion with the restriction enzyme EcoRI and inserted into EcoRI restriction cut 
and Antarctic phosphatase treated pENTR3C vector through a ligation reaction. The ZIC5 
inserts were joined to the vector in separate 1:1, 1:2 and 2:1 vector to insert ligation reactions. 
A control vector only was also completed to check that the vector was completely cut and that 
the Antarctic phosphatase treatment (which prevents self-ligation) went to completion. When 
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transformed into DH5α bacteria, the ligation showed a small increase over the control plate 
(but not the doubling or tripling of colonies as expected). The 1:1 and the 2:1 ligation showed 
the most colonies; therefore five colonies were picked from each of these plates and used to 
induce overnight cultures. As this was done for both the ZIC5R0A and the ZIC5R0B ligations, 
this gave a total of 20 cultures. However, only 12 of the 20 cultures showed the expected level 
of growth. The other eight cultures probably contained undigested or reformed pENTR3C 
which contains a toxic gene for negative selection. The twelve cultures were mini-prepped and 
digested with the restriction enzyme PstI to determine if ZIC5 was present as well as to 
indicate the orientation of ZIC5 (Figure 3.5a and b). The digestion identified ZIC5 positive 
clones for both ZIC5R0A and ZIC5R0B, however all identified ZIC5R0B clones had been inserted 
in the reverse orientation. These ZIC5 positive plasmids were sequenced with both ZIC5R0A 
and ZIC5R0B showing the mutation of interest (Figure 3.5c). As pENTR3C-ZIC5R0A was in the 
correct orientation, this plasmid was renamed pENTR3C-ZIC5-K4R, and used for downstream 
steps. 
 
3.2.2.2 Generation of ZIC1-K222R, and ZIC4-K125R 
Generation of both ZIC1-K222R and ZIC4-K125R took advantage of the close proximity of the 
site undergoing mutagenesis to a restriction enzyme site. For both ZIC1 and ZIC4 the base pair 
within the ZF-NC undergoing mutagenesis was positioned four base pairs away from a SacI 
restriction enzyme site (Figure 3.6a). As such, a method of mutagenesis was devised using a 
primer that contained both the desired mutation and was positioned so as to include the SacI 
restriction enzyme site. When the mutagenesis primer was used to PCR amplify a fragment of 
the appropriate ZIC the desired point mutation was introduced into the fragment. The SacI 
restriction enzyme site was then used to replace the corresponding portion of wildtype 
pENTR3C-ZIC to create the desired mutant clone.  
 
The two mutagenesis primers (one for each of ZIC1 and ZIC4) were tested with two different 
commercial buffers (ImmoMix and ReddyMix) with the resulting fragments analysed using gel 
electrophoresis. All amplifications gave a fragment consistent with the expected 694 bp for 
ZIC1 or 400 bp for ZIC4 (Figure 3.6b). Larger PCRs were therefore performed using ReddyMix 
and the resulting fragments were gel purified and sequenced to confirm the desired fragment 
had been amplified. KpnI and SacI restriction enzyme sites were then used to replace the 
wildtype segment of the corresponding ZIC with the mutant fragment via a ligation reaction. 
While the control ligation with no mutant insert had one colony in the case of pENTR3C-ZIC4,  
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Figure 3.5: ZIC5-K4R mutagenesis. a) Diagnostic digests of potential pENTR3C-ZIC5R0A 
plasmids. b) Diagnostic digests of potential pENTR3C-ZIC5R0B plasmids. For both (a) and (b) 
potential pENTR3C-ZIC5R0 plasmids were digested with the restriction enzyme PstI and the 
resulting fragments analysed by gel electrophoresis using a 1% agarose gel to determine size. 
Uncut plasmid samples were run on the same gel as a comparison. In total four plasmids 
showed multiple fragments after digestion consistent with a ZIC5 insert being present in the 
plasmid. However only one plasmid (indicated by an asterisk) showed bands consistent with 
the expected 680 bp, 1971 bp and 2534 bp bands expected if ZIC5 was in the correct 
orientation. c) Alignment of wildtype ZIC5 CDS with a sequencing read of pENTR3C-ZIC5R0A. In 
each case the protein translation of the sequence is shown below. The desired K4R mutation is 
indicated by an asterisk. 
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Figure 3.6: Generation of ZIC1-K222R and ZIC4-K125R. a) The position of the mutagenesis 
primer overlaps both the point of mutation (indicated by asterisk) and a SacI restriction 
enzyme site. ZIC1 is shown, but this region of ZIC4 differs by only one base pair. b) Gel 
electrophoresis analysis using 1% agarose gels of the PCR amplification of the (i) ZIC1-K222R 
and (ii) ZIC4-K125R mutant fragments tested with two buffers. Both buffers showed bands 
consistent with the expected sizes of 694 bp for ZIC1-K222R and 400 bp for ZIC4-K125R. c) 
Diagnostic digests of potential pENTR3C-ZIC4-K125R plasmids. Potential pENTR3C-ZIC4-K125R 
plasmids were digested with the restriction enzyme XmaI and the resulting fragments analysed 
by gel electrophoresis using a 2% agarose gel to determine size. Uncut plasmid samples were 
run on the same gel as a comparison. All plasmids showed bands consistent with the expected 
sizes of 495 bp and 2814 bp. d) Alignment of wildtype ZIC CDS with sequencing reads of 
generated plasmids showing the desired ZIC1-K222R and ZIC4-K125R point mutations are 
present (mutations indicated by asterisk. L = Ladder, ntc = no template control.  
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and no colonies for pENTR3C-ZIC1, the ligation plates both had over 50 colonies, suggesting 
the background of wildtype ZIC should be very low. As such, only four colonies were mini-
prepped for each of the two ligations. To confirm the pENTR3C-ZIC1-K222R and pENTR3-ZIC4-
K125R had correctly formed, diagnostic digests were performed with EcoRI in the case of ZIC1 
and XmaI in the case of ZIC4, with the results analysed by gel electrophoresis (Figure 3.6c). All 
pENTR3C-ZIC1-K222R clones showed bands consistent with the expected 1350 and 2296 bp 
and all pENTR3C-ZIC4-K125R clones showed bands consistent with the expected 495 and 2814 
bp, suggesting the ligation was successful. The presence of the mutation was confirmed in all 
clones via sequencing (Figure 3.6d). Sequencing was also used to identify a pENTR3C-ZIC1-
K222R clone and a pENTR3C-ZIC4-K125R clone with no secondary mutations, which were used 
for all further experiments. 
 
3.2.2.3 Generation of ZIC2-K253R and ZIC1-K333R 
The ZIC2-K253R and ZIC1-K333R constructs could not be generated using the previous method, 
as the site of mutation was not located close to a restriction enzyme target site. For this reason 
overlap extension PCR was used to generate these mutations. Mutagenesis via overlap 
extension PCR involves amplifying the gene being mutated as two fragments: one fragment 
from the start of the gene to the point of mutation (dubbed LF) and the other from the point 
of mutation to the end of the gene (dubbed RF) (Figure 3.7a). In each case, the primer 
overlapping the point of mutation is designed so that it contains the mutation of interest; the 
initial PCR amplification therefore introduces the desired mutation into the two fragments. 
The primers overlapping the site of mutation are also designed so the LF and RF fragments 
contain at least 18 bp of overlap. The fragments can therefore be joined using an overlap 
extension PCR in which the overlapping regions (at the site of mutagenesis) anneal and act as 
primers causing the original gene to be reformed, but now containing the mutation of interest. 
 
The LF and RF fragments were amplified using two sets of primers. In each set, one of these 
primers was 37 bp long, for which 21 bp corresponded to the start or end of the appropriate 
ZIC and the remainder corresponded to the sequence of pENTR3C, which was needed once the 
mutagenesis was complete for inserting the mutated cDNA into the vector. The other primer in 
each of these sets is 30 bp long and has been designed so that the desired mutation falls in the 
middle of the primer. The two primers over the site of mutation are also designed to be the 
reverse complement of each other, thus the resulting fragments would have 30 bp of overlap. 
The ZIC1 and ZIC2 LF and RF fragments were amplified using PCR and analysed using gel 
electrophoresis. The fragments were consistent with the expected sizes of 1023 bp for ZIC1-LF, 
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375 bp for ZIC1-RF, 808 bp for ZIC2-LF and 906 bp for ZIC2-RF (Figure 3.7b), consequently the 
fragments were gel purified to remove any remaining template, and sequenced to check the 
correct fragment had been amplified. While the majority of sequencing showed the desired 
fragments, a small region of the ZIC2-LF failed to produce a clean read.  
 
As the remainder of the sequencing read showed the desired ZIC2 fragment was present, the 
mutagenesis process was continued. In each case, the two fragments were joined via overlap 
extension PCRs to recreate full length ZIC1 and ZIC2 with the desired mutations. In both cases 
the overlap extension PCR resulted in a single band when analysed with gel electrophoresis, 
which was consistent with the expected size of 1376 bp for ZIC1-K333R and 1764 bp in the 
case of ZIC2-K253R (Figure 3.7c). To confirm that the fragments had been generated correctly, 
both were sequenced. While the sequencing of ZIC1-K333R showed that the full length 
fragment had formed correctly, a region in the 3’ of the ZIC2-K253R sequencing produced 
multiple reads. It was eventually determined that during the ZIC2-K253R PCR product had lost 
a small 148 bp fragment (Figure 3.8). The multiple reads were due to the size of the missing 
fragment varying slightly between different PCR products. 
 
To determine if this deletion occurred as part of the original PCR, ZIC2-RF was digested with 
the restriction enzyme NotI, which has a target site within the missing segment. ZIC2-LF was 
also digested with NotI to act as a positive control. Gel electrophoresis analysis of ZIC2-LF 
showed two bands consistent with the expected 317 bp and 490 bp fragments, indicating the 
enzyme was functional [Figure 3.9a(i)]. RF, on the other hand, showed no evidence of cutting, 
with gel electrophoresis analysis showing only a single fragment, not consistent with the 
expected 316 bp and 662 bp if the entire fragment was present [Figure 3.9a(ii)], indicating that 
the 148 bp deletion occurred during the original ZIC2-RF PCR. In order to generate the full 
length ZIC2-RF fragment the original PCR conditions were modified and assessed for any 
changes in band size. The PCR was repeated using three different buffers, all tested at six 
different annealing temperatures, but no difference in the band size when analysed using gel 
electrophoresis was detected (data not shown). The PCR was then retested using a shorter end 
primer, with the DNA digested before the PCR and with DMSO added to the PCR. Only adding 
DMSO produced a notable shift in band size (Figure 3.9b). To confirm that the full length 
fragment had now been amplified, the remainder of the PCR with DMSO was purified and 
digested with NotI. The resulting fragments were analysed using gel electrophoresis and were 
consistent with the expected bands at 316 bp and 662 bp (Figure 3.9c) confirming the missing 
region was present. The ZIC2-RF PCR was thus repeated under these conditions, gel purified 
and sequenced. 
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Figure 3.7: Overlap extension PCR mutagenesis to generate pENTR3C-ZIC2-K253R and 
pENTR3C-ZIC1-K333R. a) Illustration of method to seamlessly introduce mutations into 
plasmids via overlap extension PCR. (i) First the wildtype CDS is PCR amplified as two 
fragments. The primers used to amplify these regions are designed to incorporate the desired 
mutation into the fragments during the PCR process and so that the two fragments contain a 
small region of overlap. (ii) The two fragments are seamlessly joined via an overlap extension 
PCR to recreate the wildtype CDS with the desired mutation. b) Gel electrophoresis analysis 
using a 1% agarose gel of the LF and RF mutagenesis fragments. (i) PCR amplification of the 
ZIC1-LF and ZIC1-RF fragments was tested using two buffers. Both buffers produced a band 
consistent with the expected size of 1023 bp for ZIC1-LF and 375 bp for ZIC1-RF. (ii) PCR 
amplification of the ZIC2-LF and ZIC2-RF fragments was tested using ImmoMix. The bands 
produced were consistent with the expected sizes of 808 bp for ZIC2-LF and 906 bp for ZIC2-
RF. c) Gel electrophoresis analysis using a 1% agarose gel of the overlap extension PCRs to 
create (i) ZIC1-K333R and (ii) ZIC2-253R. The bands produced were consistent with the 
expected 1376 bp for ZIC1-K333R and 1764 bp for ZIC2-K253R. L = Ladder, ntc = no template 
control.  
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Figure 3.8: Sequencing of ZIC2 showing position of deletion. A sequencing read of the 
potential pENTR3C-ZIC2-K253R plasmid aligned with the wildtype ZIC2 CDS shows 148 bp of 
the ZIC2-K253R sequence is missing. The identical sequence on either side of the missing 
region is underlined by purple boxes. 
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Figure 3.9: Analysis of region missing from ZIC2-K253R. a) Diagnostic digests of (i) ZIC2-LF and 
(i) ZIC2-RF. The fragments were digested with the restriction enzyme NotI and the resulting 
fragments analysed by gel electrophoresis to determine size. Uncut samples were run on the 
same gel as a comparison. Although digestion of ZIC2-LF produced two bands consistent with 
the expected size of 317 bp and 490 bp, indicating the NotI enzyme was functioning correctly, 
digestion of ZIC2-RF produced no difference in size compared to the uncut sample, suggesting 
the restriction enzyme site is missing. b) Gel electrophoresis analysis of the ZIC2-RF PCR 
amplification with and without DMSO. The addition of DMSO produces a notable increase in 
size of the ZIC2-RF fragment. c) Diagnostic digests of the ZIC2-RF fragments produces when 
DMSO is present. The fragments were digested with the restriction enzyme NotI and the 
resulting fragments were analysed by gel electrophoresis to determine size. Uncut samples 
were run on the same gel as a comparison. Digestion of ZIC2-RF produced two bands 
consistent with the expected size of 316 bp and 662 bp, the entire fragment is now present. 
For (b-c) lanes marked (a) used primer 1168, and lanes marked (b) used a shorter primer, 
primer 1309. L = Ladder, ntc = no template control. All analysis used 1% agarose gels. 
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Once the purified correct ZIC2-RF was obtained the overlap extension PCR was repeated. Given 
the problems that occurred previously when amplifying the RF fragment, this overlap 
extension PCR was tested using with and without the addition DMSO. Once again the addition 
of DMSO produced a notable increase in the size of the ZIC2-K253R fragment when analysed 
using gel electrophoresis. The larger fragment produced by the addition of DMSO was gel 
purified and sequenced before being transferred into pENTR3C using the In-Fusion cloning 
system. Ten of the resulting colonies were mini-prepped and digested with the NotI restriction 
enzyme. When analysed using gel electrophoresis, six of the digests gave a banding pattern 
consistent with the expected fragments of 316 bp, 1122 bp and 2596 bp. The corresponding six 
DNA samples were sequenced showing the presence of the desired mutation (Figure 3.10b) 
with a clone showing no unwanted side mutations used for all downstream applications. 
 
The ZIC1-K333R fragment was inserted into pENTR3C, using KpnI and XhoI restriction enzyme 
sites. Essentially, both the ZIC1-K333R fragment and pENTR3C were digested with SacI and 
XhoI and the desired fragments gel purified. The digested fragment and pENTR3C were then 
joined in a ligation reaction, alongside a vector only control. The vector only control produced 
no colonies, whereas the ZIC1-K333R ligation produced over 100, therefore it was assumed 
very little background would be present. As such only four colonies were mini-prepped and 
digested with the EcoRI restriction enzyme to determine if ZIC1 was present. All clones showed 
bands consistent with the 1350 and 2296 bp predicted if ZIC1 was present (Figure 3.10a), 
therefore the clones were sequenced. One sample which showed the desired K333R mutation 
(Figure 3.10b) with no side mutations was used for all down-stream applications. 
 
3.2.2.4 Generation of ZIC5-C528S 
Aside from the forms of ZIC containing lysine to arginine mutations within the potential 
SUMOylation sites, other mutated forms of ZIC were also required for the completion of this 
project. For example, a non DNA binding form of ZIC5 was needed. Mutagenesis of ZIC5 by PCR 
based methods has previously proven difficult due to the length and high GC content of ZIC5. 
In particular, attempts to PCR across the entirety of ZIC5 have failed (Arkell Laboratory, 
unpublished observation), which has prevented mutagenesis by overlap extension PCR and has 
necessitated the use of recombineering. However, introducing mutations into ZIC5 using 
recombineering is a lengthy process and therefore undesirable. In order to avoid using 
recombineering to introduce the mutation into ZIC5, the overlap extension mutagenesis 
process was modified so that only a section of ZIC5 needed to be amplified which overcame 
the previous problems with mutating ZIC5 via PCR. 
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Figure 3.10: Analysis of ZIC1-K333R and ZIC2-K253R. a) Example diagnostic digests of potential 
pENTR3C-ZIC1-K333R plasmids. Potential pENTR3C-ZIC1-K333R plasmids were digested with 
the restriction enzyme EcoRI and the resulting fragments analysed by gel electrophoresis using 
a 1% agarose gel to determine size. Uncut plasmid samples were run on the same gel as a 
comparison. In all cases digestion production produced two bands consistent with the 
expected sizes of 1350 bp and 2296 bp if pENTR3C-ZIC1-K333R had formed correctly. b) 
Sequencing reads of (i) ZIC1-K333R and (ii) ZIC2-K253R in each case aligned with the relevant 
wildtype CDS. The asterisk marks the desired mutation. L = Ladder, UC = Uncut plasmid, E = 
EcoRI cut plasmid.   
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As mutation of the second cysteine of the fourth zinc finger of ZIC2 has previously been shown 
to prevent DNA binding (Brown et al., 2005), the non DNA binding form of ZIC5 was generated  
by mimicking this mutation, to generate C528S. As before, mutagenesis via overlap extension 
PCR involved amplifying the ZIC5 gene in two fragments: ZIC5-LF and ZIC5-RF. Given the 
problems that have occurred previously when PCR amplifying ZIC5, two different potential RF 
fragments were attempted: the first used a primer situated 25 bp prior to the end of the ZIC5 
CDS (called fragment ZIC5-RFA), whereas the other used a primer positioned 86 bp after the 
end of the ZIC5 CDS (called fragment ZIC5-RFB) (Figure 3.11a). Rather than amplifying the 
entire start section of the gene the primers amplifying ZIC5-LF were designed so as to only 
cover the region 597 bp prior to the mutation. In each case the fragments were amplified with 
the same commercial buffer (ImmoMix), but were trialed initially both with and without 
DMSO. Under analysis by gel electrophoresis, both the ZIC5-RFA and ZIC5-LF showed a product 
consistent with the expect sizes (of 522 bp and 597 bp respectively) when amplified in the 
presence of DMSO, however ZIC5-RFB showed no amplification under any conditions (Figure 
3.11b). Consequently, ZIC5-RFA and ZIC5-LF were used for remainder of the mutagenesis. 
 
The ZIC5-RFA and ZIC5-LF were joined together via an overlap extension PCR. When analysed 
via gel electrophoresis, this overlap extension PCR produced a band consistent with the 
expected size of 979 bp. The fragment was thus purified and sequenced to confirm the desired 
ZIC5 mutant fragment was present. To introduce the mutation into pENTR3C-ZIC5, a 
SacI/BstEII fragment was digested and purified from the overlap extension PCR. pENTR3C-ZIC5 
underwent the same digestion and the vector backbone and start of ZIC5 fragment was 
purified. The two fragments were then joined via a ligation reaction to recreate full length ZIC5 
with the desired C528S mutation. Four of the resulting colonies were mini-prepped and 
sequenced, with all showing the desired mutation (Figure 3.11c). One clone which showed no 
unwanted side mutations was used for all further experiments. 
 
3.2.2.5 Generation of pENTR3C-ZIC3-K248R;C365S 
For the experiments of Chapter 7, a version of ZIC3 containing two different mutations (K248R 
and C365S) was required. To create such a construct, sections of pENTR3C-ZIC3-K248R and 
pENTR3C-ZIC3-C365S were isolated and joined together to recreate pENTR3C-ZIC3 containing 
both the mutations (Figure 3.12a). To achieve this goal, the two constructs were digested with 
HinCII which cuts pENTR3C-ZIC3 constructs before start of ZIC3 and within ZFD between the 
two mutations. The desired portions of these two constructs were then isolated via gel 
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purification (with the larger fragment containing the vector backbone first Antarctic 
phosphatase treated) and joined together in a ligation reaction. The original constructs were 
digested with only a single enzyme: as such it is likely that this ligation would result in the 
fragments joining in both the desired orientation and with one fragment in the reverse 
orientation. The resulting bacterial colonies were therefore assessed by colony PCR to identify 
those containing the desired arrangement (Figure 3.12b). Six such colonies were mini-prepped 
and sequenced. One clone that showed the desired mutations with no side mutations was 
used for all down-stream applications. 
 
3.2.3 Generation of UBC9 fusion constructs 
To generate the UBC9-ZIC fusion constructs required for Chapter 5, UBC9 CDS with the stop 
codon removed was inserted at the 5’end of the ZIC CDSs within the various pENTR3C-ZIC 
constructs. UBC9 CDS was PCR amplified from pSG5-HA-hUBC9 (Chang et al., 2007) with 
primers designed to both remove the stop codon sequence and add KpnI restriction enzyme 
sites. The resulting fragment was analysed by gel electrophoresis to confirm the amplified 
fragment was consistent with the expected 490 bp before purification. The UBC9 fragment and 
14 different pENTR3C-ZIC plasmids were then digested with the KpnI restriction enzyme. After 
digestion the pENTR3C-ZIC plasmids were treated with Antarctic phosphatase to prevent the 
original plasmids from reforming during the ligation reaction without the desired insert. The 
digested UBC9 was then inserted into the digested pENTR3C-ZIC plasmids via a ligation 
reaction. 
 
All ligation reactions included vector only controls, which in each case produced fewer colonies 
than the ligation plates, indicating a low level of background was present. In the case of each 
of the ZIC2, ZIC3 and ZIC5 pENTR3C constructs ten of the colonies resulting from the ligation 
were mini-prepped and digested with the restriction enzymes PstI and StuI to determine if 
UBC9 was present and in the correct orientation. In the case of ZIC1 and ZIC4, ten colonies for 
each of the wildtype and mutant constructs were screened using a colony PCR for the 
presence of UBC9 (Figure 3.13a). Three or four of the colonies that showed the presence of 
UBC9 were mini-prepped and the resulting DNA was digested with PstI and StuI to determine if 
the UBC9 was in the correct orientation (Figure 3.13b). In all cases, constructs found to contain 
Ubc9 were sequenced and one clone for each of the constructs that showed no side mutations 
was used for further experiments. 
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Figure 3.11: Generation of pENTR3C-ZIC5-C528S. a) Diagram of ZIC5 CDS demonstrating the 
position of C528 (orange) and of three primers (green) used to mutate the site. Two additional 
primers (one forward and one reverse) are situated at the site of the desired C528 mutation. 
Also shown are the target sites of the SacI and BstEII restriction enzymes. b) Gel 
electrophoresis analysis using a 1.5% agarose gel of the ZIC5-RFA, the ZIC5-RFB and the ZIC5-LF 
PCR amplifications with and without DMSO. Although a band consistent with the expected size 
of 522 bp appeared for ZIC5-RFA in both the presence and absence of DMSO, a band 
consistent with the expected size of 597 bp appeared for ZIC5-LF only in the presence of DMSO 
and no bands appeared for ZIC5-RFB. c) Two sequencing reads of pENTR3C-ZIC5-C528S aligned 
with wildtype ZIC5 CDS. In each case the protein translation is shown below. C528 and base 
mutated are highlighted yellow. L = Ladder, D = DMSO included in PCR, ntc = no template 
control. 
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Figure 3.12: Generation of pENTR3C-ZIC3-K248R;C365S. a) Diagram of the method of placing 
the two mutations in tandem. The pENTR3C-ZIC3-K248R and pENTR3C-ZIC3- C365S plasmids 
were digested with HinCII, which in both cases produced two fragments. In each case the 
fragment contain the point mutation was isolated, after which the two mutant fragments were 
joined together to recreate pENTR3C-ZIC3, but containing both mutations. b) Gel 
electrophoresis analysis using a 1% agarose gel of pENTR3C-ZIC3-K248R;C365S colony PCRs. 
Potential colonies were resuspended in water, a small amount of which was used as template 
for two independent colony PCRs. (i) Colony PCR using primers 1256/1172, which should give a 
470 bp fragment if the desired plasmid is present and a larger fragment if the wrong plasmid is 
present. (ii) Colony PCR using primers 1225/1153, which are positioned within the ZIC3 
sequence and thus will give a 1298 bp fragment if ZIC3 is present. Both PCRs identified the 
same six colonies as representing pENTR3C-ZIC3-K248R;C365S. +ve = positive control, ntc = no 
template control and L = Ladder 
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Figure 3.13: Screening of potential UBC9 fusion plasmids. a) Example of a colony PCR for the 
presence of UBC9. Potential colonies were resuspended in water, a small amount of which was 
used as template for the colony PCR. Primers used for the PCR were positioned outside the 
UBC9 sequence so that a fragment was produced in both the presence and absence of UBC9. 
However, the presence of UBC9 increases the size of the fragment by 474 bp to give a total 
size of 914 bp. When analysed by gel electrophoresis using a 1% agarose gel, six colonies which 
contain a fragment consistent with the presence of UBC9 are indicated by an asterisk. ntc = no 
template control, -ve = negative (no UBC9) control. b) Example of diagnostic digests of 
potential pENTR3C-UBC9-ZIC plasmids. Potential pENTR3C-UBC9-ZIC plasmids were digested 
with the restriction enzymes SacI and StuI and the resulting fragments analysed by gel 
electrophoresis using a 1.5% agarose gel to determine size. Uncut plasmid samples were run 
on the same gel as a comparison. Two of the plasmids (indicated by asterisk) showed bands 
consistent with the expected sizes of 472 bp and 3320 bp if UBC9 was present in the correct 
orientation. In the other plasmids UBC9 was likely inserted in the opposite orientation. L = 
Ladder.   
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3.2.4 Conversion to expression constructs 
All the construct building described so far was undertaken in the pENTR3C vector which has 
been designed purely for cloning and will not express the integrated ZIC CDSs. However, the 
pENTR3C plasmid is designed with this issue in mind and as such is able to undergo a Gateway 
Technology Left Right (LR) reaction (for more detail see Chapter 2) to transfer the ZIC CDSs into 
various expression constructs. For all of the ZIC constructs generated within this Chapter an LR 
reaction was undertaken to transfer the ZIC CDS into pcDNA3.1/nV5-DEST™, which as well as 
acting as an expression vector adds a V5 epitope tag to the ZIC CDS for western blot detection. 
All wildtype and SUMOylation consensus site mutated ZIC constructs without the Ubc9 fusion 
were also transferred via a LR reaction into pDEST-V1-ORF, which acts as an expression 
construct in mammalian cell lines, but also adds the N-terminal half of a modified GFP protein 
(called Venus) to the 5’ terminal of the ZIC for BiFC experiments of Chapter 7. TCF7L2 was 
transferred via an LR reaction into pDEST-V2-ORF, which acts as an expression construct in 
mammalian cell lines and also adds the C-terminal half of the GFP protein to the 5’ terminal of 
TCF7L2 for BiFC experiments of Chapter 7. In each case two of the resulting colonies were 
mini-prepped and digested to confirm the LR reaction was successful, after which the entire 
ZIC or TCF7L2 CDS was sequenced to confirm no side mutations had been produced during the 
LR reaction. 
 
3.2.5 Generation of SUMO1 expression constructs 
The experiment of Chapter 5 required a SUMO1 expression construct. To generate such a 
construct the SUMO CDS was amplified from pEYFPC3-SUMO1 (Harder et al., 2004) with 
primers which added a BamHI restriction enzyme site to the 5’ end and a XhoI restriction site 
to the 3’ end of SUMO1. The generated fragment and the empty pENTR3C vector were then 
digested with these restriction enzymes and joined together in a ligation reaction to create 
pENTR3C-SUMO1-WT. 
 
These sites were used to insert the SUMO1 CDS into the pENTR3C vector. A negative control 
form of SUMO was also produced. Normally, the SUMO protein is translated as a non-
functional form of the protein, which is then cleaved by sentrin-specific proteases (SENPs) to 
release a di-glycine motif through which the SUMO protein binds target proteins (Kamitani et 
al., 1997; Mukhopadhyay and Dasso, 2007). To produce the negative control form of SUMO-1, 
a cDNA of SUMO1 missing the critical di-glycine motif was synthesised and cloned into 
pENTR3C by the commercial company GenScript, to produce pENTR3C-SUMO1-ΔGG. 
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3.2.5.1 Generation of EGFP-SUMO1 expression construct 
In order for SUMO1 protein to be expressed in mammalian cells, the wildtype SUMO1 CDS was 
inserted into the pEGFP-C1 empty vector. To transfer the wildtype SUMO1 CDS into this 
construct, the SUMO1 CDS was amplified from pEYFPC3-SUMO1 with primers which added a 
BglII restriction enzyme site to the 5’ end and a KpnI restriction site to the 3’ end of SUMO1. 
The generated fragment and the empty pENTR3C vector were then digested with these 
restriction enzymes and joined together in a ligation reaction to create EGFP-SUMO1. 
 
3.2.5.2 Generation of EmGFP-SUMO1 expression constructs 
A second SUMO-1 expression construct was also created. To create these constructs, the two 
versions of SUMO to be expressed in mammalian cell lines were transferred into the 
destination construct Vivid colors pcDNA 6.2/N-EmGFP-DEST (Life Technologies) via a Gateway 
L-R reaction. pcDNA 6.2/N-EmGFP-DEST acts as both an expression construct for SUMO1 and 
adds a GFP tag for detection during western blots. In each case two of the resulting colonies 
were mini-prepped and digested to confirm the L-R reaction was successful, after which the 
SUMO1 CDSs were sequenced to confirm no side mutations had been produced during the L-R 
reaction. 
 
3.2.6 Generation of Wnt/β-catenin Reporter constructs 
In order to determine the effect of ZIC inhibition on Wnt/β-catenin signalling (see Chapter 4) 
several different Wnt/β-catenin reporter constructs were generated, with varying numbers of 
optimal TCF binding sites and with different minimal promoters. 
 
3.2.6.1 Generation of pGL4.20-TCFx6 and pGL4.20-mutTCFx6 reporter 
constructs 
The first Wnt/β-catenin signalling reporter construct generated was designed to mimic the 
number and arrangement of optimal TCF sites found in the UPSTATE reporter plasmid called 
here TK-TOPflash, with three TCF binding sites in the forward orientation followed by three 
TCF binding sites in the reverse orientation. To achieve this, oligonucleotides were designed to 
contain either three optimal TCF binding sites or three mutated TCF binding sites (designated 
mutTCF) in each case separated by linker fragments. KpnI and HindIII restriction enzyme sites 
were added to either end of the oligonucleotides for insertion of the oligonucleotides into the 
pGL4.20[luc2/Puro] vector. In order to recreate the arrangement of optimal TCF sites found in 
the TK-TOPflash reporter, the oligonucleotide needed to be inserted twice in opposite 
orientations to give a total of six TCF binding sites. To generate this construct the annealed 
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oligonucleotides were digested with both KpnI and HindIII followed by purification, whereas 
pGL4.20 was digested with only KpnI before Antarctic phosphatase treatment to prevent re-
circulation without an insert. As such, during the subsequent ligation reaction of the digested 
oligonucleotide and pGL4.20, the plasmid could only re-circularise if the oligonucleotide was 
inserted twice, once forwards and once backwards (Figure 3.14a). 
 
The ligation was performed side by side with a vector only control ligation to estimate 
background from either uncut pGL4.20 or the Antarctic phosphatase treatment not reaching 
completion. The ligation resulted in four times as many bacterial colonies as the vector only 
control, suggesting a large proportion of the colonies should contain the correct insert. To 
identify these colonies containing the desired repeated TCF or mutTCF binding sites a colony 
PCR was used which was based on the presence of the insert increasing the size of the multiple 
cloning site by 96 bp (see Figure 3.14b). Two colonies showing a size increase for each of the 
TCF and mutTCF inserts were mini-prepped and sequenced. As sequencing across the TCF sites 
was inhibited by the presence of a hairpin created by the TCF sites being inserted in opposite 
orientation, the clones were either digested with HindIII prior to sequencing or sequenced 
using a PCR product ending between the inserts. One plasmid for each of the TCF and mutTCF 
inserts that was found to be correct were dubbed pGL4.20-TCFx6 and pGL4.20-mutTCFx6 
respectively. 
 
3.2.6.2 Generation of pGL4.20-TCFx3 and pGL4.20-mutTCFx3 reporter 
constructs 
As part of Chapter 4 it became necessary to create a Wnt/β-catenin signalling reporter 
construct with a different number of TCF binding sites to pGL4.20-TCFx6. As such, the pGL4.20-
TCFx6 and pGL4.20-mutTCFx6 constructs were used as a basis to create a Wnt/β-catenin 
signalling reporter construct with half the number of TCF binding sites. To create such 
constructs, pGL4.20-TCFx6 and pGL4.20-mutTCFx6 were digested with the restriction enzyme 
HindIII and the large resulting fragment gel purified. As there was one HindIII restriction site 
between the TCF binding sites and a second in the MCS slightly downstream of the TCF binding 
sites of the pGL4.20-TCFx6 and pGL4.20-mutTCFx6 plasmids (see Figure 3.15a), this cutting and 
re-ligation should in both cases remove the three TCF binding sites in the reverse orientation, 
along with an XhoI restriction enzyme site. After the digested plasmids were re-ligated without 
an insert, one possible colony for each of the potential pGL4.20-TCFx3 and pGL4.20-mutTCFx3 
constructs was mini-prepped and the resulting DNA digested with XhoI and BamHI, which 
would produce two fragments for pGL4.20-TCFx6. When analysed by gel electrophoresis, 
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Figure 3.14: Generation of pGL4.20-TCFx6. a) Arrangement of optimal TCF sites within the 
pGL4.200-TCFx6. Position of the HindIII and KpnI restriction enzymes sites is also shown. b) 
Colony PCR to identify pGL4.20-TCFx6 plasmids. Primers used for the PCR were positioned 
outside the TCF binding sites so that a fragment was produced in both the presence and 
absence of the TCF binding sites. However, the presence of TCF binding sites increases the size 
of the fragment by 96 bp to give a total size of 387 bp. When analysed by gel electrophoresis 
using a 2% agarose gel, eight of the colonies (indicated by asterisk) showed bands consistent 
with the presence of TCF binding sites. pGL4.20 control represents the PCR on the uncut 
vector. ntc = no template control and L = Ladder. 
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neither plasmid produced two fragments (Figure 3.15b) indicating the fragment had been 
removed to produce the desired plasmids, which was confirmed by sequencing. 
 
3.2.6.3 Inserting promoters into pGL4.20-TCFx6 and pGL4.20-TCFx3 
As part of Chapter 4, it became desirable to understand how the presence of different 
promoters changed ZIC based inhibition perceived by the pGL4.20-TCFx6 and pGL4.20-TCFx3 
constructs. As such, three different minimal promoters (TK, cfos and β-globin) were inserted 
into the pGL4.20-TCFx6 and pGL4.20-TCFx3 constructs. The TK and cfos minimal promoters 
were obtained from the TK-TOPflash and cfos-TOPflash reporters respectively, whereas the β-
globin promoter was amplified from pGL4.20-β-globin-Z3M2.  
 
To insert the cfos and TK promoters into pGL4.20-TCFx6 and pGL4.20-mutTCFx6, the 
respective promoters were PCR amplified with primers which also added an XhoI restriction 
enzyme site to the 5’ end of the promoters and a BglII restriction enzyme site to the 3’ end of 
the promoters. These promoter fragments, as well as the pGL4.20-TCFx6 and pGL4.20-
mutTCFx6 vectors, were then digested with BglII and XhoI before being inserted into the 
vectors via a ligation reaction. There was no significant increase in the number of colonies 
obtained from the ligation compared to the no insert control ligation. As such the potential 
colonies were screened using a colony PCR designed so that in each case the PCR used one 
primer within the appropriate promoter and one primer within the pGL4.20 backbone and 
therefore would only produce a product if both the backbone and insert were present. For 
each of the different vector and promoter combinations, ten colonies were screened. In all 
cases except for TCFx6 with TK (which showed the desired result for two colonies), at least six 
colonies produced a result consistent with the correct plasmid being generated (Figure 3.15c). 
In each case, two of these colonies were mini-prepped and sequenced, with one of the 
resulting DNA samples which showed no point mutations used for all further applications.  
 
To insert the cfos, TK and β-globin minimal promoters into pGL4.20-TCFx3/mutTCFx3, the 
respective promoters were PCR amplified using primers that added HindIII restriction enzyme 
sites to each end of the promoter fragments. These fragments, as well as pGL4.20-TCFx3 and 
pGL4.20-mutTCFx3 were digested with HindIII. The digested pGL4.20-TCFx3 and pGL4.20-
mutTCFx3 vectors were treated with Antarctic phosphatase to prevent re-circulation without 
an insert. The promoters were then inserted into each of the vectors via a ligation reaction. 
The number of colonies produced was greater than on the vector only control plate,  
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Figure 3.15: Generation of pGL4.20-TCFx3. a) Arrangement of optimal TCF sites within the 
pGL4.20-TCFx6 demonstrating the region deleted from pGL4.20-TCFx6 using the HindIII sites 
shown. Position of the XhoI and BglII restriction enzyme target sites are also shown. b) 
Diagnostic digests of potential pGL4.20-TCFx3 and pGL4.20-mutTCFx3 plasmids. Potential 
pGL4.20-TCFx3 and pGL4.20-mutTCFx3 plasmids were digested with the restriction enzymes 
XhoI and BamHI and the resulting fragments analysed by gel electrophoresis using a 1% 
agarose gel to determine size. pGL4.20-TCFx6 was also included for comparison and to confirm 
the enzymes were performing as expected. Uncut plasmid samples were run on the same gel. 
As the XhoI restriction site is included in the portion of plasmid removed from pGL4.20-TCFx6 
to create pGL4.20-TCFx3, the desired constructs should not be cut by this enzyme and 
therefore will be cut only once by BglII. pGL4.20-TCFx6 on the other hand will be cut by both 
enzymes, and thus digestion will produce two fragments. The double digests of both pGL4.20-
TCFx3 and pGL4.20-mutTCFx3 plasmids produced only a single band, indicating the deletion 
had occurred, and therefore the desired plasmids had been successfully created. L = Ladder, 
UC = Uncut plasmid, D = Digested plasmid. c) Example colony PCR of pGL4.20-cfos-mutTCFx6. 
Potential colonies were resuspended in water, a small amount of which was used as template 
for the colony PCRs. The PCR used one primer within the cfos promoter and one inside the 
vector backbone and therefore should only give a fragment if the promoter has been inserted 
correctly. When analysed by gel electrophoresis using a 2% agarose gel to determine presence 
and size of bands, seven colonies (indicated by asterisk) showed bands consistent with the 
expected 380 bp, suggesting the cfos promoter was correctly inserted into these plasmids. -ve 
= PCR on uncut pGL4.20-mutTCFx6, ntc = no template control and L = Ladder. 
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suggesting the ligation was successful. However, as ligation was non-directional, and therefore 
the promoter fragments could have been inserted in either direction, colonies were screened 
using a directional colony PCR. The directional PCR used a forward primer that bound the 
pGL4.20 backbone 5’ of where the insert was located and reverse primer that bound the 3’ 
end of the relevant promoter. One colony that came up positive in this screen was mini-
prepped, with the resulting DNA sample digested with HindIII and sequenced to confirm the 
presence of the insert. As the DNA samples showed no unwanted point mutations they were 
used for all downstream applications. 
 
3.2.7 Generation of Foxd3 enhancer reporter constructs 
A putative enhancer Foxd3 acted on by the ZICs was recently identified in chick (Simões-Costa 
et al., 2012). For the experiments of parts of Chapter 6 and Chapter 7 a reporter construct was 
generated based on part of the equivalent enhancer in mouse (see Chapter 6 for more detail). 
To achieve this goal primers targeting the regions approximately 250 bp either side of the 
identified consensus ZIC binding site within the putative enhancer were designed. These 
primers were also designed so as to add KpnI and BglII restriction enzyme sites to either end of 
the generated product. Once the product was amplified the fragment was digested with KpnI 
and BglII. At the same time the pGL4.20-β-globin-Z3M2 reporter plasmid was digested with the 
same enzymes which removed the Z3M2 motifs to leave a pGL4.20-β-globin fragment after gel 
purification. The pGL4.20-β-globin and Foxd3 enhancer fragments were then joined together in 
a ligation reaction. Ten of the resulting colonies were screened for the presence of Foxd3 via 
colony PCR, with the three that showed the insert mini-prepped and sequenced. One clone 
which showed the insert and no unwanted side mutations was used for subsequent 
experiments. 
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3.3 Discussion 
The results section of this Chapter describes the generation of a total of 77 new expression or 
reporter plasmids. The generation of these constructs required many different cloning 
techniques, often made more complicated due to the nature of the ZICs. For example, while 
mutations in plasmids are often introduced by commercial site-directed kits this was not 
possible in this case due to the length and GC content of the ZICs. As such, several different 
techniques were used for mutagenesis, including overlap-extension PCR and recombination. It 
should be noted that none of the mutagenesis techniques described here were routinely used 
in the Arkell Laboratory before the start of this project. As such, much of the work described 
here has also involved extensive trouble shooting of techniques, such as determining why PCR 
amplification deletes a section of ZIC2 sequence or finding ways to introduce mutations into 
ZIC5 without amplifying the entire 1992 bp sequence. In addition, diagnostic techniques such 
as colony PCR were improved over the project, so that not only the presence but also the 
direction of inserts could be determined via colony PCR. As such, the results found within this 
Chapter represent a step forward in studying ZIC function, not only by increasing the 
availability of wildtype and mutant ZIC expression and reporter constructs, but also by 
enabling these constructs to be more easily and quickly made in the future. 
 
3.3.1 Partial deletion of ZIC2 during PCR 
As part of the ZIC2 mutagenesis it was observed that under certain conditions PCR 
amplification results in deletion of a small 148 bp region of the ZIC2 CDS (Section 3.2.2.3). Such 
deletion during PCR is not unique to ZIC2. For example, it has also been reported that PCR 
amplifying across GPIbα gene produces a 84 bp deletion under certain conditions (Hadj Kacem 
et al., 2008). In the case of the GPIbα gene, the deletion is thought to be caused by an identical 
12 bp sequences found on either side of the deletion, which creates a secondary structure in 
the original template, thus producing a deletion during PCR amplification. As the ZIC2 CDS 
deletion region is also flanked by repeated 12 bp DNA sequences (see Fig 3.8), the deletion is 
likely caused by the same mechanism. The addition of DMSO likely denatures this secondary 
structure to an extent that the deletion no longer occurs.  
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Chapter 4: Generating an assay to analyse ZIC 
based inhibition of Wnt signalling 
4.1 Introduction 
Establishing precise levels of Wnt signalling is critical for correct development, as 
demonstrated by the myriad of defects caused by loss or gain of Wnt function in the mouse 
(Grigoryan et al., 2008). While carrying out the experiments that comprise this thesis, two 
studies were published demonstrating that the ZICs could inhibit canonical/β-catenin Wnt 
signalling (Fujimi et al., 2012; Houtmeyers et al., 2013). Such a role was of great interest due to 
the importance of Wnt signalling, the potential to explain several ZIC associated phenotypes 
and as it was thought to represent a co-factor role for the ZICs. However, the reporter systems 
used to evaluate ZIC based inhibition of Wnt/β-catenin signalling varied greatly between 
studies and it was unclear how these differences influenced the ZIC repression activity. As 
such, the aim of this Chapter was to optimise the cell based protocol for transcription assays 
and to generate a new more robust assay for measuring ZIC based inhibition of Wnt/β-catenin 
signalling. 
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4.2 Results 
4.2.1 An optimised protocol for transcription assays 
4.2.1.1 Decreasing internal variability 
Luciferase reporter assays can suffer from high variability, both between internal repeats and 
between external repeats. Such high variability impairs discrimination of functional changes. 
Several potential sources of error were identified in the protocol previously used to produce 
Figure 1.8. To decrease the variability of reporter assays a new protocol was devised (see 
Figure 4.1) which incorporated the following changes predicted to reduce both internal and 
external experimental variability: 
 
• The overall cell density of the 96-well plate was reduced to be in line with other 
published ZIC luciferase assays (Lim et al., 2010; Salero et al., 2001). 
• Rather than performing three separate transfections per plasmid combination, only a 
single transfection was performed which was subsequently split to give three internal 
repeat samples. 
• The wells on the edges of 96-well plates were not used for samples due to potential 
edge effects. For the same reason the wells used were surrounded by a row of wells 
containing media. 
• The position of each transfection was randomised both within 96-well plates and 
between experiments to prevent possible position effects. 
 
When the two protocols were compared in side-by-side experiments using ZIC5 activation of 
several ApoE (-189/+1) promoter based reporter constructs, it was found in each case that the 
new protocol showed lower standard deviation (S.D.) (Figure 4.2), indicative of the desired 
decreased variability. It is important to note that in either case the internal repeats represent 
technical repeats and are thus not sufficient to show whether there is a statistically significant 
difference between treatments. Throughout this thesis, when L.S.D. and S.E.M. are shown, 
these values are calculated from external repeats, not the technical repeats described here. As 
such, all further experiments were performed using the new protocol. 
 
4.2.1.2 Optimising DNA amount 
Plasmid concentration is thought to greatly influence transfection efficiency (Felgner et al., 
1987; Romoren et al., 2004). Therefore, to determine the ideal DNA concentration for our  
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Figure 4.1: Comparison of luciferase assay protocols. Protocol A: Cells transfected in a 96-well 
plate, triplicate transfections were performed. Protocol B: Cells transfected in 12-well, 
replated after 5.5 hours into a 96-well plate at a lower density. Position of internal repeats was 
randomised and cells were surrounded by a row of wells containing media to reduce edge 
effects. Remaining cells were replated in a 6-well plate so that the success of transfection 
could be confirmed via western blot analysis. 
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Figure 4.2: 12-well based luciferase assays show lower variability than 96-well plate based 
luciferase assays. HEK293T cultured in either (i) 96-well plates or (ii) 12-well plates were 
transfected with an ApoE based luciferase reporter construct (corresponding reporter name is 
above each graph) and either the ZIC5 expression construct V5-ZIC5 or the empty construct 
V5-DEST. 48 hours post transfection, luciferase levels were measured. In each case the S.D. is 
lower for the 12-well plate transfection. Error bars = S.D., N = 3 internal repeats. 
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experiments, side-by-side experiments were performed to compare transfections with the 
recommended DNA concentration (1.6 μg total DNA) to either twice or half the recommended 
amount of DNA. For the comparison the ZIC5 based activation of pXP2-ApoE (-189/+1) reporter 
construct shown in the previous section was used. In addition, as it was critical that partial 
loss-of-function be detected using the assay, the ZIC5-K393R allele was also included in the 
assessment as the mouse experiments with the equivalent murine ZIC5-K363R allele show it to 
represent a hypomorphic allele (see section 1.4.1).  
 
The increase in amount of DNA correlated with an increase in fold activation levels, potentially 
due to increasing the DNA amounts leading to higher plasmid intake by cells (Figure 4.3b). 
However, the difference between the wildtype and hypomorph alleles was greatest when 
using the recommended concentration (Figure 4.3). As such, the recommended concentration 
was considered optimal for our purposes and used for all further experiments 
 
4.2.2 Negative controls for the Wnt transcription assays 
Ideally every transcription assay should include two forms of negative control. The first should 
assess the reporter construct, in this case achieved by the cfos-FOPflash reporter. cfos-
FOPflash is identical to cfos-TOPflash except for the tandem optimised TCF binding sites, which 
have been mutated to prevent TCF binding. As such, the plasmid is not activated by Wnt 
signalling and can therefore be used to confirm proteins are influencing the TCF sites and 
therefore Wnt signalling, rather than influencing the remainder of the plasmid. The second 
negative control is a form of the expressed protein that cannot undertake normal 
activation/repression. In this case, as Wnt inhibition activity by the ZICs is being assessed, such 
a negative control would be a form of ZIC that cannot repress. Although ZIC based repression 
of Wnt signalling is not completely understood, domain mapping experiments have 
demonstrated the ZFD region is necessary for the repression (Pourebrahim et al., 2011). As 
such, the Katun allele of ZIC3 which contains a point mutation resulting in a premature stop 
codon and thus produces a severely truncated protein missing the entire ZFD (Ahmed et al., 
2013), represented a strong candidate as the desired negative control, assuming human ZIC3 
showed inhibition ability. 
 
To test these controls, the assay in Pourebrahim et al., 2011 was utilized. Specifically, the assay 
was performed using the cfos-TOPflash reporter activated by the ΔN89-β-CATENIN in HEK293T 
cells. ΔN89-β-CATENIN expresses a form of β-CATENIN that lacks the first 89 amino acids and is  
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Figure 4.3: Total amount of DNA included in transfection alters perceived difference 
between wildtype and hypomorphic alleles. a) HEK293T were transfected with the reporter 
construct pXP2-ApoE (-189/+1) and either V5-ZIC5-WT, V5-ZIC5-K393R or the empty construct 
V5-DEST. While the reporter to expression construct ratio was kept consistent between 
experiments the total amount of DNA was varied, with either (i) 3.2 μg, (ii) 1.6 μg or (iii) 0.8 μg 
total DNA used. When the largest amount of DNA was used no difference could be discerned 
between the wildtype and hypomorphic alleles. b) Activation levels calculated relative to the 
respective backgrounds. The decrease in total amount of DNA correlates with a decrease in 
fold activation over background. - = V5-DEST. In all cases error bars = S.D., N = 3 internal 
repeats.  
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therefore considered stabilized as it is not degraded via the β-CATENIN degradation complex 
(Munemitsu et al., 1996). To assess the reporter negative control, cells were transfected with 
cfos-TOPflash alone or in the presence of ΔN89-β-CATENIN. As expected, the presence of 
ΔN89-β-CATENIN increased the Wnt/β-catenin signalling levels, with the presence of β-
CATENIN producing approximately 30 fold higher activation levels (Figure 4.4 column 1 vs 
column 2). On the other hand when cells were transfected with cfos-FOPflash, the presence of 
exogenous ΔN89-β-CATENIN did not produce any activation (Figure 4.4 column 5 vs column 6) 
confirming the cfos-TOPflash response to β-CATENIN is due to Wnt based activity at TCF sites 
rather than the backbone or promoter regions. 
 
To confirm the ZIC negative control was behaving as expected, cfos-TOPflash and ΔN89-β-
CATENIN were co-transfected with either V5-ZIC3-WT or V5-ZIC3-KATUN. The high level of 
activation demonstrated by cfos-TOPflash reporter plasmid in the presence of exogenous 
ΔN89-β-CATENIN was significantly reduced by the addition of V5-ZIC3-WT (Figure 4.4 and 
Figure 4.5a columns 2 vs columns 3), demonstrating that human ZIC3 shows the same Wnt 
inhibition ability as human ZIC2. In contrast, the presence of V5-ZIC3-KATUN produced no 
inhibition effect, confirming this control is functioning as desired (Figure 4.4 and Figure 4.5a 
column 2 vs column 4). Interestingly, the presence of ZIC3-WT, but not ZIC3-KATUN, appeared 
to deplete the ΔN89-β-CATENIN both in the nucleus and cytoplasm, consistent with previous 
findings that the presence of Xenopus zic3 leads to degrade β-catenin (Fujimi et al., 2012). 
Together, these results show for the first time that human ZIC3 is able to inhibit Wnt signalling, 
and that both negative controls are behaving as desired. 
 
These experiments also allowed comparison of the consistency of external repeats using the 
newly optimised assay. The three repeats completed for this experiment showed very low 
levels of variation between separate experiments, either when comparing the raw luciferase 
values (Figure 4.5b), or when comparing the fold values relative to background (Figure 4.5c). 
Analysing the pooled raw data via an ANOVA thus results in a small Standard Error of the Mean 
(S.E.M.) (Figure 4.5.a) and Least Significant Difference (L.S.D.), which results in a clear 
indication of the difference between the wildtype and Katun ZIC3 alleles and further 
emphasises the robust nature of the assay. 
 
  
123 
 
 
 
 
 
 
 
 
Figure 4.4: Wildtype ZIC3, but not the ZIC3 Katun allele represses Wnt/β-catenin signalling. 
HEK293T were transfected with the Wnt/β-catenin reporter construct cfos-TOPflash or the 
mutated reporter construct cfos-FOPflash, along with either only V5-DEST or ΔN89-β-CATENIN 
and either V5-ZIC3-WT, V5-ZIC3-KATUN or the empty construct V5-DEST. cfos-TOPflash 
showed an increase in luciferase levels in the presence of ΔN89-β-CATENIN, which was 
reduced by the further addition of V5-ZIC3-WT, but not by addition of V5-ZIC3-Katun. cfos-
FOPflash on the other hand showed no reaction to either ΔN89-β-CATENIN, V5-ZIC3-WT or V5-
ZIC3-KATUN. Error bars = S.D., N = 3 internal repeats. Western blots of lysates of the 
transfected cells are shown below graphs. Two different exposure of the cytoplasmic α-β-
CATENIN blots are shown. α-TBP and α-β-TUBULIN blots are included as loading controls. Note 
the significantly reduced expression of β-CATENIN in the presence of V5-ZIC3-WT. ΔN89-β-CAT: 
ΔN89-β-CATENIN. 
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Figure 4.5: cfos-TOPflash luciferase assay shows consistency across repeats. HEK293T were 
transfected with the Wnt/β-catenin reporter construct along with either only V5-DEST or 
ΔN89-β-CATENIN and either V5-ZIC3-WT, V5-ZIC3-KATUN or the empty construct V5-DEST. a) 
Pooled data across three experiments. Presence of ZIC3 produces a significant decrease 
compared to ΔN89-β-CATENIN alone. Error bars = S.E.M., N = 3 external repeats; *: p˂0.05, 
two-way ANOVA with Fischer’s unprotected post ad hoc test. b) Raw data, showing the level of 
consistency across repeats. Error bars = S.D., N = 3 internal repeats. c) Data adjusted relative to 
DEST, showing the level of consistency across repeats. - = V5-DEST. Error bars = S.D., N = 3 
internal repeats. ΔN89-β-CAT: ΔN89-β-CATENIN. 
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4.2.3 TCF binding element for inclusion in Wnt transcription assay 
4.2.3.1 Analysis of pre-existing Wnt transcription assays 
As previously stated, two different TOPflash reporter plasmids have been used recently to 
assay ZIC based inhibition of the canonical Wnt signalling pathway: cfos-TOPflash, which was 
described as containing three optimal TCF binding sites upstream of a cfos promoter and TK-
TOPflash which was described as containing three optimal TCF binding sites upstream of a TK 
promoter. In order to confirm this information was correct, both reporter constructs were 
acquired and sequenced. While sequencing enabled the identification of the promoter regions 
present in the TK-TOPflash and cfos-TOPflash reporter constructs, in both cases the actual 
number of TCF binding sites was greater than previously reported and some of the optimal TCF 
sites contained sequence variation which could alter the function of these sites (Figure 4.6). As 
such, new Wnt reporter constructs with known numbers of optimal TCF binding sites needed 
to be generated and analysed. 
 
4.2.3.2 The number of TCF binding influences transcription levels 
It was unclear what effect the observed variation in number of TCF binding sites would have, 
as while it is likely that increasing the number of optimal TCF binding sites included in the 
reporter would increase the fold activation by Wnt signalling, it was unclear whether such an 
increase would be a benefit or a hindrance to detecting the ZIC based repression of Wnt/β-
catenin signalling. As such, the effect of altering the number of optimal TCF binding sites was 
evaluated. In order to directly determine the effect of increasing the number of TCF sites, the 
ZIC based inhibition of Wnt/β-catenin signalling was measured using two reporter constructs 
generated in Chapter 3 which were identical apart from the number of binding sites. One of 
the constructs (dubbed pGL4.20-cfos-TCFx6) contained six optimal TCF binding sites in order to 
be consistent with the TK-TOPflash, whereas the other (dubbed pGL4.20-cfos-TCFx3) 
contained half this number, for ease of comparison and cloning, but also in order to be roughly 
consistent with cfos-TOPflash. As all previous reporters included a promoter region, both 
constructs included the cfos promoter identified from sequencing of the cfos-TOPflash 
reporter construct. These two constructs were generated within the pGL4.20[luc2/Puro] 
vector backbone (Promega) which has been specifically designed for expression in mammalian 
systems and to prevent undesired non-specific transcription factor binding.  
 
To confirm the assay was performing as anticipated and to determine whether increasing the 
number of optimal TCF sites improved the ability of the constructs to detect changes in  
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Figure 4.6: Sequencing of optimised binding sites of the TOPflash reporter constructs. The 
two TOPflash reporter plasmids acquired were sequenced to identify the promoter regions and 
confirm the number and orientation of TCF binding sites. a) Sequencing of the tkTOPflash 
reporter construct aligned with the sequenced provided by the manufacturer. The sequencing 
read failed to cover the entire region, but identified sites in two different orientations. b) 
Sequencing of the cfos-TOPflash reporter construct identified four TCF binding sites, however 
two of these contained mutations. 
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Wnt/β-catenin signal levels, HEK293T cells were transfected with the reporter constructs alone 
or in the presence of ΔN89-β-CATENIN and the fold change assessed. As expected both 
constructs showed an increase in luciferase levels in the presence of ΔN89-β-CATENIN, 
although the fold activation differed for the two constructs (Figure 4.7). Doubling the number 
of TCF binding sites appeared to approximately double the fold activation, with addition of 
ΔN89-β-CATENIN stimulating pGL4.20-cfos-TCFx3 to a 28.5 fold higher level than in 
unstimulated cells (Figure 4.7b, column 1 vs column 2) whereas addition of ΔN89-β-CATENIN 
stimulated pGL4.20-cfos-TCFx6 to a 56.76 fold higher level (Figure 4.7b, column 5 vs column 6), 
demonstrating the number of optimal TCF binding present clearly changes how the reporter 
constructs behave. 
 
To determine how the differences in behaviour between the two constructs alters detected 
ZIC based inhibition of Wnt/β-catenin, side-by-side experiments were performed with 
pGL4.20-cfos-TCFx6 and pGL4.20-cfos-TCFx3, which were co-transfected with ΔN89-β-
CATENIN, to stimulate Wnt signalling levels, and a ZIC expression construct or an empty vector 
to estimated background levels. Human ZIC2 and ZIC3 were chosen for the analysis as both 
had previously been found to act as Wnt/β-catenin signalling inhibitor, either in the published 
literature or by analysis in this thesis.  Consistent with previous experiments, both ZIC2 and 
ZIC3 were able to inhibit Wnt/β-catenin signalling measured by pGL4.20-cfos-TCFx3 (Figure 
4.7b columns 2-4). In contrast, only one of the two family members, ZIC2, showed any 
detectable inhibition of pGL4.20-cfos-TCFx6 (Figure 4.7b columns 6-8). Curiously, although 
ZIC2 was able to inhibit in both cases, the detected inhibition measured by pGL4.20-cfos-TCFx3 
was larger than the detected inhibition measured by pGL4.20-cfos-TCFx6 (down to ≈25% of 
background levels vs down to ≈48% of background levels; Figure 4.7c), suggesting the ability of 
ZIC2 to produce detectable Wnt/β-catenin signalling inhibition was also reduced by the 
presence of additional TCF binding sites. Together, these results imply that increasing the 
number of optimal TCF sites, and thus the fold activation of the reporter constructs, hinders 
the ability of the reporter constructs to detect ZIC based inhibition of Wnt/β-catenin signalling. 
As such, all further reporter constructs designed and analysed included only three optimal TCF 
binding sites. 
 
4.2.4 Promoter for inclusion in Wnt transcription assay 
4.2.4.1 Promoter comparison 
The ZICs have been shown to influence a range of DNA sequences, including promoters of 
several genes such as MLP, ZIC1, SV40, TK (Ishiguro et al., 2004; Mizugishi et al., 2001) and 
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Nanog (Lim et al., 2010) and enhancers of various genes including Math1 (Ebert et al., 2003). 
As such, it is highly likely that choice of minimal promoter incorporated into the Wnt/β-catenin 
signalling reporter construct could influence the detected inhibition due to the potential of the 
ZICs to bind the promoter region. To determine if this was the case ZIC inhibition of reporter 
constructs containing different minimal promoters was compared. 
 
Although there were a wide variety of promoters that could be potentially included in the 
Wnt/β-catenin signalling reporter constructs, those of main interest were the cfos and TK 
promoters, as these were already used in published analysis of ZIC based Wnt inhibition. In 
addition, as there is evidence that the β-globin minimal promoter is not influenced by the ZICs 
(unpublished data, Arkell Laboratory) this promoter was also included in the analysis to 
provide a control promoter known to be ZIC independent. The three promoters were analysed 
by incorporation into identical pGL4.20[luc2/Puro] vector backbones, in each case inserted 
between three optimal TCF binding sites and the luciferase gene. In each case the reporter 
construct was co-transfected with ΔN89-β-CATENIN alone to assess fold activation, as well as 
with both ΔN89-β-CATENIN and ZIC expression construct, to determine if repression could be 
detected. As the results from the previous section demonstrate that ZIC based inhibition of 
Wnt/β-catenin signalling varies in strength for different members of the family, all five ZIC 
genes were included in this analysis. 
 
The three promoters demonstrated some similarities in terms of ZICs based inhibition of 
Wnt/β-catenin signalling (Figure 4.8a-c). For example, regardless of the promoter included the 
reporter constructs detected inhibition of Wnt/β-catenin signalling by ZIC1 and ZIC2. In 
addition, the WB analysis indicated that all the ZICs showed partial depletion of β-catenin 
independent of the promoter present. However there were also some important differences 
between promoters. For example, inhibition by ZIC3 could only be detected when assessed by 
TK and cfos promoter containing construct, whereas ZIC4 only inhibited when the β-globin 
promoter was used. In addition, the promoters also showed ZIC independent differences, such 
as the β-globin promoter showing much lower raw values than the other promoters (Figure 
4.8d(i)), but higher relative fold due to the addition of ΔN89-β-CATENIN (Figure 4.8d(ii)). These 
ZIC dependent and ZIC independent differences clearly illustrate the choice of promoter can 
influence detected Wnt/β-catenin signalling levels and suggest therefore that the choice of 
promoter incorporated into the reporter vectors is absolutely critical. In addition, these results 
demonstrate why an additional vector was not included in the various experiments as a 
transfection control, as different ZIC proteins clearly interact in unpredictable ways with 
different promoters, thus ZIC interaction with transfection controls could confound results. 
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Figure 4.7: Increasing the number of TCF binding sites decrease the effectiveness of ZIC 
based Wnt/β-catenin inhibition. HEK293T were transfected with a Wnt/β-catenin reporter 
construct along with either only V5-DEST or ΔN89-β-CATENIN and either V5-ZIC3-WT, V5-ZIC2-
WT or the empty construct V5-DEST. Two Wnt/β-catenin reporter constructs were assessed: 
pGL4.20-cfos-TCFx3 (which contains three optimal TCF binding sites) and pGL4.20-cfos-TCFx6 
(which contains six optimal TCF binding sites). a) Single representative experiment. Error bars = 
S.D. of three internal repeats. Western blots corresponding to particular transfection are 
shown below graphs. α-TBP and α-β-TUBULIN blots are included as loading controls. b) Pooled 
data relative to DEST. pGL4.20-cfos-TCFx6 shows twice the fold activation due to the addition 
of ΔN89-β-CATENIN than pGL4.20-cfos-TCFx3. c) Pooled data relative to ΔN89-β-CATENIN 
alone. ZIC2 is able to inhibit when measured by either reporter construct, whereas ZIC3 is only 
able to inhibit when measured by pGL4.20-cfos-TCFx3. For b and c, Error bars = S.E.M., N = 3 
external repeats; *: p˂0.05, two-way ANOVA with Fischer’s unprotected post ad hoc test. 
ΔN89-β-CAT: ΔN89-β-CATENIN. 
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Figure 4.8: Promoter choice affects perceived ZIC based Wnt/β-catenin inhibition. HEK293T 
were transfected with a Wnt/β-catenin reporter construct along with either only V5-DEST or 
ΔN89-β-CATENIN and a ZIC expression construct or the empty construct V5-DEST. Three 
Wnt/β-catenin reporter constructs were assessed, which were identical except for the minimal 
promoter present.  Promoters analysed were a) the TK promoter, b) the cfos promoter or c) 
the β-globin minimal promoter. In each case the top graph shows a single representative 
experiment with error bars = S.D., N = 3 internal repeats. Western blots corresponding to 
particular transfection are shown below graphs. α-TBP and α-β-TUBULIN blots are included as 
loading controls. In each case the bottom graph shows pooled data relative to DEST. Error bars 
= S.E.M. of three external repeats, * : p˂0.05, two-way ANOVA with Fischer’s unprotected post 
ad hoc test. d)(i) Raw values of pooled data showing response of the three constructs to 
presence of ΔN89-β-CATENIN. (ii) Pooled data relative to DEST only showing response of the 
three constructs to presence of ΔN89-β-CATENIN. For d) Error bars = S.E.M., N = 3 external 
repeats; * : p˂0.05, two-way ANOVA with Fischer’s unprotected post ad hoc test. ΔN89-β-CAT: 
ΔN89-β-CATENIN, βg = β-globin. 
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4.2.4.2 A promoter is required for Wnt transcription assays 
The promoter influence demonstrated in the previous section could sway the reporter assay 
results in unpredictable and undesirable ways, and thus cause changes to the ZICs influencing 
the promoter region to be mistaken for altered ability of the ZICs to inhibit Wnt/β-catenin. 
Such issues could potentially be overcome by completely removing any promoter region from 
the reporter constructs; however it was unknown whether such a promoterless vector would 
actually be able to detect changes in Wnt/β-catenin signalling. 
 
To assess this possibility, a promoterless Wnt/β-catenin signalling reporter was created by 
insertion of three optimal TCF sites into the pGL4.20[luc2/Puro] vector backbone (see Chapter 
3), dubbed pGL4.20-TCFx3. To determine whether a promoterless reporter could detect 
changes in Wnt/β-catenin signalling cells were co-transfected with pGL4.20-TCFx3 and either 
ΔN89-β-CATENIN to stimulate Wnt/β-catenin signalling or an empty vector to measure 
background levels. As a control, the experiment was performed side-by-side with the pGL4.20-
cfos-TCFx3 reporter construct. While the pGL4.20-cfos-TCFx3 showed the expected large fold 
activation (Figure 4.9b, columns 3 and 4), which indicated the ΔN89-β-CATENIN was behaving 
correctly, the promoterless pGL4.20-TCFx3 showed only a relatively low 1.7 fold activation, 
despite the fact that based on the associated WB the amount of ΔN89-β-CATENIN was roughly 
equivalent (Figure 4.9b columns 1 and 2). Due to the low fold activation of the promoterless 
pGL4.20-TCFx3, it would be very difficult to detect small changes in function such as those that 
might be seen with hypomorphs and therefore would not be useful for study of the ZICs 
function. 
 
Together these results indicate both that a promoter is needed in the Wnt/β-catenin reporter 
constructs and that the promoter choice can influence the perceived ZIC based inhibition of 
Wnt signalling. As such all further experiments were performed with the β-globin minimal 
promoter as it has been shown not to be activated or repressed by the ZICs (Arkell Laboratory, 
unpublished results). Specifically, all further Wnt/β-catenin signalling experiments described in 
this thesis (unless stated otherwise) were performed using the pGL4.20-β-globin-TCFx3 
reporter construct. 
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Figure 4.9: Presence of promoter greatly increases perceived Wnt/β-catenin activation. 
HEK293T were transfected with a Wnt/β-catenin reporter construct along with either V5-DEST 
or ΔN89-β-CATENIN. Two Wnt/β-catenin reporter constructs were compared: pGL4.20-TCFx3 
which contains no promoter and pGL4.20-cfos-TCFx3 which contains the cfos minimal 
promoter. a) Single representative experiment. Western blots corresponding to particular 
transfection are shown below graphs. α-β-TUBULIN blots are included as loading controls. 
Error bars = S.D., N = 3 internal repeats. b) Pooled data relative to DEST. While both reporters 
show a significant activation in response to addition of ΔN89-β-CATENIN, the fold activation is 
less than two-fold in the absence of a promoter. Error bars = S.E.M., N = 3 external repeats; * : 
p˂0.05. ΔN89-β-CAT = ΔN89-β-CATENIN. 
 
  
136 
4.2.5 ZIC proteins inhibit Wnt dependent transcription in a low Wnt 
environment 
While the TOPflash reporter plasmids can be used to measure inhibition of endogenous WNT 
levels, the levels of β-CATENIN are usually first raised before measuring a particular proteins 
ability to elicit Wnt inhibition. One of the ways to increase Wnt levels for reporter based cell 
assay is to transfect cells with a ΔN89-β-CATENIN expression plasmid. Indeed, the Wnt/β-
catenin signalling reporter assays described so far in this thesis used transfection of a 
truncated form of β-CATENIN, ΔN89-β-CATENIN, to increase detected Wnt/β-catenin signalling 
levels. The truncation present in ΔN89-β-CATENIN removes the N-terminal region of the 
protein that is normally associated with the phosphorylation. Lack of phosphorylation prevents 
the subsequent degradation of the protein (Munemitsu et al., 1996), which should stabilise the 
protein and therefore drive higher levels of Wnt/β-catenin signalling than if full length β-
CATENIN was used. However, the results of section 4.2.3 indicate that in some cases increasing 
the detected levels of Wnt/β-catenin signalling can interfere with the ability of the ZICs to 
inhibit, suggesting stimulating the Wnt/β-catenin reporter constructs to lower levels may be 
advantageous, particularly as at least one of the members of ZIC family, ZIC5, has not shown 
any Wnt inhibition ability in any assay yet tested. 
 
To drive Wnt signalling levels to a lower extent a full length β-CATENIN expression construct, 
V5-β-CATENIN, was acquired. The activation ability of this construct was assessed by co-
transfecting cells with the pGL4.20-β-globin-TCFx3 reporter construct and either ΔN89-β-
CATENIN, V5-β-CATENIN or an empty vector. As desired V5-β-CATENIN produced a lower fold 
activation than ΔN89-β-CATENIN (21 fold vs 33fold, Figure 4.10c), illustrating V5-β-CATENIN is 
an appropriate β-CATENIN expression construct for driving lower levels of Wnt/β-catenin 
activation than ΔN89-β-CATENIN. 
 
Once it was established that V5-β-CATENIN drove lower fold activation levels than ΔN89-β-
CATENIN, the inhibition by the ZICs of Wnt/β-catenin signalling when driven by the V5-β-
CATENIN was determined by co-transfecting cells with pGL4.20-β-globin-TCFx3, V5-β-CATENIN 
and either a ZIC expression construct or an empty vector to estimate background. All five 
members of the ZIC family were included in this analysis. Unlike ΔN89-β-CATENIN, all members 
of the ZIC family showed detectable inhibition of Wnt/β-catenin signalling when driven by the 
V5-β-CATENIN (Figure 4.10a). In addition, comparison of the repression relative to background 
indicates that the ZICs which showed inhibition of ΔN89-β-CATENIN, such as ZIC1 and ZIC2, 
showed increased inhibition when Wnt/β-catenin signalling was stimulated with V5-β-CATENIN 
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(Figure 4.10d). Both these observations suggest that the higher levels of Wnt/β-catenin 
signalling driven by ΔN89-β-CATENIN interferes with the inhibition of this pathway by the ZICs 
and thus that ZICs inhibit in low Wnt environments. In most circumstances, V5-β-CATENIN 
would be a more useful β-CATENIN expression construct for stimulating Wnt signalling when 
interested in inhibition by the ZICs. However, it should be noted that in instances where an 
increase in inhibition was thought possible, V5-β-CATENIN might not be useful as two 
members of the ZIC family, ZIC1 and ZIC2, already show maximum inhibition levels and as such 
further increases in inhibition cannot be detected. 
 
4.2.6 The new Wnt transactivation assay is dependent upon the TCF 
elements 
Over the course of this chapter, multiple properties of potential reporter assays for measuring 
ZIC based inhibition of Wnt/β-catenin signalling were analysed and optimised, including the 
number of optimal TCF binding sites, the promoter incorporated and the β-CATENIN 
expression construct used to increase Wnt/β-catenin signalling levels. Based on these 
optimisation experiments an ideal assay has been created, which incorporates three optimal 
TCF binding sites and a β-globin promoter into the pGL4.20[luc2/Puro] vector backbone. As all 
elements of the assay have been tested and optimised, a negative control reporter is now 
required to confirm the specificity of the assay. 
 
Similar to the previously described FOPflash assay the negative control assay was identical to 
the newly generated reporter, pGL4.20-β-globin-TCFx3, except that the optimal TCF sites had 
been mutated to prevent TCF/LEF binding (dubbed pGL4.20-β-globin-TCFmutx3). The pGL4.20-
β-globin-TCFx3 and pGL4.20-β-globin-TCFmutx3 were used in identical side-by-side 
experiments, performed with all the ZICs as described in the previous section. Unlike pGL4.20-
β-globin-TCFx3 (Figure 4.10a), pGL4.20-β-globin-TCFmutx3 showed no significant activation or 
repression when either V5-β-CATENIN or the ZIC expression constructs were present (Figure 
4.10b). It should be noted that even in the absence of the Wnt reporter, β-CATENIN still 
showed depletion in the presence of the ZICs. The lack of activation indicates that the 
activation and inhibition seen with pGL4.20-β-globin-TCFx3 is not due to either V5-β-CATENIN 
or the ZIC proteins acting on either the pGL4.20 backbone or the β-globin minimal promoter 
but rather is specific β-CATENIN based activation at the TCF sites. 
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Figure 4.10: Specificity of ZIC based Wnt/β-catenin signalling inhibition measured by 
pGL4.20-β-globin-TCFx3 and comparison of ZIC inhibition of V5-β-CATENIN and ΔN89-β-
CATENIN. HEK293T were transfected with a wildtype or mutant reporter construct, along with 
either only V5-DEST or V5-β-CATENIN and a ZIC expression construct or the empty construct 
V5-DEST. a) Single representative experiment of the Wnt/β-catenin reporter construct 
pGL4.20-β-globin-TCFx3. Western blots corresponding to particular transfection are shown 
below graphs. α-ZIC5 was used to detect V5-ZIC5 as V5-β-catenin and V5-ZIC5 are similar size 
and thus can not be distinguished using the V5 antibody. α-TBP and α-β-TUBULIN blots are 
included as loading controls. Error bars = S.D. of three internal repeats. aʹ ) Pooled data relative 
to DEST. Every ZIC shows inhibition of Wnt/β-catenin signalling measured by pGL4.20-β-globin-
TCFx3 when activated by V5-β-CATENIN. Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, 
two-way ANOVA with Fischer’s unprotected post ad hoc test. b) Single representative 
experiment of the mutated Wnt/β-catenin reporter construct pGL4.20-β-globin-mutTCFx3. 
Western blots corresponding to particular transfection are shown below graphs. Error bars = 
S.D. of three internal repeats. bʹ ) Pooled data relative to DEST. Neither V5-β-CATENIN nor any 
of the ZICs shows significant activation or inhibition of pGL4.20-β-globin-mutTCFx3. Error bars 
= S.E.M., N = 3 external repeats; * : p˂0.05, two-way ANOVA with Fischer’s unprotected post 
ad hoc test. c) Comparison of relative fold activation of pGL4.20-β-globin-TCFx3 by V5-β-
CATENIN and ΔN89-β-CATENIN in the absence of ZIC. d) Comparison of ZIC inhibition of 
pGL4.20-β-globin-TCFx3 activation by V5-β-CATENIN and ΔN89-β-CATENIN relative to 
background. V5-β-CAT: V5-β-CATENIN, ΔN89-β-CAT: ΔN89-β-CATENIN. 
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4.2.7 ZIC DNA binding ability is not critical for inhibition of Wnt 
transcription 
Much of our interest in the ZIC2 based repression of the Wnt/β-catenin signalling pathway is 
due to the previous discovery that mutant ZIC2 which is incapable of binding DNA is still able 
to repress Wnt/β-catenin signalling  (Pourebrahim et al., 2011). As such, the newly created 
pGL4.20-β-globin-TOPx3 assay was used to confirm the result, and to determine whether the 
other ZICs were also able to inhibit Wnt/β-catenin signalling without interacting with DNA. 
 
Previous experiments to determine whether the ZICs were able to inhibit Wnt/β-catenin 
signalling without interacting with DNA used an allele of ZIC2 containing a serine (S) to cysteine 
(C) point mutation in the fourth zinc finger which has been shown to prevent DNA binding of 
ZIC2 (Brown et al., 2005; Pourebrahim et al., 2011). Given the highly conserved nature of the 
ZIC ZFD it is likely that the equivalent mutation would disrupt DNA binding in other ZIC family 
members. As such, the same strategy was used with the equivalent alleles in the other ZICs. 
The results of this assay were consistent with the previous result (Figure 4.11): DNA-binding 
incompetent ZIC2 was able to inhibit Wnt signalling. In fact this result was conserved 
throughout the family, as in every case the zinc finger mutant forms of the ZICs which have lost 
the ability to bind DNA are still able to inhibit Wnt/β-catenin signalling. Comparing the Wnt/β-
catenin inhibition abilities of the wildtype and zinc finger mutant forms of ZIC, it appears for 
some members of the ZIC family (i.e. ZIC2 and ZIC5) the mutant forms of the ZICs do show 
reduced inhibition activity, however this could be explained by the reduced protein levels of 
the zinc finger mutant ZIC compared to wildtype ZIC. Curious, several of the wildtype ZICs 
caused a greater depletion of β-catenin than their mutant forms, even though there was no 
significant difference in ZIC based repression. It is therefore clear that the second cysteine of 
the fourth zinc finger is not absolutely essential for ZICs to act as Wnt inhibitor suggesting that 
DNA binding is not essential for Wnt inhibition. 
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4.3 Discussion 
Correct repression of canonical Wnt signalling is crucial during early development as evidenced 
by the severe defects caused by increased or ectopic activity, such as loss of caudal structures. 
As well as creating and optimising a new β-globin promoter containing TOPflash reporter 
construct, this chapter also provides the first evidence that the entire mammalian ZIC family 
can inhibit Wnt signalling, as previous studies have either focused on Xenopus zic, or focused 
on a single ZIC family member. These results also confirm the previous critical finding that loss 
of ZIC2 DNA binding does not alter Wnt inhibition (Pourebrahim et al., 2011), and further 
extends this result to other ZICs by showing they also do not need the second cysteine of the 
fourth ZIC finger to inhibit Wnt/β-catenin. Given the ZFD is thought to confer DNA binding to 
the ZICs, this suggests that DNA binding and therefore transactivation ability is not necessary 
for ZIC based inhibition of Wnt/β-catenin, but ideally DNA binding studies need to be 
completed with these mutants to confirm the result. In addition, as these experiments utilised 
a point mutation affecting the fourth zinc finger, and as the two roles are differently affected 
by this mutation, it further implies that the different domains of the ZIC proteins have differing 
importance for the two roles of the family. 
 
The conservation of Wnt/β-catenin inhibition throughout the family is intriguing as it implies 
that the protein region responsible for inhibition is conserved throughout the entire family 
ruling out the ZOC domain that is only found in a subset of ZICs. In fact the only regions that 
show conservation throughout the ZIC family are the ZFD and the ZF-NC. While the ZFD of the 
ZICs has previously been associated with their DNA binding function, it is entirely possible that 
they undertake both these roles as usually only 3-4 zinc fingers within a multi zinc finger 
protein undertake DNA binding, with the remainder having other functions such as protein 
interaction (Brayer and Segal, 2008). There is in fact evidence that the ZFD might be the 
domain responsible for Wnt signalling inhibition as another group has shown that loss of the 
ZFD prevents ZIC2 based inhibition of Wnt signalling (Pourebrahim et al., 2011). However, as a 
similar truncation of ZIC3 has been shown to drastically alter the sub-cellular localisation of the 
protein (Ahmed et al., 2013), it is possible that the previous result is due to a loss of nuclear 
localisation, rather than a loss of Wnt inhibition ability per se. Further studies are therefore 
required to better understand the ZIC protein regions of importance for the Wnt inhibition 
function. Such domain mapping studies will be of particular interest in predicting if mutations 
identified in the ZIC genes of humans affect this ability. 
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Figure 4.11: DNA binding incompetent ZICs are able to inhibit Wnt/β-catenin signalling. 
HEK293T were transfected with the Wnt/β-catenin signalling reporter construct pGL4.20-β-
globin-TCFx3 along with V5-β-CATENIN and the empty construct V5-DEST, a wildtype ZIC 
expression construct or a DNA binding incompetent ZIC expression construct (indicated by Ku). 
In addition one transfection included only pGL4.20-β-globin-TCFx3 and V5-DEST, to assess 
background. All five members of the ZIC family were assessed, with a) displaying ZIC2, b) ZIC5, 
c) ZIC3, d) ZIC1 and e) ZIC4. In each case the top graph shows a single representative 
experiment, western blots corresponding to transfection are shown below. For ZIC1-3 and ZIC5 
two exposures of α-β-CATENIN are shown. α-TBP and α-β-TUBULIN blots are included as 
loading controls. Error bars = S.D., N = 3 internal repeats. The bottom graph shows the pooled 
data relative to DEST. In each case the DNA binding incompetent forms of ZICs were able to 
inhibit Wnt/β-catenin signalling when measured by pGL4.20-β-globin-TCFx3. Error bars = 
S.E.M., N = 3 external repeats; * : p˂0.05, two-way ANOVA with Fischer’s unprotected post ad 
hoc test. V5-β-CAT: V5-β-CATENIN. 
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4.3.1 ZIC based depletion of β-CATENIN 
It has been suggested previously that ZIC based degradation of β-CATENIN is a major part of 
the ZIC mechanism of Wnt/β-catenin signalling inhibition (Fujimi et al., 2012). The results 
presented here also show evidence of ZIC based depletion of β-CATENIN, consistent with 
degradation. While these results do not fully explain the depletion, they do eliminate several 
potential mechanisms of depletion and thus further our understanding of this phenomenon. 
For example, several proteins have been found to inhibit Wnt signalling by depleting nuclear β-
CATENIN via promoting exportation of β-CATENIN from the nucleus to the cytoplasm (Feng-
Qian et al., 2008; MacDonald et al., 2009). However, based on the results presented here it is 
unlikely to be the case for the ZICs as the β-CATENIN depletion has been observed in both the 
nuclear and cytoplasmic fractions. Another possibility is that the ZICs promote the localisation 
of the degradation complex into the nucleus and thus promote nuclear β-CATENIN 
phosphorylation, leading to more efficient degradation, which is a Wnt inhibition mechanism 
that has been observed for Sox9 (Topol et al., 2009). It is unlikely that the ZIC proteins act in a 
similar mechanism, as ZIC1 and ZIC2 are still able to promote the depletion of truncated ΔN89-
β-CATENIN, which is missing the critical phosphorylation sites and therefore escapes targeting 
by the degradation complex. Together, these findings suggest that β-CATENIN is being 
depleted rather than relocated, but not via the β-CATENIN phosphorylation degradation based 
pathway usually associated with inhibition of Wnt signalling. One possibility is that ZICs triggers 
degradation of β-catenin levels by promoting methylation/demethylation of β-catenin 
armadillo repeats, a mechanism by which Kdma2a was recently shown to regulate nuclear 
non-phosphorylated β-catenin levels (Lu et al., 2015). 
 
Other findings call into question whether the β-CATENIN degradation is critical for ZIC Wnt 
signalling inhibition. If ZIC based inhibition of Wnt/β-catenin signalling acted through depletion 
of β-CATENIN, we would expect loss of β-CATENIN depletion to correlate with loss of Wnt/β-
catenin signalling inhibition. Such a correlation is not present for the ZICs as several of the zinc 
finger mutant forms of ZIC show reduced ability to deplete β-CATENIN (Figure 4.11) while 
maintaining their ability to inhibit Wnt/β-catenin signalling. In particular, the zinc finger 
mutant versions of ZIC1 and ZIC2 inhibit Wnt/β-catenin signalling without showing any ability 
to deplete nuclear β-CATENIN levels. These findings/observations strongly suggest that the 
major mechanism of ZIC based inhibition of Wnt/β-catenin signalling is distinct from the ZIC 
based depletion of β-CATENIN levels. 
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4.3.2 ZIC based inhibition of Wnt-dependent transcription is 
concentration dependent 
By varying the reporter or source of activation, it is possible to vary the activation of Wnt 
reporters. In particular doubling the number of TCF binding sites within the Wnt reporter 
construct appears to approximately double the response to β-CATENIN (Figure 4.7). Using a 
truncated form of β-CATENIN missing several of the phosphorylation sites which normally 
direct β-CATENIN to proteasomal degradation also drives higher levels of activation than full 
length β-CATENIN (Figure 4.10c). Interestingly, in either case increasing the background 
activation levels of the reporter constructs appears to reduce the ability of the ZICs to inhibit. 
It therefore appears that the ZICs show a bi-phasic response to Wnt signalling: in low Wnt 
environments the ZICs can inhibit Wnt signalling, whereas in higher Wnt environments the 
inhibition ability of the ZICs is lost. It is therefore critical that the experiments are first 
optimised so that ZIC activity falls in the partial inhibition range. In addition, care should be 
taken when interpreting the ZIC based Wnt inhibition observed in low Wnt environments 
when considering the ZIC actions in vivo, as it should be considered whether they exist in high 
or low Wnt environments in vivo, which would potentially alter detected inhibition. These 
observations could also partially explain why the Wnt inhibition functions of the ZICs took a 
long time to be confirmed, as the standard UPSTATE TOPflash reporter contains a high number 
of TCF binding sites, and therefore any inhibition ability could have been swamped by the high 
activation levels.  
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Chapter 5: The ZIC proteins are SUMOylated 
5.1 Introduction 
Since the identification of the SUMOylation modification of RanGAP (Matunis et al., 1996), 
thousands of proteins have been found to be SUMOylated (Geiss-Friedlander and Melchior, 
2007). These proteins are involved in an increasingly wide range of cellular processes including 
transcriptional regulation, cell cycle regulation, DNA repair, chromatin organisation and 
nuclear transport (Droescher et al., 2013; Flotho and Melchior, 2013). SUMOylation levels are 
known to be potentially affected by a range of factors including cell cycle stage, differentiation 
and cell stress. In some cases, protein SUMOylation levels are known to be increased in 
response to up-regulation of the major signalling pathways, such as FGF (Roy et al., 2014) or 
Wnt signalling (Choi et al., 2011; Liu et al., 2013). 
 
Little is currently known about how the ZIC family protein function is controlled. SUMOylation 
may represent a source of regulation, however it has been found that not all consensus sites 
are SUMOylated. As such this Chapter aims to: 
 
• Use bioinformatics analysis to identify sites within the ZICs predicted to be SUMOylated 
• Use several methods to determine whether the ZIC proteins are targeted by the post-
translational modification SUMOylation 
• Determine if any of the high probability SUMOylation sites identified within the ZICs are 
targeted by the SUMO modification 
• Determine if Wnt/β-catenin signalling pathway influences ZIC SUMOylation levels 
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5.2 Results 
5.2.1 Identification of high probability SUMOylation consensus motifs 
within ZIC proteins 
As mentioned previously (see Chapter 1), a consensus SUMOylation motif has been identified 
within the highly conserved ZF-NC domain of ZIC5. It is therefore predicted that the ZIC5 
protein would be SUMOylated at that point. However, it is unclear whether this was the only 
potential point of modification or if the ZIC5 protein also contained additional consensus 
SUMOylation motifs. In order to identify such sites the human ZIC5 amino acid sequence was 
analysed using multiple bioinformatics programs, each designed to identify high probability 
SUMOylation motifs within protein sequences. The three programs, [SUMOsp 2.0 (Ren et al., 
2009), SUMOplot Prediction (Abgent) and SUMOhydro (Chen et al., 2012)], gave similar results. 
Each program identified a second potential SUMOylation motif between the third and fourth 
zinc fingers in addition to the already detected site within the ZF-NC (Tables 5.1 and 5.2). In 
addition, SUMOplot identified a third site close to the N-terminal of ZIC5 which was not 
detected by the other programs (Tables 5.3).  
 
The ZFD and ZF-NC domain are considered to be highly conserved regions within the ZIC 
family. As such, it could be expected that the potential SUMOylation sites would be conserved 
throughout the family, which would suggest that the post-translation modification may be a 
family wide regulatory mechanism. To determine if these sites were conserved, the other ZICs 
were subjected to the same bioinformatics analysis. Unlike for ZIC5, for the remaining four 
members of the family the different prediction programs gave identical results. Curiously, the 
three potential sites showed vastly different levels of conservation within the family: the site in 
the ZF-NC was perfectly conserved within the entire ZIC family (Table 5.1), the site within the 
ZFD was only found in ZIC1, ZIC3 and ZIC5 (Table 5.2), whereas the site found at the N-terminal 
of ZIC5 was not present in any other ZIC (Table 5.3). The same variation in conservation was 
found when comparing the ZICs of different species, with only the ZF-NC showing conservation 
across all vertebrate species (Figure 5.1). Whether the levels of conservations reflect a 
difference in function for these regions is currently unclear. In total nine different potential 
SUMOylation sites were identified within the different ZIC members. 
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Lysine SUMOplot SUMOsp SUMOhydro 
ZIC1 K222 0.94 3.389 0.512 
ZIC2 K253 0.94 2.2725 1.028 
ZIC3 K248 0.94 3.389 0.595 
ZIC4 K125 0.94 3.389 0.498 
ZIC5 K393 0.94 3.389 0.495 
 
Table 5.1: SUMOylation probability scores for the lysine within the ZF-NC of the different 
human ZIC family members. Scores were produced by three different programs: SUMOplot. 
SUMOsp and SUMOhydro. In each case, the scores calculated suggest there is a high 
probability the lysines are SUMOylated. 
 
 
 
Lysine SUMOplot SUMOsp SUMOhydro 
ZIC1 K333 0.85 0.422 0.052 
ZIC2 - 
   ZIC3 K359 0.85 0.422 0.052 
ZIC4 - 
   ZIC5 K522 0.85 0.422 0.085 
 
Table 5.2: SUMOylation probability scores for the lysine situated between the third and 
fourth zinc finger of the different human ZIC family members. Scores were produced by three 
different programs: SUMOplot. SUMOsp and SUMOhydro. The lysine of interest is not found in 
ZIC2 or ZIC4. For the other ZICs, the scores calculated suggest there is a high probability the 
lysines are SUMOylated. 
 
 
 
Lysine SUMOplot SUMOsp SUMOhydro 
ZIC5 K4 0.73 - - 
 
Table 5.3: SUMOylation probability scores for the lysine situated at the end terminal of the 
human ZIC5 protein. Scores were produced by three different programs: SUMOplot. SUMOsp 
and SUMOhydro. Only SUMOplot predicted that this lysine would be SUMOylated. 
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Figure 5.1: Alignment of the potential SUMOylation sites of various species. All vertebrate 
ZICs contain the SUMOylation site within the ZF-NC (labelled here as Motif 1), but for ever 
vertebrate species only a subset of ZICs contain the site between the third and fourth zinc 
finger (labelled here as Motif 2). As only human ZIC5 contains the N-terminal site it is not 
shown here. It should be noted that some non-vertebrate species, such as D. melanogaster, 
contain both Motif 1 and 2, whereas others, such as C. elegans, have neither. 
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5.2.2 Use of the UFDS system to determine whether the ZIC family 
proteins can undergo SUMOylation 
Several in vitro and cell-based methods exist for determining whether proteins undergo the 
SUMO modification. Many of these systems involve increasing protein SUMOylation levels, 
either by removing the deSUMOylating enzymes or by increasing the rate of SUMOylation. One 
such method is UBC9 fusion directed SUMOylation (UFDS) system (Jakobs et al., 2007a; Jakobs 
et al., 2007b). 
 
As discussed previously, (see Chapter 1) the conjugation of the SUMO protein to target 
proteins usually involves three steps and three types of enzyme (Figure 1.10 and Figure 5.2). 
Briefly, first the SUMO protein is activated through binding the E1 SUMO-activating enzyme, 
the heterodimer Aos1/Uba2. In the second step, the SUMO protein is transferred to the E2 
conjugating enzyme. Most target proteins require a third step in which one of several E3 
ligating enzymes assists in transferring the SUMO protein to specific target proteins. So far at 
least 12 different SUMO E3 ligases have been identified in mammalian cells (Watts, 2013), 
each of which only acts on a subset of SUMOylation targeted proteins. The UFDS system acts 
to bypass this final step by fusing UBC9 to the protein of interest, forcing the enzyme and 
target protein into close proximity (Jakobs et al., 2007a; Jakobs et al., 2007b) (Figure 5.2). As 
UBC9 is able to recognise consensus SUMOylation sites within target proteins the close 
proximity enables efficient SUMOylation without the need for E3 ligase. Given that it is 
unknown whether the E3 ligase involved in ZIC SUMOylation is present within HEK293T cells, 
this UFDS system was initially used to analyse ZIC SUMOylation. 
 
To test the UFDS system, the UBC9 fused version of ZIC3, V5-UBC9-ZIC3, was transfected into 
HEK293T cells. In addition, to further increase the rate of SUMOylation, the levels of cellular 
SUMO1 were increased by co-transfection of YFP-SUMO1. 24 hours post-transfection cells 
were lysed and the lysates subjected to SDS-PAGE to separate the proteins based on molecular 
weight, followed by western blot analysis. Conjugation of YFP-SUMO would increase the 
molecular weight of the ZIC3 protein by approximately 40 kDa, therefore the presence of a 
higher molecular form would indicate that the protein is SUMOylated. Several such higher 
molecular weight forms are present in the presence of YFP-SUMO (Figure 5.3a), consistent 
with the protein undergoing the post-translational modification. As such it was confirmed that 
at least one of the members of the ZIC family, ZIC3, was capable of undergoing the SUMO 
modification. 
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Figure 5.2: SUMO conjugation pathway and UFDS system. SUMOylation is a multistep 
process. First, the SUMO protein is activated by through binding the E1 SUMO-activating 
enzyme, the heterodimer Aos1/Uba2. In the second step, the SUMO protein is transferred to 
the E2 conjugating enzyme, UBC9. Most target proteins require a third step in which one of 
several E3 ligating enzymes assists in transferring the SUMO protein to specific target proteins. 
The need for specific E3 enzymes is thought to act as a rate limiting step, restricting which 
proteins and the amount of protein SUMOylated at any point in time. The UFDS system acts to 
bypass this final step by fusing UBC9 to the protein of interest, forcing the enzyme and target 
protein into close proximity, enabling efficient SUMOylation without the need for E3 ligases. 
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Figure 5.3: The UFDS system enables detection of ZIC SUMOylation. HEK293T cells were 
transfected with V5-UBC9-ZIC3 and either YFP-SUMO1 or EmGFP-SUMO1. The molecular 
weight of the resulting V5-UBC9-ZIC3 protein was determined with SDS-PAGE and western blot 
analysis. a) A higher molecular weight form of ZIC3 is present in the presence but not the 
absence of YFP-SUMO1. b) Addition of EmGFP-SUMO1-WT but not a mutant form that cannot 
act in the SUMOylation pathway (EmGFP-SUMO1-ΔGG) produces a higher molecular weight 
form of ZIC3. In all cases N = nuclear enriched fragment, C = cytoplasmic enriched fragment. If 
not stated the nuclear enriched fragment is shown. 
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5.2.2.1 Identifying an appropriate negative control 
One particular step of the SUMO conjugation system was utilised to create an appropriate 
control for the cell-based system of detecting protein SUMOylation. SUMO is translated as a 
precursor protein that must be cleaved at a di-glycine motif by SENPs before it can be attached 
to target proteins (Kamitani et al., 1997). The cleavage removes a small C-terminal fragment of 
SUMO, which exposes the glycine residue through which the SUMO is attached to other 
proteins. By deleting the di-glycine motif from the SUMO protein (to create SUMO1-ΔGG) a 
form of the protein was created which was unable to act in the SUMO conjugation pathway. 
 
For reasons outlined in Appendix 3, the wildtype and ΔGG control forms of SUMO1 were 
transferred into the Vivid colors™ pcDNA™ 6.2/N-EmGFP-DEST expression vector. When co-
transfected with V5-UBC9-ZIC3-WT into HEK293T cells and analysed as described in the 
previous section, EmGFP-SUMO1-WT but not EmGFP-SUMO1-ΔGG produced higher molecular 
weight forms representing SUMOylated ZIC (Figure 5.3b), confirming the control plasmid was 
functioning correctly, and thus that the higher molecular weight form of ZIC3 was dependent 
on the SUMO conjugation pathway. 
 
5.2.3 All members of the ZIC family can be SUMOylated 
The previous experiments suggest that the ZIC3 protein can undergo the SUMO modification. 
Given the highly conserved nature of the potential SUMOylation sites, this modification would 
be expected to be conserved throughout the family. In order to determine whether the other 
members of the ZIC family were also able to undergo the post-translational modification 
SUMOylation, the constructs expressing the different members of this family fused to UBC9 
(V5-UBC9-ZIC1-WT, V5-UBC9-ZIC2-WT, V5-UBC9-ZIC3-WT, V5-UBC9-ZIC4-WT and V5-UBC9-
ZIC5-WT) were transfected into HEK293T cells either alone, or in a co-transfection with either 
EmGFP-SUMO1-WT or the control construct EmGFP-SUMO1-ΔGG. As with previous 
experiments, 24 hours post-transfection cells were lysed and the lysates subjected to SDS-
PAGE to separate the proteins based on molecular weight and analysed using western blotting.  
 
In the absence of co-transfected SUMO1 all of the western blots showed a band consistent 
with the predicted weight of the UBC9-ZIC fusion constructs (Figure 5.4, lane 1 in each blot) 
which represent unmodified ZIC. In some cases a second band was visible at a slightly higher 
molecular weight, most likely representing a small proportion of ZIC which has undergone 
additional modification, such as phosphorylation; however this band did not appear 
consistently across external repeats of the experiments. In the presence of exogenous 
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wildtype SUMO1, (Figure 5.4, lane 2 in each blot) in each case the unmodified ZIC band was 
still present, but a range of higher molecular weight bands also appeared. The presence of the 
higher molecular weight bands are consistent with the conjugation of SUMO1 increasing the 
molecular weight of the ZICs, particularly as the lowest of these bands always represent an 
increase in molecular weight of around 40 kDa, the approximate molecular weight of EmGFP-
SUMO1. Furthermore, addition of EmGFP-SUMO1-ΔGG, which is unable to act in the SUMO 
conjugation pathway, produced no higher molecular weight bands (Figure 5.4, lane 3 in each 
blot). As such, the higher molecular weight forms of ZIC seen with addition of EmGFP-SUMO1-
WT represent a SUMO conjugation pathway dependent shift.  
 
Together, these experiments indicate that all members of the ZIC family are able to undergo 
the post-translation modification SUMOylation via the SUMO conjugation pathway. 
 
5.2.4 Analysis of high probability SUMOylation consensus motifs using 
the UFDS system 
Although the finding that the entire ZIC family is able to undergo the post-translational 
modification is a critical step forward in understanding the regulation of this protein family, it 
is of equal importance to understand where in the protein structure the modification is 
occurring. As described in Section 5.2.1, several potential SUMOylation sites within the ZICs 
were identified using bioinformatics analysis. These sites can be placed into three groups: the 
first group (conserved sequence IKQE) is found in a very highly conserved region of the ZICs 
termed the ZF-NC and is seen in all human members (as well as in a range of other species); 
the second (conserved sequence FKCE) is located between the third and fourth zinc finger, but 
only in ZIC1, ZIC3 and ZIC5; the third was identified in the N-terminal region of ZIC5 and is not 
found in any other member. Each of these sites was assessed via mutagenesis analysis to 
determine if any represented true SUMO attachment sites. 
 
To determine whether any of these sites are the position at which the ZICs are being 
SUMOylated, each of the potential SUMOylation sites was mutated to change the lysine (K) 
which would normally be the site of SUMO attachment into an arginine (R), thereby preventing 
SUMOylation at that point. The UFDS system was then employed to determine if mutating the 
sites produced any difference in SUMOylation status compared to wildtype ZIC. Consistent 
with previous experiments, the UBC9 fused wildtype and mutant forms of ZIC were transfected 
into HEK293T cells either with or without co-transfection of EmGFP-SUMO1, followed by lysis 
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Figure 5.4: All members of the ZIC family can be SUMOylated. HEK293T cells were transfected 
with V5-UBC9-ZIC alone or along with either EmGFP-SUMO1-WT or EmGFP-SUMO1-ΔGG. The 
molecular weight of the resulting V5-UBC9-ZIC protein was determined with SDS-PAGE and 
western blot analysis of the nuclear enriched protein lysates. α-TBP and α-LAMIN B1 blots are 
included as loading controls. In each case the V5 tagged ZIC and EmGFP tagged SUMO were 
detected with separate western blots and thus two loadings controls are shown, each directly 
below the related western blot. a) ZIC1, b) ZIC4, c) ZIC2, d) ZIC3 and e) ZIC5. Lane 1 of (e) is not 
shown. For each member of the ZIC family, a higher molecular weight form was present in the 
presence of EmGFP-SUMO1-WT, but not in the absence of exogenous SUMO1 or in the 
presence of EmGFP-SUMO1-ΔGG. N = at least three independent repeats. 
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after 24 hours and analysis via SDS-PAGE and western blotting. While the number of potential 
SUMOylation sites varied between the different members of the ZIC family, all five members 
showed the same pattern when analysed using the UFDS system: when the SUMO consensus 
motif within the ZF-NC was disrupted several of the higher molecular weight bands were either 
no longer present or severely depleted compared to wildtype (Figure 5.5, lanes 4 compared to 
lanes 2), suggesting this is a point of SUMOylation. In contrast, mutation of any of the other 
potential SUMOylation sites had no effect (Figure 5.5, panels a, c and e, lanes 6 compared to 
lanes 2), which both indicates that these sites are not targets of SUMOylation and proves that 
increasing ZIC SUMOylation levels using the UFDS system cannot force SUMOylation of every 
lysine, thereby strengthening the validity of the assay. Together these results indicate that out 
of the identified potential sites within ZICs, only the sites within the highly conserved ZF-NC 
region represent true target SUMOylation sites. 
 
5.2.5 Analysis of ZIC SUMOylation without the UFDS system 
The UFDS experiments provide strong evidence that all members of the ZIC family are 
SUMOylated within the conserved ZF-NC region. However, it is possible that this result is due 
to the UBC9 fusion forcing SUMOylation of these proteins. As such, SUMOylation of the ZICs 
was also assessed without the UBC9 fusion. As the lack of ZIC fusion to UBC9 should 
dramatically decrease the rate of SUMOylation, these experiments were completed with a 
greatly increased amount of starting cellular material. Aside from this difference, these 
experiments were completed identically to the UFDS experiments: HEK293T cells were 
transfected with the different V5-ZIC constructs either alone, or in a co-transfection with 
either EmGFP-SUMO1-WT or the control construct EmGFP-SUMO1-ΔGG. 24 hours post-
transfection cells were lysed and the lysates analysed via SDS-PAGE and western blotting.  
 
As with the UFDS experiments, in each case addition of EmGFP-SUMO1-WT produced an 
additional higher molecular weight band which was not present either when V5-ZIC was 
transfected alone, or co-transfected with EmGFP-SUMO1-ΔGG (Figure 5.6 and Figure 5.7 lanes 
1-3). The presence of such a higher molecular weight form confirms all members of the ZIC 
family undergo the post-translation modification SUMOylation via the SUMO conjugation 
pathway. 
 
5.2.6 Mutation of the ZF-NC is sufficient to prevent all ZIC SUMOylation 
Together, the bioinformatics analysis and the UFDS experiments suggest that while multiple 
potential SUMOylation sites are present in several members of the ZIC family of these only the 
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site within the ZF-NC is actually a target of SUMOylation. To confirm this finding the wildtype 
V5-ZIC expression constructs and the V5-ZIC expression constructs containing the lysine to 
arginine mutations within the various potential SUMOylation sites were transfected into 
HEK293T cells with and without EmGFP-SUMO1 co-transfection. For this experiment, only the 
SUMOylation sites that are conserved between multiple ZICs were analysed. As with previous 
experiments cells were lysed 24 hours after transfection and analysed via SDS-PAGE and 
western blotting.  
 
Given previous difficulties detecting ZIC5, western blot analysis for this protein was completed 
both with the anti-V5 antibody used previously and an anti-ZIC5 rabbit sera. Consistent with 
UFDS analysis, the western analysis with the V5 antibody showed mutation of the ZF-NC 
prevented formation of the higher molecular weight band (Figure 5.7). Surprisingly, initial 
analysis of V5-ZIC5 (with V5 antibody) appeared to indicate mutation of the other analysed 
consensus SUMO motif between the third and fourth zinc fingers (K522R) reduced the levels of 
the higher molecular weight band representing the SUMOylated form of ZIC5 (Figure 5.7). 
However, analysis of the same lysate with rabbit anti-ZIC5 sera shows these bands are of equal 
intensity, suggesting the V5 antibody result is slightly skewed due to the high levels of protein 
present. The rabbit anti-ZIC5 sera also detects multiple other higher molecular weight bands, 
but as these are present in both the presence and absence of EmGFP-SUMO1-WT and were 
not detected by the V5 antibody, it is likely they represent non-specific background.  
 
The other members of the ZIC family were consistent with the ZIC5 and UFDS results, with only 
mutation of the site in the ZF-NC showing any impact on SUMOylation of the ZICs (Figure 5.8). 
In fact mutation of this single lysine removed all higher molecular weight forms of the protein, 
indicating mutation of this single site is sufficient to prevent all ZIC SUMOylation, which 
strongly suggests that the ZF-NC is the only point of SUMOylation within members of the ZIC 
family. 
 
5.2.7 Wnt/β-catenin signalling increases the levels of ZIC SUMOylation 
There are several factors that are thought to promote protein modification by SUMOylation, 
including cell cycle stage, stress and differentiation (Watts, 2013). Which of these factors alters 
ZIC SUMOylation is unclear. Given that loss of ZIC5 SUMOylation in mice lead to a loss of 
neural crest phenotype (see Section 1.4.1), one intriguing possibility is that ZIC SUMOylation is 
driven by one of the major signalling pathways involved in initial specification of neural crest. 
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Figure 5.5: All members of the ZIC family can be SUMOylated within the ZF-NC conserved 
region. HEK293T cells were transfected with wildtype or potential SUMO site mutant V5-UBC9-
ZIC alone or along with either EmGFP-SUMO1-WT. The molecular weight of the resulting V5-
UBC9-ZIC protein was determined with SDS-PAGE and western blot analysis of the nuclear 
enriched protein lysates. α-TBP and α-LAMIN B1 blots are included as loading controls. In each 
case the V5 tagged ZIC and EmGFP tagged SUMO were detected with separate western blots 
and thus two loadings controls are shown, each directly below the related western blot. a) 
ZIC1, b) ZIC2, c) ZIC3, d) ZIC4 and e) ZIC5. For each member of the ZIC family, higher molecular 
weight forms were present in the presence of EmGFP-SUMO1-WT, but not in the absence of 
exogenous SUMO1. However, the ZICs with mutation of the ZF-NC (lanes 4 for each blot) 
showed loss of several of the higher molecular bands, consistent with these mutations 
preventing SUMOylation of the proteins. N = at least three independent repeats. 
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Figure 5.6: All members of the ZIC family are SUMOylated. HEK293T cells were transfected 
with V5-ZIC alone or along with either EmGFP-SUMO1-WT or EmGFP-SUMO1-ΔGG. The 
molecular weight of the resulting V5-UBC9-ZIC protein was determined with SDS-PAGE and 
western blot analysis of the nuclear enriched protein lysates. α-TBP and α-LAMIN B1 blots are 
included as loading controls. In each case the V5 tagged ZIC and EmGFP tagged SUMO were 
detected with separate western blots and thus two loadings controls are shown, each directly 
below the related western blot. a) ZIC1, b) ZIC2, c) ZIC3 and d) ZIC4. For each member of the 
ZIC family, a higher molecular weight form was present in the presence of EmGFP-SUMO1-WT, 
but not in the absence of exogenous SUMO1 or in the presence of EmGFP-SUMO1-ΔGG. N = at 
least three independent repeats.  
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Figure 5.7: ZIC5 is SUMOylated. HEK293T cells were transfected with wildtype or potential 
SUMO site mutant V5-ZIC5 alone or along with either EmGFP-SUMO1-WT or EmGFP-SUMO1-
ΔGG. The molecular weight of the resulting V5-ZIC protein was determined with SDS-PAGE and 
western blot analysis of the nuclear enriched protein lysates. α-TBP (for the α-V5 blot) and α-
LAMIN B1 (for the α-GFP blot) blots are included as loading controls. The top panel shows the 
western blot analysis with V5 antibody. For wildtype ZIC5 and the ZIC5 mutant K522R a higher 
molecular weight form was present in the presence of EmGFP-SUMO1-WT (although the band 
was fainter for the K522R mutant), but not in the absence of exogenous SUMO1 or in the 
presence of EmGFP-SUMO1-ΔGG. On the other hand, no such higher molecular weight form 
was present for ZIC5-K393R. The bottom two panels show two different exposures for the 
western blot analysis with anti ZIC5 sera. For wildtype ZIC5 and the K522R mutant, a higher 
molecular weight form of ZIC5 not present in the absence of exogenous SUMO1 or in the 
presence of EmGFP-SUMO1-ΔGG, but present in the presence of EmGFP-SUMO1-WT (although 
some background higher molecular weight forms were present in all cases). On the other 
hand, no such higher molecular weight form was present for ZIC5-K393R. N = three 
independent repeats.  
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Figure 5.8: All members of the ZIC family are SUMOylated within the ZF-NC conserved 
region. HEK293T cells were transfected with wildtype or potential SUMO site mutant V5-UBC9-
ZIC alone or along with EmGFP-SUMO1-WT. The molecular weight of the resulting V5-ZIC 
protein was determined with SDS-PAGE and western blot analysis of the nuclear enriched 
protein lysates. α-TBP and α-LAMIN B1 blots are included as loading controls. In each case the 
V5 tagged ZIC and EmGFP tagged SUMO were detected with separate western blots and thus 
two loadings controls are shown, each directly below the related western blot. a) ZIC1, b) ZIC4, 
c) ZIC2 and d) ZIC3. For each member of the ZIC family, a higher molecular weight form was 
present in the presence of EmGFP-SUMO1-WT, but not in the absence of exogenous SUMO1. 
However, the ZICs with mutation of the ZF-NC (but not any of the other mutants) showed loss 
of the higher molecular bands, consistent with these mutations prevent SUMOylation of the 
proteins. N = two independent repeats.  
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In particular activation of Wnt signalling has been found to drive the SUMOylation of several 
proteins including TBL1, TBR1 and SOX9 (Choi et al., 2011; Liu et al., 2013). 
 
In order to determine if activation of Wnt/β-catenin signalling altered levels of ZIC 
SUMOylation, two members of the ZIC family, ZIC1 and ZIC2, were selected for further 
analysis. HEK293T cell were co-transfected with EmGFP-SUMO1 and either V5-ZIC1 or V5-ZIC2. 
24 hours after transfection the cell media was replaced with either untreated media or media 
containing the Wnt activator (2’Z,3’E)-6-Bromoindirubin-3’-oxime (BIO). BIO inhibits the action 
of GSKβ, a member of the β-CATENIN degradation complex, and thus increases Wnt/β-catenin 
signalling levels (Meijer et al., 2003; Sato et al., 2004). After the transfected cells were 
incubated with either BIO treated or untreated media for 24 hours the cells were lysed and the 
SUMOylation levels of the ZICs were determined via SDS-PAGE and western blotting. The 
activation of Wnt signalling by addition of BIO produced a visible increase in the SUMOylated 
forms of both ZIC1 and ZIC2 (Figure 5.9a, b). By quantifying the amounts of SUMOylated ZIC 
relative to the loading control in the presence and absence of BIO across three independent 
repeats, the increase was found to be statistically significant (Figure 5.9c), which indicates that 
activation of Wnt/β-catenin signalling is sufficient to increase levels of SUMOylated ZIC. 
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Figure 5.9: Elevation of Wnt signalling alters ZIC SUMOylation. HEK293T cells were 
transfected with EmGFP-SUMO1 and either V5-ZIC1-WT or V5-ZIC2-WT. The transfected cells 
were then incubated with in presence or absence of 5 µM BIO, which stimulates Wnt 
signalling. The resulting lysates were analysed via SDS-PAGE and western blotting. α-TBP blots 
are included as loading controls a) Single representative experiment showing resulting western 
blots. b) Relative levels of protein of the western blots shown in (a). Levels were Quantified 
using Image J. c) Pooled data of three independent experiments. In each case (i) ZIC1 and (ii) 
ZIC2. * : p˂0.05, student’s T-test. Error bars = S.E.M.  
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5.3 Discussion 
5.3.1 ZF-NC is conjugated in each case by at least two SUMO molecules 
The presence of a higher molecular weight form of the ZIC proteins in the presence of wildtype 
SUMO1, but not the glycine mutant SUMO1-ΔGG, indicates all members of this family of 
proteins undergo the post-translation modification SUMOylation. Although attachment of one 
EmGFP-SUMO1 moiety should increase the molecular weight of the proteins by approximately 
40 kDa, when analysed either by the UFDS system or without the UBC9 fusion, the actual shift 
is closer to double this value (≈80 kDa), or triple (≈120 kDa) in the case of ZIC2, which is 
consistent with several SUMO1 moieties simultaneously attaching to the ZIC proteins. There 
are two different ways that multiple SUMO moieties can be attached to target proteins: either 
single SUMO moieties can be attached at multiple points of the protein, termed multi-mono-
SUMOylation, or all the SUMO moieties can be attached through a single point via formation 
of a SUMO chain, termed poly-SUMOylation. The finding that all the higher molecular weight 
forms of the ZICs are lost when a single point mutation is introduced into the ZF-NC domain 
suggests that all the SUMOylation occurs through that single point and therefore represents a 
case of poly-SUMOylation (Figure 5.10).  
 
Originally it was anticipated only SUMO2 and SUMO3 could form poly-SUMO chains as SUMO1 
lacks an internal SUMO consensus motif found in SUMO2 and SUMO3 which allows these 
proteins to be targeted for the modification (Tatham et al., 2001). However, this theory has 
since been disproved with the observation of SUMO1 chain formation (Pichler et al., 2002), 
presumably occurring through a non-consensus SUMOylation motif. The function of SUMO 
chains is not completely clear but in some cases the formation of such chains may be up-
regulated in response to cellular stresses (Golebiowski et al., 2009; Tomanov et al., 2014) and 
loss of these chains in yeast causes defects in maintenance of chromatin organization resulting 
in widespread transcriptional activation (Srikumar et al., 2013). Some proteins, including CENP-
E, RNF4, STUbL and ZIP1, are through to interact with proteins modified by SUMO chains, but 
not either non-modified proteins or proteins modified by single SUMO moieties (Vertegaal, 
2010). Often, but not always, these proteins contain multiple closely spaced SUMO-binding 
domains such as SIMs, which are thought to favour the interaction with multiple SUMO 
moieties. For example the poly-SUMO-specific E3 ubiquitin ligase RNF4 contains four tandem 
SIMs (Tatham et al., 2008), which allows interaction with SUMO chains, resulting in 
dimerization and thus activation (Figure 5.11) (Rojas-Fernandez et al., 2014). 
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Figure 5.10: Schematic of ZIC family proteins demonstrating the site of SUMO modification. 
In each case at least two of two SUMO moieties are thought to be attached at the ZF-NC 
domain, representing an instance of poly-SUMOylation.  
 
 
  
169 
 
 
 
 
 
 
 
Figure 5.11: RNF4 interacts with poly-SUMOylated, but not mono-SUMOylated proteins. a) If 
SUMOylation targets are mono-SUMOylated or unmodified RNF4 does not interact with the 
substrates. b) If SUMOylation targets are poly-SUMOylated RNF4 interacts with the resulting 
SUMO chains through four tandem SIMs, which cause RNF4 dimerization. Adapted from Rojas-
Fernandez et al., 2014. 
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No matter the purpose of the SUMO chain, the finding of SUMO1 attachment represents the 
first potential explanation of the hitherto uncharacterised ZF-NC region. In fact the high level 
of conservation of this region, with the ZF-NC conserved region being present in species as 
diverse as the invertebrate Drosophila, suggests the ZF-NC region, and therefore the 
SUMOylation site, is of critical importance of all vertebrates ZIC members. 
 
5.3.2 Why is the ZF-NC SUMOylated but not the other potential sites? 
Although all of the bioinformatics programs predict that ZIC1, ZIC3 and ZIC5 have at least two 
sites that would undergo the post-translation modification SUMOylation in each case out of 
the high probability sites only the motif only the site within the ZF-NC appears to actually be 
SUMOylated. Even when analysed using the UFDS system, which greatly increased the 
efficiency of protein SUMOylation, the other potential sites showed no evidence of SUMO1 
attachment. Potentially this difference is due to the site within the ZF-NC showing higher 
probability values than the other site. It is also possible that the difference in modification is 
due to the difference in position of the two potential sites. Most confirmed points of SUMO 
attachment occur in unstructured regions or extended loops (Gareau and Lima, 2010), 
whereas the partially conserved site within the ZICs which is not SUMOylation partially 
overlaps with the fourth zinc finger. It is therefore possible that the secondary structure 
produced by these zinc fingers domains blocks SUMOylation conjugation enzymes from 
accessing this site and thus prevents the post-translation modification of this site. In addition, 
the protein regions around SUMOylated lysines are usually deficient in cysteine residues 
(Hendriks et al., 2014) which is presumed to further prevent formation of secondary 
structures. The potential site at the start of zinc finger four on the other hand contains a 
cysteine residue immediately adjacent to the lysine. Together these factors may work to 
prevent SUMOylation at this site. 
 
5.3.3 Wnt/β-catenin signalling promotion of ZIC SUMOylation could 
explain observed synergism 
The observed control of ZIC post-translational modification by Wnt signalling has the potential 
to explain previously observed occurrences of the ZICs and Wnt acting in concert. For example, 
Xenopus animal explant experiments have shown that while ectopic zic expression activates 
mild expression of the neural crest specifier foxd3, co-injection of Wnt is required for strong 
activation of the neural crest specifier (Sato et al., 2005). The data presented here suggests a 
mechanism of this synergism with activation of Wnt signalling triggering the post-translation 
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modification of the ZIC proteins. Thus Wnt signalling could influence ZIC activity and therefore 
neural crest formation without the need for WREs. 
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Chapter 6: SUMOylation alters the activity of the 
ZICs 
6.1 Introduction 
As outlined in Chapter 1, the members of the ZIC family have various critical regulatory roles 
during early development. Part of the reason for this plethora of roles is the multifunctional 
nature of these proteins, which are able to undertake both transcription factor and co-factor 
functions (Ali et al., 2012). Whether these proteins can undergo both of these functions 
simultaneously is currently unclear. In addition, some of the roles of the ZIC family appear to 
be opposing in function. For example the ZICs promote expression of Foxd3 (Simões-Costa et 
al., 2012) and thus promote neural crest formation, and yet the ZICs also promote expression 
of Nanog (Lim et al., 2007), which has been shown to repress neural crest cell fate (Wang et 
al., 2012). It is of great interest how these opposing roles are differentially regulated. One 
possible source of such regulation of activity is the SUMOylation modification of the conserved 
ZF-NC region of the ZICs identified in Chapter 5. As such, the aim of this chapter is to assess the 
effect of SUMOylation on ZIC function using cell based reporter assays which represent the in 
vivo functions of the ZICs. 
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6.2 Results 
6.2.1 SUMOylation inhibits the ability of ZIC1, ZIC2 and ZIC3 to activate 
Z3M2 
To assess the regulatory effect of ZIC SUMOylation, the activity of wildtype and SUMOylation 
incompetent forms of ZIC identified in Chapter 5 were compared using the cell based 
luciferase method developed in Section 4.2.1 (optimisation of transfection for the experiments 
of this Chapter is described in Appendix 4). There are several possible choices of ZIC reporter 
for such a comparison, of which the most widely used is pXp-ApoE. However, despite the 
numerous studies that have utilised this reporter in the past (Ahmed et al., 2013; Brown et al., 
2005; Salero et al., 2001), the lack of known overlap in expression of the ZICs and ApoE 
suggests that the ZIC family does not regulate this promoter in vivo. To overcome this issue the 
effect of SUMOylation on ZIC transactivation was measured using a new reporter, pGL4.20-β-
globin-Z3M2, developed by another member of the Arkell Laboratory. pGL4.20-β-globin-Z3M2 
contains a multimerized ZIC3 consensus binding motif identified in two independent studies by 
universal protein binding microarray of purified proteins (Badis et al., 2009) and via genome-
wide chromatin precipitation in mouse ESCs (Lim et al., 2010). It is therefore thought to better 
represent the role of the ZICs in vivo than pXp-ApoE. 
 
Despite the strong conservation within the zinc finger region of the ZIC family, it has previously 
been found only ZIC1, ZIC2 and ZIC3 activate the pGL4.20-β-globin-Z3M2 reporter in cell based 
assays (Arkell Laboratory, unpublished observation), and as such the other members of the 
family were not assessed here. Comparison of the wildtype to the SUMO incompetent forms 
shows a consistent pattern across all ZICs tested (Figure 6.1, (i) panels): under normal cellular 
conditions in all cases the SUMOylation incompetent form of the ZICs drove significantly higher 
activation levels than wildtype ZIC, suggesting SUMOylation decrease the transactivation 
ability of the ZICs. However, it is also possible that the reduction is due to a different effect of 
the mutant, such as a structural change or different modification.  
 
To confirm any change in function was due to loss of the SUMO post-translational 
modification, these experiments were repeated in the presence of FLAG-UBC9-C93S, a mutant 
form of the mouse E2 conjugating enzyme UBC9, the presence of which inhibits global 
SUMOylation in a dominant negative manner. If the difference between wildtype and ZF-NC 
mutated ZIC was due to loss of SUMOylation, then we would expect that blocking global 
SUMOylation would result in the loss of wildtype ZIC SUMOylation and thus cause wildtype 
and ZF-NC mutant forms of ZIC to act identically in the pGL4.20-β-globin-Z3M2 assay. On the 
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other hand, if the difference in activity was due to any other effect of the mutation then it 
should not be affected by changes in global SUMOylation. When FLAG-UBC9-C93S was 
incorporated into the experiment the wildtype and ZF-NC mutant forms of ZIC showed no 
significant difference in activation of pGL4.20-β-globin-Z3M2 (Figure 6.1 (ii) panels). As such, 
together these results suggest that SUMOylation inhibits ZIC based activation of pGL4.20-β-
globin-Z3M2. 
 
6.2.2 ZIC SUMOylation promotes neural crest formation in vivo 
The finding that SUMOylation decreases ZIC based activation of pGL4.20-β-globin-Z3M2 was 
somewhat unexpected, given the previous Zic5-K363R mouse based experiments (see Chapter 
1) have suggested SUMOylation incompetent ZIC5 acts as a hypomorphic allele. To clarify this 
difference, the gene expression changes of the Zic5-K363R mice were further investigated. 
 
Ventral white belly spots observed for Zic5-K363R heterozygous mice are an indication of trunk 
neural crest hypoplasia. Several of the ZICs are thought to act as neural plate border genes 
during neural crest development. Although zic1 is known to be a neural plate border gene 
critical for the formation of neural crest in Xenopus (Plouhinec et al., 2014; Sato et al., 2005) 
Zic2, Zic3 and Zic5 likely undertake this process in mammals. Collectively the neural plate 
border genes act with several of the major signalling pathways (including Wnt, BMP and FGF 
signalling) to initiate expression of the neural crest specifiers (Groves and LaBonne, 2014; 
Stuhlmiller and García-Castro, 2012). In situ analysis of one such specifier, Foxd3, at 8.5 dpc 
shows expression was reduced in Zic5-K363R homozygous embryos, and in particular the 
posterior limit of Foxd3 is shifted rostrally (Figure 6.2a and b). However, the depletion was less 
than when all Zic5 function was lost (Figure 6.2c), suggesting loss of SUMOylation produces a 
partial loss of ZIC5 ability to promote neural crest. 
 
6.2.3 Creating a reporter assay to measure ZIC based promotion of 
neural crest 
To better understand the discrepancy between the in vivo and cell based results a new ZIC 
based cell reporter assay needed to be generated which better represented the ZICs activity 
during early development as neural plate border genes. Although ZIC activation of Foxd3 
expression in mice is not completely understood, ZIC1 activation of FOXD3 expression in chick 
has recently been suggested to occur through a well-conserved FOXD3 enhancer (Simões-
Costa et al., 2012). Given Zic2Ku/Ku mice have previously been shown to have down regulated  
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Figure 6.1: SUMOylation decreases the activation of Z3M2 by ZIC1-3. HEK293T were 
transfected with the pGL4.20-β-globin-Z3M2 reporter construct along with either wildtype ZIC, 
the SUMOylation incompetent ZIC mutants or the empty construct V5-DEST. In addition the 
experiment was performed in the (i) presence and (ii) absence of the dominant negative 
SUMOylation inhibitor FLAG-UBC9-C93S. a) ZIC1, b) ZIC2 and c) ZIC3. In each case the top panel 
shows single representative experiment. Error bars = S.D. of three internal repeats. Western 
blots corresponding to particular transfection are shown below graphs. α-TBP blots are 
included as loading controls. In the case of (a) two western blots were performed and thus two 
loadings controls are shown, each directly below the related western blot. In each case the 
bottom panel shows pooled data relative to DEST. For all ZICs in the absence of FLAG-UBC9-
C93S the SUMOylation incompetent ZIC mutants showed significantly higher levels of 
activation than the wildtype ZICs. The difference was lost in the presence of FLAG-UBC9-C93S.  
Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, two-way ANOVA with Fischer’s 
unprotected post ad hoc test. 
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Figure 6.2: Expression of Foxd3 in wildtype and Zic5 mutant mice. In situ hybridisation of 
Foxd3 at 8.5 d.p.c. Embryos were stage matched based on the number of somites. 
Zic5K363R/K363R = Zic5-K363R homozygous, Zic5-/- = Zic5 null homozygous. Arrows indicate 
posterior limit of Foxd3 expression. 
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Foxd3 expression (Elms et al., 2003) and zic3 knockdown has been shown to reduce foxd3 
expression in zebrafish (Winata et al., 2013), the regulation of this region by ZICs is most likely 
conserved across species.  
 
In order to further investigate the enhancer, the corresponding region in the mouse genome 
was identified using the ECR browser. Consistent with previous findings, the enhancer region 
showed strong conservation across a number of species, including Xenopus, chick, mouse and 
human (Figure 6.3). However, the enhancer was observed to be considerably further away 
from the Foxd3 coding sequence in mouse than in chick (approximately 150 kb vs 44 kb). Once 
identified, the enhancer region was analysed using rVista to identify the ZIC binding site, as 
well as to identify any other protein binding sites (Figure 6.4). While a number of binding sites 
for proteins including OCT4 and TCF where identified, the majority of these were at least 400 
bp away from the ZIC binding site. As the purpose of the desired reporter was to measure ZIC 
based transactivation, it was decided to exclude the majority of the non-ZIC protein binding 
sites by only including the portion of the enhancer flanking the ZIC site by 250 bp in the new 
ZIC reporter (Figure 6.4). While the majority of non-ZIC protein binding sites were excluded, a 
notable exception of a SMAD binding site located 50 bp downstream of the ZIC binding site. 
The chosen region was amplified from mouse genomic DNA and inserted into pGL4.20-β-globin 
to create pGL4.20-β-globin-Foxd3, the desired ZIC reporter. 
 
It should be noted that the other reporter constructs mentioned in this chapter also contain 
the enhancer/protein binding site of interest upstream of the β-globin within the 
pGL4.20[luc2/Puro] vector, thus are identical apart from the enhancer/protein binding site 
thought to be influenced by direct ZIC interaction (in the case of pGL4.20-β-globin-Foxd3 and 
pGL4.20-β-globin-Z3M2) or through ZIC interacting with other proteins (in the case of pGL4.20-
β-globin-TCFx3, which ZICs influence through interaction with the TCF proteins). 
 
6.2.3.1 Testing the pGL4.20-β-globin-Foxd3 assay 
To determine the usefulness of the newly created pGL4.20-β-globin-Foxd3 reporter, cells were 
transfected with the reporter and the expression constructs for the different ZICs. The 
activation of the newly created pGL4.20-β-globin-Foxd3 reporter was tested with all five 
members of the ZIC family, as transactivation assays previously used to measure ZIC activity 
have often only shown activation by a subset of the ZICs (Ishiguro et al., 2004 and Arkell 
Laboratory, unpublished result). It was also thought that given ZIC1 and ZIC4 were not  
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Figure 6.3: Conservation of the Foxd3 enhancer. Screenshot of the ECR browser after comparison of the genomic region 5’to Foxd3 between several species 
including human, mouse, Xenopus, zebrafish and chick. Peaks shown in red show a high level of conservation between species. The enhancer of interest is 
indicated by the blue box. 
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Figure 6.4: Protein binding sites within the Foxd3 enhancer. Mouse genomic region equivalent to the FOXD3 enhancer identified in chick by Simões-Costa et 
al., 2012. The region identified by the ECR browser as showing a high level of conservation across several species is marked by a grey box. Predicted protein 
binding sites identified by rVista are marked by purple boxes, with the exception of the ZIC binding site which is marked by a blue box. The region PCR amplified 
to create the pGL4.20-β-globin-Foxd3 reporter assay is marked by red box. 
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normally expressed early enough to regulate initial neural crest development (Houtmeyers et 
al., 2013) and therefore do not regulate Foxd3 expression at that stage, these two genes may 
not be able to activate the reporter. Despite these concerns all members of the ZIC family 
activated transcription of the pGL4.20-β-globin-Foxd3 reporter to varying extents (Figure 6.5). 
We thus concluded that the generation of a new ZIC reporter construct to represent ZIC 
activity as neural plate border genes was successful. 
 
6.2.4 SUMOylation of ZICs promotes activation of Foxd3 by ZIC2, ZIC3 
and ZIC5 
In order to better understand the influence SUMOylation has on the ZICs during neural crest 
development, the activity of the wildtype and SUMOylation incompetent forms of the ZICs 
were assessed using the newly generated pGL4.20-β-globin-Foxd3 reporter construct. 
Interestingly, the effect of SUMOylation on ZIC activation of the Foxd3 enhancer varies though-
out the family. In normal cellular conditions, the SUMOylation incompetent forms of ZIC2, ZIC3 
and ZIC5 show significantly reduced activation of pGL4.20-β-globin-Foxd3 compared to 
wildtype ZIC (Figure 6.6a-c (i) panels). On the other hand no significant difference in activation 
was detected between the wildtype and SUMOylation incompetent forms of ZIC1 and ZIC4, 
suggesting there is variation in the consequences of SUMOylation within the ZIC family (Figure 
6.6d-e). 
 
Consistent with the pGL4.20-β-globin-Z3M2 experiments, to determine whether the difference 
in pGL4.20-β-globin-Foxd3 activation between the wildtype and SUMOylation incompetent 
forms of ZIC2, ZIC3 and ZIC5 was due to loss of SUMOylation or a secondary effect of the 
mutation, the experiment was performed in presence of dominant negative SUMOylation 
inhibitor FLAG-UBC9-C93S. However, unlike the Z3M2 experiments the addition of FLAG-UBC9-
C93S did not give a clear cut result. ZIC5 performed as predicted: the addition of FLAG-UBC9-
C93S resulted in wildtype ZIC5 showing no significant difference in activation as SUMOylation 
incompetent ZIC5 [Figure 6.6c panel (ii)], indicating the increased activation in the absence of 
FLAG-UBC9-C93S was due to ZIC5 SUMOylation. The ZIC2 and ZIC3 result was, however, 
unexpected: presence of FLAG-UBC9-C93S reduced the activation by both wildtype and 
mutant forms of ZIC2 and ZIC3 to levels not significantly different from background levels 
(Figure 6.6a, b (ii) panels). Such a result is consistent with SUMOylation increasing the ability of 
ZIC2 and ZIC3 to activate transcription both directly and indirectly, and thus suggests that 
other proteins involved in ZIC2 and ZIC3 transactivation of Foxd3 are also positively regulated 
by SUMOylation. 
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Figure 6.5: Testing the pGL4.20-β-globin-Foxd3 assay. HEK293T were transfected with the 
pGL4.20-β-globin-Foxd3 reporter construct along with either a member of the ZIC family or the 
empty construct V5-DEST. Each member of the ZICs is able to drive activation of the Foxd3 
enhancer fragment. Note that data is pooled from multiple experiments, as such 
corresponding western blots are not shown. Error bars = S.D. of three internal repeats. 
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Figure 6.6: SUMOylation increases the activation of the Foxd3 enhancer by ZIC2, ZIC3 and 
ZIC5. HEK293T were transfected with the pGL4.20-β-globin-Foxd3 reporter construct along 
with either wildtype ZIC, the SUMOylation incompetent ZIC or the empty construct V5-DEST. In 
addition for a-c, the experiment was performed in the (i) absence and (ii) presence of the 
dominant negative SUMOylation inhibitor FLAG-UBC9-C93S. a) ZIC2, b) ZIC3, c) ZIC5, d) ZIC1 
and e) ZIC4. In each case the top panel shows single representative experiment. Error bars = 
S.D. of three internal repeats. Western blots corresponding to particular transfection are 
shown below graphs. α-TBP blots are included as loading controls. For both (a) and (c) two 
western blots were performed and thus two loadings controls are shown, each directly below 
the related western blot. In each case the bottom panel shows pooled data relative to DEST. 
For ZIC2, ZIC3 and ZIC5 the ZF-NC mutants showed significantly lower levels of repression than 
the wildtype ZICs. There was no significant difference in the presence of FLAG-UBC9-C93S. 
Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, two-way ANOVA with Fischer’s 
unprotected post ad hoc test.  
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In summary SUMOylation appears to differentially regulate members of the ZIC family ability 
to transactivate the Foxd3 enhancer, with ZIC2, ZIC3 and ZIC5 all up-regulated by 
SUMOylation, whereas ZIC1 and ZIC4 transactivation is unaffected by the modification. 
 
6.2.5 Specific prevention of SUMOylation of the ZICs increases WNT 
inhibition ability of ZIC1-3 and ZIC5 
From the results presented in this Chapter so far, it is clear that SUMOylation can alter 
transactivation activity of the ZICs. However, the ZICs are multifunctional proteins and can also 
regulate transcription through co-factor activity. In order to determine if such co-factor activity 
of the ZICs was also affected by SUMOylation, the Wnt/β-catenin inhibition ability of the 
wildtype and SUMOylation incompetent forms of ZIC was compared using the pGL4.20-β-
globin-TCFx3 reporter construct described in Chapter 4.  
 
Given the apparent variation in the strength of Wnt repression by different members of the 
ZIC family, these experiments used different β-CATENIN expression constructs to stimulate 
Wnt/β-catenin signalling. As ZIC1 and ZIC2 fully repress pGL4.20-β-globin-TCFx3 activation by 
V5-β-CATENIN (Section 4.2.5), it was judged that an increase in Wnt repressive ability would 
not be visible; thus ΔN89-β-CATENIN, which is repressed by ZIC1 and ZIC2 to a lesser extent, 
was instead used (Section 4.2.4). However, previous experiments also showed that ZIC3, ZIC4 
and ZIC5 do not repress ΔN89-β-CATENIN to a detectable extent (Section 4.2.4), and therefore 
for these ZICs V5-β-CATENIN was used to stimulate Wnt/β-catenin signalling. A β-catenin 
treatment was included in the experiment to confirm the assay was performing as expected 
and ZIC was repressing Wnt signalling. However, as only the difference between the two forms 
of ZIC was of interest it was not included the statistical analysis. Thus in Figures 6.7 and 6.8 the 
combined results have one less treatment shown than the single repeat. 
 
Similar to the pGL4.20-β-globin-Foxd3, the effect of SUMOylation of ZIC activity varied 
throughout the family. While the wildtype and mutant forms of ZIC4 showed no significant 
difference in inhibition ability (Figure 6.8), for all other members of the family the 
SUMOylation incompetent forms showed a significantly greater level of Wnt/β-catenin 
inhibition than the wildtype forms of the ZICs (Figure 6.7 (i) panels). Consistent with previous 
experiments, to confirm that the change in activity was due to loss of SUMOylation the 
assessment of Wnt/β-catenin inhibition was also completed in the presence of the global 
SUMOylation inhibition. When SUMOylation inhibitor FLAG-UBC9-C93S was incorporated into 
the experiment the wildtype and ZF-NC mutant forms of ZIC exhibited no significant difference 
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in the levels of Wnt/β-catenin signalling inhibition (Figure 6.7 (ii) panels). Together these 
results suggest that SUMOylation of ZIC1, ZIC2, ZIC3 and ZIC5 interferes with the ability of 
these ZICs to inhibit Wnt/β-catenin signalling. 
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Figure 6.7: SUMOylation increases ZIC based inhibition of Wnt signalling. HEK293T were 
transfected with the Wnt/β-catenin reporter construct along with either only V5-DEST or V5-β-
CATENIN and either wildtype ZIC, the ZF-NC ZIC mutants or the empty construct V5-DEST. In 
addition the experiment was performed in the (i) presence and (ii) absence of dominant 
negative SUMOylation inhibitor FLAG-UBC9-C93S. a) ZIC1, b) ZIC2, c) ZIC3, and d) ZIC5. In each 
case the top panel shows single representative experiment. Error bars = S.D. of three internal 
repeats. Western blots corresponding to particular transfection are shown below graphs. α-
TBP and α-β-TUBULIN blots are included as loading controls. In the case of (a) two western 
blots were performed with the nuclear enriched protein fraction and thus two loadings 
controls are shown, each directly below the related western blot. In each case the bottom 
panel shows pooled data relative to DEST. For ZIC1-3 and ZIC5 the ZF-NC mutants showed 
significantly higher levels of repression than the wildtype ZICs in the absence of FLAG-UBC9-
C93S. In the presence of FLAG-UBC9-C93S the wildtype and SUMOylation incompetent forms 
show no difference in repression ability. Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, 
two-way ANOVA with Fischer’s unprotected post ad hoc test. V5-β-CAT = V5-β-CATENIN. 
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Figure 6.8: SUMOylation does not alter ZIC4 based inhibition of Wnt signalling. HEK293T 
were transfected with the Wnt/β-catenin reporter construct along with either only V5-DEST or 
V5-β-CATENIN and either wildtype ZIC, the ZF-NC ZIC mutants or the empty construct V5-DEST. 
The top panel shows single representative experiment. Error bars = S.D. of three internal 
repeats. Western blots corresponding to particular transfection are shown below graphs. α-
TBP and α-β-TUBULIN blots are included as loading controls. In each case the bottom panel 
shows pooled data relative to DEST. The ZIC4 ZF-NC mutant shows no significant difference in 
repression than the wildtype ZICs. Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, two-
way ANOVA with Fischer’s unprotected post ad hoc test. V5-β-CAT = V5-β-CATENIN. 
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6.3 Discussion 
The results presented in this Chapter clearly illustrate that mutation of the lysines within the 
ZF-NC region has an effect on the ZIC based activation of the Foxd3 and Z3M2 reporter 
constructs as well as the ZIC-dependent transcriptional inhibition at WREs. By demonstrating 
that the same change in function is produced by inhibiting global SUMOylation, it was 
confirmed that the lysine to arginine mutations alter ZIC function due to loss of SUMOylation 
rather than changes to another modification. These effects vary depending on the assay and in 
some cases due to the member of the ZIC family assessed. In particular, SUMOylation 
increases ZIC based activation of the Foxd3 enhancer, while reducing ZIC based activation via 
the Z3M2 motif. These varying results emphasize the importance of assessing the effect of 
SUMOylation on multiple targets or functions of proteins, rather than focusing on a single 
reporter assay. 
 
These results raise an interesting question: Why would the various ZIC functions be differently 
regulated by the attachment of SUMO? Part of the explanation may lie in the fact that cell fate 
specification generally requires both transcriptional activation and transcriptional repression. 
For example consider the pGL4.20-β-globin-Foxd3 and pGL4.20-β-globin-Z3M2 reporters; while 
the Foxd3 enhancer based reporter measures the action of the ZICs in promotion of neural 
crest development, the Z3M2 based reporter measures a very different ZIC function. Z3M2 is a 
consensus motif found in the Nanog promoter (Lim et al., 2010), which suggests it is involved 
in the previously describe role of ZIC based promotion of pluripotency (Lim et al., 2007). As 
such, these reporters effectively measure opposing functions as activation of the Z3M2 site in 
the Nanog promoter would repress differentiation, whereas the activation of the Foxd3 site 
would promote differentiation to form neural crest. In addition, NANOG has been shown to 
repress neural crest cell fate (Wang et al., 2012), further emphasising the contradiction of 
these two ZIC roles. Given these opposing functions, there may be some logic to the 
differential regulation of these roles, as the ZIC based repression of Z3M2 and activation of 
Foxd3 by SUMOylation could have the overall same effect of repressing pluripotency and 
promoting formation of the neural crest. The finding of reduced expression of the neural crest 
specifier Foxd3 in ZIC5 SUMOylation incompetent embryos supports this idea. 
 
How does the Wnt signalling come into this? Although Wnt signalling was original thought to 
promote pluripotency of cells, several recent studies have found evidence that high levels of 
Wnt promote differentiation in certain circumstances (Davidson et al., 2012; Lian et al., 2012). 
Thus, in the absence of SUMOylation, the ZIC co-factor based repression of Wnt/β-catenin 
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signalling in ESCs could act in concert with the DNA-binding based ZIC activation of the Z3M2 
motif to promote pluripotency. In fact there is evidence that other pluripotency regulators, 
such as OCT4, are also able to both activate transcription of key pluripotency targets as well as 
repress Wnt signalling, so this dual functionality to promote pluripotency could be wide-
spread. In the presence of SUMOylation, the reduction of ZIC based Wnt/β-catenin inhibition 
would promote differentiation and thus be in line with the Z3M2 and Foxd3 results. In fact 
several other key pluripotency regulators, including KLF4, SOX2 and possibly OCT4 (Tahmasebi 
et al., 2013; Tsuruzoe et al., 2006; Wu et al., 2012), are also SUMOylated resulting in a loss of 
function, suggesting a wide-spread role for this modification in driving differentiation and 
specification.  
 
Another possibility is that the perceived difference in behaviour of the Foxd3 and Z3M2 
reporters in response to SUMOylation is a consequence of the two reporters. While Foxd3 
contains a genomic fragment and would thus also include nearby binding sites such as the 
identified SMAD site, the Z3M2 reporter contains only a multimerized ZIC consensus motif. As 
such, if SUMOylation normally increases interaction with nearby proteins, the lack of such 
protein binding sites could interfere with the ZICs normal behaviour, perhaps by directing the 
ZICs away from the reporter construct to genomic sequences where the protein binding sites 
for both the ZICs and interacting proteins in present. In this case whether ZIC promoted 
pluripotency or differentiation would be directed by other cell specific factors. 
 
6.3.1 Differential Regulation of Foxd3 activation by SUMOylation 
The functional changes caused by ZIC SUMOylation did not just vary between reporters but 
also within the ZIC family. In particular, SUMOylation of ZIC2, ZIC3 and ZIC5 increased their 
activation of the Foxd3 enhancer, whereas SUMOylation of ZIC1 and ZIC4 had no effect. The 
lack of SUMOylation regulating ZIC1 and ZIC4 is curious because Foxd3 expression can be 
detected in the dorsal neural ectoderm prior to ZIC1 and ZIC4 and therefore it is unlikely that 
ZIC1 and ZIC4 are endogenous regulators of Foxd3 and thus neural crest. Given ZIC1 and ZIC4 
are no longer involved in neural crest formation (though from evolutionary stand point may 
have previously been), perhaps the response to SUMOylation during neural crest formation 
has been lost. As such, it would be interesting to see if ZIC1 of other species in which it acts as 
a key neural crest regulator, such as chick or Xenopus, shows that same lack of functional 
change due to SUMOylation. 
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6.3.2 Inhibition of Wnt/β-catenin signalling by the ZICs is not caused by 
degradation of β-CATENIN 
Although not the focus of this chapter, and although unintended, analysis of the Wnt/β-
catenin inhibition reporter experiments of this Chapter furthers our understanding of the ZIC 
based depletion of β-CATENIN. In particular, the ZIC1 reporter experiments of section 6.2.5 
demonstrate that the levels of β-CATENIN can be depleted to an extent that it is no longer 
detected by western blot analysis and yet not result in any detected inhibition of Wnt/β-
catenin signalling. Together with the results of Chapter 4, which show that certain mutant 
alleles of the ZICs can inhibit Wnt/β-catenin signalling without depleting β-CATENIN, these 
results clearly demonstrate that the ZIC based inhibition Wnt/β-catenin signalling and the ZIC 
based depletion of β-CATENIN can be separated and thus that the ZIC based inhibition Wnt/β-
catenin signalling does not act solely through depletion of β-CATENIN. Such a finding is a 
critical step forward in our understanding of how this family of proteins elicit this inhibition. It 
still, however, remains possible that the β-CATENIN depletion represents a secondary method 
to reinforce ZIC based inhibition of Wnt/β-catenin signalling. 
 
6.3.3 SUMOylation of ZIC5 promotes neural crest formation in vivo. 
To our knowledge, the Zic5-K363R SUMOylation incompetent mouse represents the first direct 
demonstration that mutation of a single amino acid so as to prevent the SUMO post-
translational modification without otherwise affecting the protein function can produce an in 
vivo phenotype. A recent review on SUMOylation suggests replacing a protein with a SUMO 
incompetent mutant in vivo ‘has the potential to provide valuable insights into the role of 
individual SUMO substrates, not just at a cellular level, but also on whole animal behaviour’ 
(Henley et al., 2014), which the data presented in this Chapter confirms. In particular, by 
examining SUMOylation incompetent Zic5 behaviour in vivo, it was confirmed that ZIC5 
SUMOylation is critical for the early stages of neural crest specification, rather than the later 
stages of neural crest differentiation. In addition, the expression data suggests that ZIC5 
SUMOylation does not alter anterior Foxd3 expression, which is consistent with the previous 
finding that a second enhancer region not regulated by the ZICs controls Foxd3 expression in 
this region (Simões-Costa et al., 2012). Together, these findings confirm that SUMOylation of 
the ZICs is essential for neural crest development, while furthering our understanding of the 
general role ZIC5 plays in neural crest development and providing a direct in vivo correlate for 
the cell based experiments. 
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Chapter 7: SUMOylation alters protein-protein 
interactions of the ZICs 
7.1 Introduction 
Despite the initial problems identifying proteins undergoing the transient SUMO modification, 
improvements in technology have allowed identification of thousands of SUMOylated 
proteins. Most of these proteins have been identified through large scale screens, which also 
suggest that a subset of SUMOylated proteins is enriched for DNA-binding and other 
transcriptional regulators (Hendriks et al., 2014). By comparing the consequences of protein 
SUMOylation the diverse range of potential functional changes at the molecular level that this 
modification can cause has come to light. For example, in order to act as transcriptional 
regulators proteins need certain properties; the proteins must be stably expressed, localise to 
the nucleus, interact with DNA (in the case of transcription factors) and interact with proteins. 
Previous investigations have demonstrated that SUMOylation is able to alter all of these 
properties (Geiss-Friedlander and Melchior, 2007). 
 
It is clear from the results of Chapter 6 that SUMOylation alters the ability of the ZICs to act as 
transcriptional regulators, but not how attachment of the SUMO moiety causes these changes. 
As such this Chapter aims to determine if SUMOylation alters any of the molecular properties 
of the ZICs. In addition, a possible source of up-regulation of the levels of ZIC SUMOylation will 
also be investigated. 
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7.2 Results 
7.2.1 SUMOylation does not alter ZIC localisation 
Transcription factors/co-factors such as the ZICs must localise to DNA in order to influence 
transcription, thus their function can be regulated by altering the amount of protein that 
reaches the nucleus. As there are several studies demonstrating SUMOylation regulates 
various proteins by modifying their localisation (Georges et al., 2011; Gill, 2004), the effect of 
SUMOylation of ZIC localisation was analysed.  
 
To examine nuclear/cytoplasmic localisation, HEK293T cells were transfected with either the 
wildtype ZIC or the SUMOylation incompetent forms of ZIC identified in Chapter 5. 24 hours 
after transfection cells were fixed and immunostained with anti-V5 (with A594 secondary) to 
detect localisation of ZIC5 and anti-LAMIN B1 (with A488 secondary) to mark the location of 
the nucleus. For each transfection condition at least 100 cells (across two independent 
transfections) that showed expression of ZIC were then photographed using a confocal 
microscope (Figure 7.1a). The resulting images were then randomised and the amount of 
protein located within the nucleus and cytoplasm was then quantified blindly using ImageJ.  
 
The quantification illustrated that prevention of SUMOylation caused no large difference in 
localisation of the ZICs, as almost 100% of both all cells analysed showed the majority of 
protein localised to the nucleus (Figure 7.1b). To determine whether any small changes in 
localisation occurred due to prevention of SUMOylation the average percentage of total 
protein localising to the nucleus and cytoplasm was calculated for each cell. Even after these 
percentages were calculated, no significant difference was present between localisation of 
wildtype and SUMO incompetent forms of ZICs (Figure 7.1c). It was therefore concluded that 
changes in ZIC function due to SUMOylation is not due to loss of ZIC localisation to the nucleus. 
 
7.2.2 ZIC SUMOylation increasing Foxd3 enhancer activation is not due 
to a change in DNA binding 
Another way SUMOylation has previously been shown to alter transcription factor function is 
to alter protein-DNA interactions. The fact that the transactivation of DNA-binding 
incompetent ZIC cannot be affected by mutations that would otherwise alter ZIC activity by 
reducing DNA binding was used to determine if SUMOylation changing the DNA binding 
properties of the ZICs was responsible for the change in ZIC function. If DNA-binding  
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Figure 7.1: SUMOylation does not alter subcellular localisation of the ZICs. HEK293T were 
transfected with wildtype or SUMOylation incompetent ZIC, after which the cells were 
immunostained for V5 and LAMIN B1 followed by imaging on a confocal microscope. a) 
Representative images of (i) wildtype and (ii) SUMOylation incompetent ZIC5. b) Comparison 
of the percentage of wildtype and SUMOylation incompetent ZIC transfected cells showing 
majority of protein localising to the nucleus or cytoplasm. c) Quantified localisation of wildtype 
and SUMOylation incompetent cells, showing the average percentage of protein in each 
compartment. Error bars = S.E.M.  
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incompetent ZIC is further mutated to prevent SUMOylation there are two possible outcomes. 
If SUMOylation acts via altering DNA binding of the ZICs, then loss of SUMOylation should have 
no effect on the activity of DNA-binding incompetent ZIC. Alternatively, if SUMOylation acts via 
any other mechanism, then loss of SUMOylation will alter the activity of DNA-binding 
incompetent ZIC. 
 
To distinguish between these possibilities, the mutation within the ZF-NC which prevents ZIC3 
SUMOylation was placed in cis with a mutation of the second cysteine of the fourth zinc finger 
which prevents DNA-binding and the resulting transactivation ability of such a double mutant 
was measured with the pGL4.2-β-globin-Foxd3 assay. Although when alone both the SUMO 
incompetent and DNA-binding incompetent mutations of ZIC3 produced significant losses of 
function, when the two mutations were placed in trans a further loss of function was observed 
(Figure 7.2). As such, it was concluded that the reduction of ZIC based activation of Foxd3 due 
to loss of SUMOylation was not due to a change in DNA binding.  
 
7.2.3 The ZIC interact with TCF7L2 
Another possibility is the SUMOylation regulates the ZICs by altering the protein-protein 
interaction. Unfortunately the protein-protein interactions necessary for ZIC based 
transactivation of pGL4.2-β-globin-Foxd3 and pGL4.2-β-globin-Z3M2 are not well understood 
complicating the investigation of this possibility. However, it has been found that ZIC2 
inhibition of Wnt/β-catenin requires interaction with one of the TCF/LEF family proteins 
(Fujimi et al., 2012; Pourebrahim et al., 2011). As such the possibility that all human ZICs 
participate in such an interaction with TCF7L2 was investigated using BiFC protein-protein 
interaction assays. 
 
BiFC is a relatively new assay designed for analysing protein-protein interactions within cellular 
conditions (Hu et al., 2002; Kodama and Hu, 2012). Two proteins suspected of interacting are 
each tagged with half of the fluorescent protein, such as Venus (a modified form of GFP), and 
introduced into cells. The division of the two halves of Venus (termed V1 and V2) is specifically 
designed so that neither half is able to produce fluorescence by itself; however, if the two 
proteins come into contact and interact, the two halves of Venus reform, producing 
fluorescence. As the reformation of Venus occurs within cells, the BiFC assay is superior to 
other potential protein-protein interaction assays as it both allows visualisation of interactions 
within particular substructures of the cell and avoids disruption of the cellular compartments  
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Figure 7.2: SUMOylation does not affect ZIC activation of the Foxd3 enhancer through 
altering DNA binding. HEK293T were transfected with the pGL4.20-β-globin-Foxd3 reporter 
construct along with either wildtype ZIC3, SUMOylation incompetent ZIC3, the DNA binding 
incompetent form of ZIC3, ZIC3 containing both of the mutations or the empty construct V5-
DEST. The top panel shows single representative experiment. Error bars = S.D. of three internal 
repeats. Western blots corresponding to particular transfection are shown below graphs. A α-
TBP blot is included as a loading controls. The bottom panel shows pooled data of three 
experiments relative to DEST. Both the ZF-NC mutation and the mutation preventing DNA 
binding of ZIC3 reduces the ZIC3 based activation of the Foxd3 enhancer, but the reduction is 
greater when the two alleles are placed in trans. Error bars = S.E.M., N = 3 external repeats; * : 
p˂0.05, two-way ANOVA with Fischer’s unprotected post ad hoc test. 
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thus reducing false positives from proteins that can potentially interact, but would never do so 
in vivo due to differing localisation (Kerppola, 2006). In addition, unlike some other protein 
interaction assays the BiFC assay is also quantitative. 
 
Initial testing and optimisation of the BiFC assay is described in Appendix 4. For both ZICs 
tested an increase in signal over background was observed when V1 tagged TCF7L2 was 
present with V2-tagged ZIC, suggesting that the ZICs and TCF7L2 interact in cellular conditions. 
However, the appropriate controls are needed before this conclusion is drawn. There are two 
potential BiFC control assays which can be used to confirm interaction as legitimate rather 
than an artefact of the BiFC system (Kodama and Hu, 2012). The first potential control requires 
a form of one of the proteins missing the domain responsible for allowing the two proteins to 
interaction. In the case of the ZIC-TCF7L2 interaction the only mutations known to prevent 
interaction with TCF7L2 are large truncations of the ZIC2 protein (Pourebrahim et al., 2011). 
However, equivalent large truncations are known to cause changes in localisation of ZIC3 
(Ahmed et al., 2013) and therefore the lack of interaction could be due to a change in 
localisation rather than loss of interaction domain. As such, the truncated proteins do not 
represent appropriate controls for the BiFC assay and therefore this particular control cannot 
be performed for the ZICs. 
 
The other potential appropriate BiFC control is a competition assay. If the interaction is 
legitimate then untagged ZIC protein should compete with V1 tagged ZIC protein for 
interaction with TCF7L2. Adding increasing amounts of untagged (or differently tagged) ZIC 
should therefore decrease the amount of V1-ZIC interacting with V2-TCF7L2. On the other 
hand if the interaction is an artefact of the localisation of the two proteins then adding 
additional ZIC showed not interfere with the interaction. As shown in Figure 7.3 the addition of 
untagged ZIC reduced the interaction of V1-ZIC and V2-TCF7L2 in for each of ZIC1, ZIC2, ZIC4 
and ZIC5 confirming the interaction is legitimate and illustrating for the first time that ZIC1, 
ZIC4 and ZIC5 are able to interact with TCF7L2. However, despite multiple attempts at 
troubleshooting ZIC3 showed no such decrease. As such, ZIC3 was not included in further 
analysis. 
 
7.2.4 SUMOylation decreases ZIC interaction with TCF7L2 
The SUMO modification is thought to alter protein activity by altering the macro-molecular 
interactions, usually by either creating new protein binding sites or blocking existing protein 
interaction domains. Having confirmed that the ZICs act in such a macro-molecular with 
201 
TCF7L2, the ZIC/TCF appeared to be a potential target for alteration by the SUMO 
modification. In particular, if the SUMO modification reduced the level of interaction between 
the ZICs and TCF7L2 it could potentially explain the decrease in inhibition ability found upon 
SUMO modification observed in the previous section. 
 
To determine whether the SUMO modification altered the interaction of the ZICs with TCF7L2 
the BiFC assay was employed. The assay was used to compare the levels of TCF7L2 interaction 
with wildtype ZIC and the SUMOylation incompetent form of ZIC created by mutation of the 
lysine within the ZF-NC. In the cases of ZIC1, ZIC2 and ZIC5 the SUMOylation incompetent 
forms of ZIC showed increased levels of interaction with TCF7L2 compared with wildtype ZIC 
which is consistent with SUMOylation interfering with the ZIC/TCF interaction and thus 
reducing ZIC based inhibition of Wnt signalling (Figure 7.4). On the other hand the 
SUMOylation incompetent and wildtype forms of ZIC4 showed no difference in levels of 
interaction with TCF7L2, which is consistent with the modification not altering the Wnt 
inhibition ability of this ZIC. We can therefore conclude that SUMOylation decreases Wnt 
inhibition ability of the ZIC1, ZIC2 and ZIC5 by interfering with protein-protein interaction. 
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Figure 7.3: The ZICs interact with the TCF7L2 protein. HEK293T were transfected with V2-
TCF7L2 wildtype V1-ZIC, along with increasing levels of V5 tagged ZIC. In addition, background 
was estimated by transfecting cells with V2-TCF7L2 and V1-ORF. a) ZIC1, b) ZIC2, c) ZIC4 and d) 
ZIC5. In each case the top panel shows single representative experiment. Error bars = S.D. of 
three internal repeats. Western blots corresponding to particular transfection are shown 
below graphs. α-TBP blots are included as loading controls. In each case two western blots 
were performed and thus two loadings controls are shown, each directly below the related 
western blots. The bottom panel shows pooled data of three experiments relative to V1-ORF. 
In each case the addition of V5 tagged ZIC interferes with the V2-TCF7L2/V1-ZIC interaction. 
Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, two-way ANOVA with Fischer’s 
unprotected post ad hoc test. 
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Figure 7.4: SUMOylation decreases the interaction of TCF7L2 and the ZICs. HEK293T were 
transfected with V2-TCF7L2 along with either wildtype V1-ZIC, the ZF-NC mutant V1-ZIC or the 
empty construct V1-ORF. a) ZIC1, b) ZIC2, c) ZIC5 and d) ZIC4. In each case the top panel shows 
single representative experiment. Error bars = S.D. of three internal repeats. Western blots 
corresponding to particular transfection are shown below graphs. α-TBP blots are included as 
loading controls. In the case of (b) two western blots were performed and thus two loadings 
controls are shown, each directly below the related western blot. The bottom panel shows 
pooled data of three experiments relative to DEST. In the case of ZIC1, ZIC2 and ZIC5 the ZF-NC 
mutants show higher levels of interaction than wildtype ZIC. On the other hand ZIC4 shows no 
difference. Error bars = S.E.M., N = 3 external repeats; * : p˂0.05, two-way ANOVA with 
Fischer’s unprotected post ad hoc test. 
 
  
205 
 
 
 
  
206 
7.3 Discussion 
The post-translational modification SUMOylation is a critical form of regulation now known to 
target thousands of proteins. In particular, the data present in Chapters 5 and 6 of this thesis 
indicates that members the ZIC family are targeted by SUMOylation which results in altered 
activity of both the transcription factor and co-factor functions of these proteins. In this 
Chapter, the overlying molecular cause of these functional changes was investigated. 
Attachment of the SUMO moiety is known to cause a wide variety of functional changes 
depending on the target protein, including altering protein localisation, DNA binding and 
protein-protein interactions. The data presented here eliminates changes in ZIC localisation or 
DNA binding as causes of the altered function. In fact these possibilities were always unlikely, 
as they would not be expected to cause the up-regulation of one ZIC target at the expense of 
others shown in the previous Chapter and changes in DNA-binding would not alter ZIC based 
inhibition of Wnt/β-catenin signalling which is independent of DNA-binding. Instead, it appears 
that SUMOylation alters protein-protein interactions of the ZICs to alter their function. In 
particular attachment of the SUMO moiety disrupts the interaction of ZICs with TCF7L2 (with 
the exception of ZIC4) and thus reduces ZIC based inhibition of ZIC Wnt/β-catenin signalling. 
 
How is SUMOylation causing the reduction in TCF/ZIC interaction? At the molecular level there 
are three possible consequences of SUMOylation (see Figure 1.11): attachment of SUMO can 
physically block interaction sites, attachment of SUMO can alter the 3D structure of a target 
protein to disrupt interaction sites or attachment of SUMO promote interaction with proteins 
containing SUMO-binding modules such as SIMs (Flotho and Melchior, 2013). Out of these 
possibilities it is most likely that the SUMO moiety blocks the TCF binding domain within the 
ZICs, thus disrupting the interaction. It is possible that the disruption releases more ZIC protein 
to act in other functions, hence the increase in Foxd3 activation. Another possibility is that in 
addition to the disruption of the TCF/ZIC interaction, the attachment of SUMO also creates a 
protein binding site for a different ZIC/protein interaction. Although the identity of such a 
protein is currently unclear, both the Foxd3 and Nanog (which contains the Z3M2 binding site) 
genomic sequences contains a nearby SMAD binding site approximately 40 bp from the ZIC 
sites, suggesting the SMADs are a possible interacting protein of interest. 
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Chapter 8: Summary and General Discussion 
Neural crest cells are a transient population of multipotent cells which arise at the neural plate 
border, before migrating and going on to form such an amazing variety of cells types that these 
cells are sometimes termed the fourth germ layer. There is a general understanding of the 
signalling molecules and transcription cascade that drives neural crest specification in 
vertebrate embryogenesis (Groves and LaBonne, 2014; Simões-Costa and Bronner, 2015; 
Stuhlmiller and García-Castro, 2012). Specifically, several of the major signalling pathways, 
including the BMP, FGF and Wnt signalling pathways, act together to induce expression of 
several genes collectively termed the ‘neural plate border genes’. These genes collectively 
mark the neural plate border, but individually extend beyond this region. The neural plate 
border genes act in concert with the major signalling pathways to trigger expression of a 
second set of genes, termed the ‘neural crest specifiers’, which are the first markers of neural 
crest cell fate and are believed to ultimately control neural crest cell formation and behaviour 
through regulating expression of neural crest effector genes.   
 
Although the signalling cascade that directs neural crest specification is known, there is a lack 
of detailed understanding of the actions of specific molecules and transcription factors in 
directing neural crest development, particularly in mammals. For example activation of Wnt/β-
catenin signalling is known to act synergistically with several neural plate border genes to 
induce neural crest specification, but exactly how the major signalling pathway coordinates 
with neural plate border genes to trigger expression of specifiers is unclear as cis-regulatory 
analysis has failed to identify many WREs critical of expression of neural crest specifiers 
(Simões-Costa and Bronner, 2015). The work presented here suggests Wnt/β-catenin signalling 
directs the activity of a neural plate border transcription factor via promoting the post-
translational modification SUMOylation. In particular, modification of the neural plate border 
gene ZIC5 promotes dissociation of the ZIC/TCF repressor complex, freeing ZIC5 to activate 
through ZIC responsive elements (ZREs) (Figure 8.1). Thus through influencing ZIC SUMOylation 
high levels of Wnt signalling can promote transcription at non-WREs. 
 
The finding that ZIC SUMOylation is increased in response to activation of Wnt signalling 
suggests ZIC expression should be considered in terms of Wnt/β-catenin activation. During the 
initial steps of neural crest specification ZIC expression is not restricted to the presumptive 
neural crest, but rather is expressed through the neural plate ectoderm (Figure 8.2b) (Elms et 
al., 2004; Furushima et al., 2000). Wnt signals on the other hand are thought to signal  
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Figure 8.1: ZIC protein is SUMOylated in response to stimulation of Wnt/β-catenin signalling. 
a) In the Low Wnt state, β-CATENIN protein is continually produced, but is degraded by the β-
CATENIN degradation complex which includes AXIN and APC. As such, β-CATENIN does not 
enter the nucleus and transcription at WREs is repressed by ZIC/TCF repression. b) In the high 
Wnt state, the β-CATENIN degradation complex is inhibited in a Disheveled (Dvl) dependent 
manner which allows β-CATENIN to enter the nucleus. Activation of Wnt/β-catenin signalling 
promotes ZIC SUMOylation leading to dissociation of the ZIC/TCF repression complex, which 
allows β-CATENIN to binds TCF to act as a co-activator. ZIC SUMOylation also promotes ZIC 
based activation of the Foxd3 enhancer. 
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Figure 8.2: ZIC expression and activation of Wnt signalling overlaps in the neural crest. 
Illustration of a) the neural plate, b) ZIC expression (red), c) activation of Wnt signalling (blue), 
d) the region of overlap of ZIC expression and activation of Wnt signalling at the neural plate 
border (purple) and the resulting regions expression of the unmodified ZIC in the neural 
ectoderm and SUMO conjugated ZIC at the neural plate border. 
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from the non-neural ectoderm and possibly the underlying mesoderm, with Wnt antagonists 
expressed at the medial regions of the neural plate preventing activation of this pathway in 
most regions of ZIC expression, with the exception of the neural border (Figure 8.2c) (Groves 
and LaBonne, 2014; Simões-Costa and Bronner, 2015). The partial overlap in expression 
patterns suggests the ZICs should be thought of as existing in two forms: an unmodified form 
in the neural ectoderm and a SUMOylated form in the neural plate border (Figure 8.2d). The 
state of ZIC protein can therefore define three regions of ectoderm: the total absence of ZIC 
results in a non-neural fate such as epidermis, the presence of the non-SUMOylated form of 
ZIC results in a neural fate and the presence of the SUMOylated form of ZIC results in neural 
crest fate.  
 
Wnt/β-catenin signalling works together with ZICs at the nuclear level to define these three 
regions of ectoderm through restricting Foxd3 expression to a single domain (Figure 8.3). The 
balance between non-neural and neural fates is thought to be driven by Wnt signalling levels 
(Kimura-Yoshida et al., 2015). In the absence of ZIC, Wnt signals activate expression of Wnt 
targets to promote non-neural surface ectoderm fate. In the absence of Wnt, ZIC acts to 
represses such Wnt targets, thus promoting future lateral neurectoderm fate. Activation of 
Wnt/β-catenin in the presence of ZIC protein causes SUMOylation of ZICs, promoting 
disassociation of ZIC/TCF repression complex and allows ZICs to target ZREs to activate 
expression of specifiers such Foxd3. Thus Wnt signalling is able to alter ZIC function without 
altering ZIC expression by regulating ZIC protein activity. The coordinated action of ZICs and 
Wnt at the nuclear level restrict Foxd3 expression to the neural border to specify the neural 
crest while individually the gene and signalling pathway extend beyond neural plate border to 
promote other fates.  
 
8.1 Future Experiments 
There has been evidence that Wnt signalling regulating protein behaviour by promoting post-
translational modification is not unique to the Zics, as SUMOylation of the neural crest 
specifier Sox9 is also promoted by canonical Wnt signalling. Future studies could therefore 
determine how widespread this mechanism was for regulating neural crest development. In 
particular, another neural plate border gene, Pax3, is also known to act synergistically with 
Wnt signalling through an unknown mechanism (Sato et al., 2005). It is possible such synergism 
is due to Wnt signalling also promoting post-translational modification of Pax3, although 
current evidence suggests Pax3 is not a target of SUMOylation (Luan et al., 2013). 
 
211 
 
 
 
Figure 8.3: Wnt directed SUMOylation alters ZIC behaviour at the nuclear level to define the 
neural plate border. a) In the absence of ZIC, Wnt signals activate expression of Wnt targets to 
promote non-neural surface ectoderm fate. b) Activation of Wnt/β-catenin in the presence of 
ZIC protein causes SUMOylation of ZICs, promoting disassociation of ZIC/TCF repression 
complex and thus allowing ZICs to target ZREs to activate expression of neural crest specifiers 
such as Foxd3. c) In the absence of Wnt stimulation, ZICs acts to represses Wnt targets, thus 
promoting neural ectoderm fate. d) As such expression of Foxd3 is restricted to the neural 
plate border region (Foxd3 expression shown in green). 
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Another future line of study is to better understand how SUMOylation alters the 
macromolecular interactions of the ZICs. While the demise of the ZIC/TCF repressor complex 
can be explained due to the SUMO protein physically blocking access of TCFs to the ZIC 
proteins, it is possible that the modification also has a secondary effect of recruiting SIM 
containing proteins necessary for neural crest specification. While it is not currently clear what 
protein interactions are necessary for ZIC promotion of neural crest it is possible analysis of 
enhancers and promoters of Foxd3 and other neural crest specifiers directly regulated by the 
ZICs could identify likely candidates. Proteins thought likely to interact with the ZICs could then 
be screened in cell lines using BiFC or possibly in vivo using a Proximity Ligation Assay (PLA). 
Alternatively, for wider scale screens, Co-Immunoprecipitation (Co-IP) could be used to isolate 
proteins interacting with the ZICs either from neural crest stage embryonic lysates or, if larger 
tissue sources are needed, from ESC derived neural crest cells, which would be identified using 
Mass Spectrometry. Such a strategy may also identify the E3 ligases interacting with the ZICs, 
which would aid in future ZIC SUMOylation studies. However, the lack of highly specific 
antibodies for the ZICs currently represents a major hurdle for either PLA or Co-IP. As such to 
undertake these techniques would first require generation of better antibodies or creation of a 
transgenic mouse expressing an epitope tagged form of one member of the ZIC family. Once 
identified and validated, BiFC could then be used to determine which interactions were 
increased or decreased by SUMOylation and bioinformatics could be used to identify potential 
links to the SUMOylation pathway, such as SUMOylation consensus motifs or SIMS. 
 
As there is already evidence that SUMOylation regulates Zics at multiple stages of 
development as in addition to neural crest hypoplasia, Zic5K393R/- mice also show hydrocephaly, 
it may also be worth investigating whether Wnt promoted SUMOylation also regulates 
functions of the ZICs other than promotion of neural crest. However, given the variation in 
developmental function throughout the ZIC family, as evidenced by the fact mutation of the 
different ZICs produces unique phenotypes, to fully assess the role of SUMOylation on in vivo 
ZIC function the wildtype forms of other ZIC members would also need to be replaced with 
SUMOylation incompetent forms. Such mutation of the ZICs would need to be completed both 
to individual ZICs and, if assessing overlapping functions, to multiple ZICs in a single animal. In 
the past such targeted mutations would be difficult and time consuming to produce, 
particularly due to tandem arrangement and high GC content of the ZICs genomic sequences, 
but it was recently shown that the CRISPR/Cas9 system could be used to introduce such point 
mutations to prevent SUMOylation (Inui et al., 2014). As the Zic5K363R/K363R mice have given 
valuable insights into how SUMOylation regulates ZIC5, it would be expected that mice 
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carrying only SUMOylation incompetent forms of the other Zics would be equally as useful 
clarifying the role of ZIC modification at different stages of development. 
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Supplementary Material 
Appendix 1 Oligonucleotides used for cloning and 
sequencing 
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Number Name Purpose Tm Sequence 
1460 ZIC1_Infus_F To amplify ZIC1 CDS for insertion into pENTR3C. 60 oC ATCCGGTACCGAATTCATGCTCCTGGACGCCGG 
1461 ZIC1_Infus_R GTGCGGCCGCGAATTCTTAAACGTACCATTCGTTAAA
ATTGG 
1168 ZIC2_Infus_F To insert ZIC2 into the pENTR3C entry vector. 70 oC ATCCGGTACCGAATTCAGTGTGGTGGAATTCCTGGCC 
1150 ZIC2_Infus_R GTGCGGCCGCGAATTCGAGGGTTAGGGATAGGCTTA
C 
1449 ZIC4_Infus_F To amplify the first intron of ZIC4. ZIC4_82R was also 
designed to enable overlap extension PCR to recreate 
full length ZIC4. 
45 oC ATCCGGTACCGAATTCATGAGATACAAGACATCCTT 
1453 ZIC4_82R CAGAGCTGCTACTTGACTCTTTAAGAGTGT 
1451 ZIC4_64F To amplify the first 242 bp of the second intron of 
human ZIC4. Both primers were also designed to enable 
overlap extension PCR to recreate full length ZIC4. 
52 oC AGTCAAGTAGCAGCTCTGGACACCATG 
1454 ZIC4_315R CACCGTCAGGTTCATGCC 
1452 ZIC4_297F To amplify the 3’ end 725 bp of ZIC4. ZIC4_297F was 
also designed to enable overlap extension PCR to 
recreate full length ZIC4. 
50 oC GGCATGAACCTGACGGTG 
1450 ZIC4_Infus_R GTGCGGCCGCGAATTCTTCATTCGCTCAAGTCGG 
Table S1.1: In-Fusion primers and primers to recreate full length ZIC4. Red = homology to pENTR3C vector for In-Fusion cloning. Blue = homology to enable 
overlap extension PCRs. 
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Number Name Purpose Tm Sequence 
1535 TCF7L2_F To amplify TCF7L2 CDS for insertion into pENTR3C. 51 oC ATGGTACCATGCCGCAGCTGAACGG 
1536 TCF7L2_R CAGAATTCTATTCTAAAGACTTGGTGACGAGC 
1206 UBC9_KpnI_F To amplify UBC9 CDS (without stop codon) with Kpn1 
restriction enzyme sites for insertion into pENTR3C-ZIC 
constructs. 
66 oC TCGACTGGATCCGGTACCATGTCGGGGATCGCCCTCA
GC 
1237 UBC9_KpnI_R AGAGAGGGTGAATTCGGTACCTGAGGGCGCAAACTT
CTTGGC 
1259 SUMO_BglII_F To amplify SUMO1 cDNA for insertion into EGFP-C1. 57 oC TTAGATCTATGTCTGACCAGGAGGCAA 
1260 SUMOwt_KpnI_R To amplify SUMO1-WT cDNA for insertion into EGFP-C1. 57 oC TTGGTACCAAACTGTTGAATGACCCCCCGT 
1261 SUMOKØ_KpnI_R To amplify SUMO1-KØ cDNA for insertion into EGFP-C1. 57 oC TTGGTACCCTAAACTGTTGAATGACCCCCCGT 
1262 SUMOΔGG_KpnI_R To amplify SUMO1-ΔGG cDNA for insertion into EGFP-C1. 57 oC TTGGTACCCTAAACTGTTGAATGCGTTTGTTCC 
1252 SUMO start_BamHI To amplify SUMO1-WT CDS and incorporate BamHI and 
XhoI restriction enzyme site for insertion into pENTR3C. 
68 oC TTGGATCCATGTCTGACCAGGAGGCAA 
1253 SUMO end_XhoI GGCTCGAGAAACTGTTGAATGACCCCCCGT 
Table S1.2: Primers to amplify TCF7L2, UBC9 or SUMO and incorporate restriction enzyme sites for insertion into various vectors. Black = homology for PCR 
amplification. Red = bases to add restriction enzyme sites during amplification. Blue = extra bases to improve cutting efficiency of restriction enzymes. 
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Number Name Purpose Tm Sequence 
1254 galK_R0_F To amplify galK with homology to ZIC5 
(for galK mutagenesis of ZIC5K4R). 
60 oC AAAATGGGTTTTATTAACTTACATACATACTAGAATTCATGTTTTTGACCTGTTGAC
AATTAATCATCGGCA 
1255 galK_R0_R ATCAGGCCCATAGACCCTCACTGGGGGGACTTTATTCCCTCTGCCCGCCTCAGCAC
TGTCCTGCTCCTT 
1257 R0_F_oligo To replace galK with the K4R mutation 
(for galK mutagenesis of ZIC5K4R). 
NA AAAATGGGTTTTATTAACTTACATACATACTAGAATTCATGTTTTTGAGGGCGGGC
AGAGGGAATAAAGTCCCCCCAGTGAGGGTCTATGGGCCTGATT 
1258 R0_R_oligo AATCAGGCCCATAGACCCTCACTGGGGGGACTTTATTCCCTCTGCCCGCCCTCAAA
AACATGAATTCTAGTATGTATGTAAGTTAATAAAACCCATTTT 
Table S1.3: Oligonucleotides for galK recombineering based cloning. Blue = homology to galK for PCR amplification. Black = homology to ZIC5 for 
recombination. Red = Introduced point mutation. 
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Number Name Purpose Tm Sequence 
1463 pENTR3C_ATG Used with ZIC4K125R_R or ZIC1K222R_R.  ATCCGGTACCGAATTCATG 
1428 ZIC4K125R_R To introduce the K125R mutation into ZIC4. Used 
with pENTR3C_ATG. 
52 oC ATGAGCTCCTGTCTGATGG 
1462 ZIC1K222R_R To introduce the K222R mutation into ZIC1. 
Used with pENTR3C_ATG. 
54 oC GATGAGCTCTTGCCTGATGG 
1470 ZIC1K333R_F To introduce the K333R mutation into ZIC1. Use with 
ZIC1_Infus_F and ZIC1_Infus_R. 
54 oC AGCCCTTCAGGTGCGAGTT 
1471 ZIC1K333R_R AACTCGCACCTGAAGGGCT 
1230 ZIC2K253R_F To introduce the K253R mutation into ZIC2. Use with 
ZIC2_Infus_F or ZIC2_Infus_R. 
70 oC CGGCAGCAGTGCATCAGGCAGGAGCTAATC 
1231 ZIC2K253R_R GATTAGCTCCTGCCTGATGCACTGCTGCCG 
1517 ZIC5C528S_F To introduce the C528S mutation into ZIC5. 53 oC TGATGGCTCTGACAGGAAG 
1518 ZIC5C528S_R 51 oC CTTCCTGTCAGAGCCATC 
1572 TCF7L2K297R_F To introduce the K297R mutation into TCF7L2. Used 
with TCF7L2_F or TCF7L2_R. 
65 oC CACCAACAGTCAGACAGGAATCGTCC 
1573 TCF7L2K297R_R 70 oC TGGGACGATTCCTGTCTGACTGTTGGTG 
Table S1.4: Primers used for mutagenesis. Red = introduced point mutation. Blue = SacI restriction enzyme site. 
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Number Name Purpose Sequence 
1456 TOP_3xTCF_F 3x optimal TCF binding sites with KpnI and HindIII 
restriction enzyme sites for insertion into pGL4.2. 
AAGGTACCAAGATCAAAGGGGGTAAGATCAAAGGGGGTAAGATCA
AAGGGAAGCTTGG 
1457 TOP_3xTCF_R CCAAGCTTCCCTTTGATCTTACCCCCTTTGATCTTACCCCCTTTGATCTT
GGTACCTT 
1458 FOP_3xTCF_F 3x mutated TCF binding sites with KpnI and HindIII 
restriction enzyme sites for insertion into pGL4.2. 
AAGGTACCAAGGCCAAAGGGGGTAAGGCCAAAGGGGGTAAGGCCA
AAGGGAAGCTTGG 
1459 FOP_3xTCF_R CCAAGCTTCCCTTTGGCCTTACCCCCTTTGGCCTTACCCCCTTTGGCCTT
GGTACCTT 
 
Table S1.5: Oligonucleotides for introduction of TCF binding sites into the pGL4.2 vector. Underlined bases = TCF (optimal or mutated) binding sites. Red = 
Kpn1 restriction enzyme target site. Blue = HindIII restriction enzyme target site. 
221 
 
 
 
Number Name Purpose Tm Sequence 
1510 β-globin_F To amplify the β-globin promoter for insertion into 
various reporter constructs. 
56 oC TGAAGCTTATGAACTAGTGGATCCC 
1507 β-globin_R CTAAGCTTTCGGCTAGAAGCAAATG 
1496 TK_XhoI_F To amplify the TK promoter for insertion into pGL4.2-
TCFx6 and pGL4.2-mutTCFx6. 
66 oC TACTCGAGCCCCGCCCAGCGTCTTGT 
1497 TK_BglII_R TGGAGATCTGCGGCACGCTG 
1498 cfos_ XhoI_F To amplify the cfos promoter for insertion into pGL4.2-
TCFx6 and pGL4.2-mutTCFx6. 
53 oC TACTCGAGCCCAGTGACGTAGGAAGTC 
1499 cfos_BglII_R GTGAGATCTAGACACTGGTGGGAGCTG 
1513 TK_HindIII_F To amplify the TK promoter for insertion into various 
reporter constructs. 
60 oC CGAAGCTTACGACTCTAGAGGATCCG 
1514 TK_ HindIII_R GTAAGCTTATGATCTGCGGCACGCTG 
1515 cfos_ HindIII _F To amplify the cfos promoter for insertion into various 
reporter constructs. 
64 oC CAAAGCTTCAACCCCAGTGACGTAGG 
1516 cfos_HindIII _R GCAAGCTTGCTCTAGAGAGACACTGG 
1555 Foxd3_F To amplify a 568 bp region of a mouse Foxd3 enhancer. 52 oC TAGGTACCGATCAATACCACTCATTCAGC 
1556 Foxd3_R CCAGATCTCAGTGCTGTTGACAAGTAGC 
Table S1.6: Primers for generation of reporter constructs. Black = homology to promoter/enhancer. Red = Restriction enzyme target sites. Blue = extra bases to 
improve cutting efficiency. 
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Number Name Target Sequence 
1468 ZIC1_655F ZIC1 AACCCATCAAGCAAGAGC 
1469 ZIC1_1064R ACGTGCATGTGCTTCTTGC 
1287 ZIC2_353F ZIC2 ACTTCCTGTTCCGCAGC 
1175 ZIC2_571F TCGGAGCAATACCGCCAGGT 
1177 ZIC2_961F GTCAACCACATCCGCGTGCA 
1247 ZIC2_1114R GGTCGCAGCCCTCAAACTCAC 
1176 ZIC2_570R ACCTGGCGGTATTGCTCCGA 
1225 ZIC3_196F ZIC3 CTATCTTCAGGCCAGAGC 
1172 ZIC3_297R GCTGGTGTGGTGATGATGGTG 
1153 ZIC3_Infus_R 3’ end of ZIC3 GTGCGGCCGCGAATTCCCGCTCTAGAACTAGTGG 
1427 ZIC4_386R ZIC4 ATGAGCTCCTGTTTGATGG 
1426 ZIC4_787R GCTTGTCGCTAGTGTGCAC 
1424 ZIC4_199F GCTCCCTGGAGACATGTA 
1425 ZIC4_698F CTTCAGATGCGAGTTCGAG 
Table S1.7: Primers for sequencing the ZIC1-4 constructs. Primers in tables S1.1, S1.4 and S1.8 were also used for sequencing ZIC constructs. 
 
223 
Number Name Target Sequence 
1026 ZIC5_989F ZIC5 TGAACTTAAACCTGAACCTG 
963 ZIC5_1967R GGGTTCCCGTAAATTTCCTC 
1119 ZIC5_536R GTGTAGCCCGAGAGGGCAGG 
957 ZIC5_467F CTCTTCCTCCCACCCCTTC 
961 ZIC5_1337R GTGACGTGATTCACCAGCTC 
Table S1.8: Primers for sequencing the ZIC5 constructs. Primers in tables S1.1, S1.4 and S1.7 were also used for sequencing ZIC constructs. 
 
Number Name Position Sequence 
1256 pENTR3C pENTR3C GACTGATAGTGACCTGTTCGTTG 
930 BGH_R V5-DEST backbone TAGAAGGCACAGTCGAGG 
929 T7 TAATACGACTCACTATAGGG 
1308 SP6 ATTTAGGTGACACTATAGAATAG 
1474 pGL4.2_seqFA 283 bp prior to MCS of pGL4.2 GCAAAGAAGGGAATGAGTG 
1266 pGL4.2_seqFB 32 bp prior to MCS of pGL4.2 CTAGCAAAATAGGCTGTCCC 
1267 pGL4.2_seqR 120 bp into luciferase cDNA of pGL4.2 ATATGTGCGTCGGTAAAGGC 
Table S1.9: Non-ZIC Sequencing primers. Primers in other Supplementary Tables were also used for sequencing. 
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Appendix 2 Generated Plasmids 
The following is a list of all plasmids made for this project within Chapter 3, listed by the 
section in which they were created. 
 
3.2.1.1: 
• pENTR3C-ZIC1-WT 
• pENTR3C-ZIC4-WT 
 
3.2.1.2: 
• pENTR3C-TCF7L2 
 
3.2.2.1: 
• P[acman]-ZIC5-K4R 
• pENTR3C-ZIC5-K4R 
 
3.2.2.2: 
• pENTR3C-ZIC1-K222R 
• pENTR3C-ZIC4-K125R 
 
3.2.2.3 
• pENTR3C-ZIC2-K253R 
• pENTR3C-ZIC1-K333R 
 
3.2.2.4: 
• pENTR3C-ZIC5-C528S 
 
3.2.2.5: 
• pENTR3C-ZIC3-K248R;C365S 
 
3.2.3: 
• pENTR3C-UBC9-ZIC1-WT 
• pENTR3C-UBC9-ZIC1-K222R 
• pENTR3C-UBC9-ZIC1-K333R 
• pENTR3C-UBC9-ZIC2-WT 
• pENTR3C-UBC9-ZIC2-K253R 
• pENTR3C-UBC9-ZIC3-WT 
• pENTR3C-UBC9-ZIC3-K248R 
• pENTR3C-UBC9-ZIC3-K359R 
• pENTR3C-UBC9-ZIC4-WT 
• pENTR3C-UBC9-ZIC4-K125R 
• pENTR3C-UBC9-ZIC5-K4R 
• pENTR3C-UBC9-ZIC5-K393R 
• pENTR3C-UBC9-ZIC5-K522R 
 
3.2.4: 
• V5-ZIC1-WT 
• V5-ZIC1-K222R 
• V5-ZIC1-K333R 
• V5-ZIC2-K253R 
• V5-ZIC3-K248R;C365S 
• V5-ZIC4-WT 
• V5-ZIC4-K125R 
• V5-ZIC5-C528S 
• V5-UBC9-ZIC1-WT 
• V5-UBC9-ZIC1-K222R 
• V5-UBC9-ZIC1-K333R 
• V5-UBC9-ZIC2-WT 
• V5-UBC9-ZIC2-K253R 
• V5-UBC9-ZIC3-WT 
• V5-UBC9-ZIC3-K248R 
• V5-UBC9-ZIC3-K359R 
• V5-UBC9-ZIC4-WT 
• V5-UBC9-ZIC4-K125R 
• V5-UBC9-ZIC5-K4R 
• V5-UBC9-ZIC5-K393R 
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• V5-UBC9-ZIC5-K522R 
• V1-ZIC1-WT 
• V1-ZIC1-K222R 
• V1-ZIC2-WT 
• V1-ZIC2-K253R 
• V1-ZIC3-WT 
• V1-ZIC3-K248R 
• V1-ZIC4-WT 
• V1-ZIC4-K125R 
• V2-TCF7L2 
 
3.2.5: 
• pUC57-SUMO1-ΔGG 
• pENTR3C-SUMO1-WT 
• pENTR3C-SUMO1-ΔGG 
 
3.2.5.1: 
• EGFP-SUMO1-WT 
• EGFP-SUMO1-ΔGG 
 
3.2.5.2: 
• EmGFP-SUMO1-WT 
• EmGFP-SUMO1-ΔGG 
 
3.2.6.1: 
• pGL4.20-TCFx6 
• pGL4.20-mutTCFx6 
 
3.2.6.2: 
• pGL4.20-TCFx3 
• pGL4.20-mutTCFx3 
 
3.2.6.3: 
• pGL4.20-TK-TCFx6 
• pGL4.20-TK-mutTCFx6 
• pGL4.20-cfos-TCFx6 
• pGL4.20-cfos-mutTCFx6 
• pGL4.20-TK-TCFx3 
• pGL4.20-TK-mutTCFx3 
• pGL4.20-cfos-TCFx3 
• pGL4.20-cfos-mutTCFx3 
• pGL4.20-β-globin-TCFx3 
• pGL4.20-β-globin-mutTCFx3 
 
3.2.7: 
• pGL4.20-β-globin-Foxd3 
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Appendix 3 Valuation of SUMO1 expression constructs 
Initial experiments provided strong evidence that the UFDS system would be useful for 
observing ZIC SUMOylation. However, the YFP-SUMO1 expression construct used to boost 
cellular SUMO1 levels was not the ideal: the YFP tag has previously been found to cause issues 
with immunofluorescence experiments (Helen Bellchambers, unpublished observation prior to 
PhD) and, more relevant for the experiments presented in this thesis, as the YFP-SUMO1 
construct was acquired for another laboratory the backbone construct was not available. Lack 
of the backbone construct made further cloning difficult, particularly original cloning had 
deleted the restriction enzyme sites between the YFP tag and the SUMO protein. As such the 
control form of SUMO1 (SUMO1-ΔGG), which cannot act in the SUMO conjugation pathway 
and was generated specifically for these experiments, could not be inserted into the YFP 
vector. 
 
To overcome these issues, both the wildtype form of SUMO1 and SUMO1-ΔGG were shifted 
into the EGFP-C1 expression vector to create EGFP-SUMO1-WT and EGFP-SUMO1-ΔGG. 
However, when EGFP-SUMO1-WT was co-transfected into cells with V5-UBC9-ZIC3, the higher 
molecular weight forms representing SUMOylated ZIC3 were no longer present when analysed 
by western blot (Figure S3.1b). In fact the lower molecular weight bands representing 
unmodified ZIC were also greatly diminished in the presence of EGFP-SUMO1-WT. At first it 
was thought this result could be due to the YFP-SUMO and EGFP-SUMO1-WT varying in 
transfection efficiency or producing different amounts of protein. However, neither increasing 
nor decreasing the levels of EGFP-SUMO1-WT produced the desired SUMOylated form of ZIC3 
(Figure S3.1c). As the unmodified form of ZIC3 was consistently diminished with addition of 
EGFP-SUMO1 our next hypothesis was that the EGFP-SUMO1 construct might interfere with 
the transfection. However immunofluorescence experiments confirmed this was not the case 
(Figure S3.2), with EGFP-SUMO1-WT appearing to show higher expression levels than YFP-
SUMO1. As such it was decided to test whether this lack of SUMOylated form was a ZIC specific 
issue or a general problem of the EGFP-SUMO1-WT construct by testing the EGFP-SUMO1-WT 
construct with UBC9-Stat, a fusion protein known to show high levels of protein SUMOylation 
(Jakobs et al., 2007b). Consistent with the ZIC3 result, while co-transfection of YFP-SUMO1 
produced higher molecular weight form of UBC9-Stat, addition of EGFP-SUMO1-WT caused all 
bands to disappear (Figure S3.1d), suggesting the issue is with the EGFP-SUMO1-WT construct. 
Together, these results suggest that for some unknown reason, EGFP-SUMO1-WT does not 
promote cellular SUMOylation. 
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Supplementary Figure S3.1: Different SUMO expression constructs show different abilities to 
influence SUMOylation of ZICs. HEK293T cells were transfected with V5-UBC9-ZIC3 and either 
YFP-SUMO1, EGFP-SUMO1 or EmGFP-SUMO1. The molecular weight of the resulting V5-UBC9-
ZIC3 protein was determined with SDS-PAGE and western blot analysis. a) A higher molecular 
weight form of ZIC3 is present in the presence but not the absence of YFP-SUMO1. b) Addition 
of EGFP-SUMO1 does not produce a higher molecular weight form of V5-UBC9-ZIC3. c) 
Increasing amounts of EGFP does not produce the higher molecular forms of V5-UBC9-ZIC3 
seen with addition of YFP-SUMO1. d) A higher molecular weight form of STAT-UBC9 is present 
in the presence of YFP-SUMO1, but not EGFP-SUMO1. e) Addition of EmGFP-SUMO1-WT but 
not a mutant form that cannot act in the SUMOylation pathway (EmGFP-SUMO1-ΔGG) 
produces a higher molecular weight form of ZIC3. In all cases N = nuclear enriched fragment, C 
= cytoplasmic enriched fragment. If not stated the nuclear enriched fragment is shown. 
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Supplementary Figure S3.2: Immunofluorescence of EGFP-SUMO1-WT. HEK293T cells were 
transfected with V5-UBC9-ZIC and either EmGFP-SUMO1-WT or EmGFP-SUMO1-ΔGG. Cells 
were immunostained for V5 with an Alexa 594 secondary and for GFP with an Alexa 488 
secondary. In both cases, both the V5 and GFP proteins detected proteins. 
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Given the YFP-SUMO1 is functional and identical SUMO1 CDSs were contained in YFP-SUMO1 
and EGFP-SUMO1, the lack of SUMOylation must be cause by either the EGFP vector backbone 
or the Amino Acid link between the GFP tag and the SUMO1 protein. As there was no reason 
that the SUMO1 CDS needed to be expressed by this particular vector, both these potential 
issues were overcome by shifting the SUMO1-WT and SUMO1-ΔGG sequences into a different 
backbone, called Vivid colors™ pcDNA™ 6.2/N-EmGFP-DEST (InvitrogenTM), to create EmGFP-
SUMO1 and EmGFP-SUMO1-ΔGG. When EmGFP-SUMO1-WT was co-transfected into cells with 
V5-UBC9-ZIC3-WT, the higher molecular weight forms representing SUMOylated ZIC3 were 
present (Figure S3.1e, lane 2), indicating the shift of SUMO1-WT into the Vivid colors™ 
pcDNA™ 6.2/N-EmGFP-DEST vector overcame the previous issues. In addition, the co-transfect 
of the control expression plasmid, EmGFP-SUMO1-ΔGG, acted as desired with no higher 
molecular weight forms produced by the presence of this plasmid (Figure S3.1e, lane 3). As 
such, all further experiments requiring addition of exogenous SUMO used the EmGFP-SUMO1 
constructs. 
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Appendix 4 Optimisation of DNA amounts for UBC9-
C93S experiments 
Several of the experiments of Chapter 6 required co-transfection of UBC9-C93S with the other 
reporter components. Before these experiments were completed, the co-transfection was 
optimised with V5-DEST to confirm the addition of extra construct did not adversely affect the 
transfection and thus obscure the results. The ZIC based Wnt inhibition was chosen for the 
analysis as due to the need for β-CATENIN co-transfection, it required a more complicated 
combination of plasmids than either the Z3M2 assay or the Foxd3 based assay.  
 
Due to the timing of these experiments, Wnt/β-catenin signalling was assessed with the cfos-
TOPflash reporter plasmid in HEK293T cells. As ZIC5 failed to inhibit Wnt signalling activated by 
ΔN89-β-CATENIN (Section 4.2.4), the reporter was activated by V5-β-CATENIN. First, the 
activity of wildtype and SUMOylation incompetent forms of ZIC5 were compared to determine 
what, if any, difference was present in the absence of an additional construct in the co-
transfection (Figure S4.1). While both ZIC5-WT and ZIC5-K393R were able to inhibit Wnt/β-
catenin signalling, ZIC5-K393R showed a stronger inhibition than wildtype ZIC5. As the 
mutation prevents SUMOylation of ZIC5, this suggests SUMOylation reduces the ability of ZIC5 
to inhibit Wnt/β-catenin signalling. 
 
Once it was determined there was a detectable difference in the wildtype and SUMOylation 
incompetent alleles, the effect of an addition construct in the co-transfection was assessed. In 
order to add an additional construct into the transfection either the previously used amounts 
of the constructs must be lowered in order to keep the total DNA levels the same or the total 
DNA amount must be increased. As it was unknown how either of these changes would alter 
the measurable difference between wildtype and SUMOylation incompetent ZIC, both these 
options were tested. Consistent with the previous section, when the experiment was repeated 
with the previous amounts of DNA (and therefore without the additional construct) the ZIC5-
K393R SUMOylation incompetent allele showed a measurable increase in Wnt/β-catenin 
signalling inhibition compared to wildtype ZIC5 (Figure S4.2a). However, this difference 
between wildtype and SUMOylation incompetent ZIC5 disappeared when the DNA amounts of 
reporter and expression constructs were dropped to allow addition of the empty construct 
DEST without altering the total levels of DNA (Figure S4.2b). On the other hand, if empty 
construct DEST was added without changing the amounts of reporter and expression 
constructs, thus increasing the total amounts of DNA, the difference between wildtype and 
SUMOylation incompetent ZIC was still evident (Figure S4.1c).   
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Supplementary Figure S4.1: The K393R point mutation increases inhibition of Wnt signalling 
by ZIC5. HEK293T were transfected with the cfos-TOPflash Wnt/β-catenin reporter construct 
along with either only V5-DEST or V5-β-CATENIN and either V5-ZIC5-WT, V5-ZIC5-K393R or the 
empty construct V5-DEST. Top panel shows single representative experiment. Error bars = S.D. 
of three internal repeats. Western blots corresponding to particular transfection are shown 
below graphs. Bottom panel shows pooled data relative to DEST. V5-ZIC5-K393R shows 
significantly higher levels of repression than V5-ZIC5-WT. Error bars = S.E.M., N = 3 external 
repeats; *p˂0.05, two-way ANOVA with Fischer’s unprotected post ad hoc test. V5-β-CAT = V5-
β-CATENIN.  
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Supplementary Figure S4.2: Optimising transfection conditions of the Wnt assay. HEK293T 
were transfected with the Wnt/β-catenin reporter construct along with either only V5-DEST or 
V5-β-CATENIN and either V5-ZIC5-WT, V5-ZIC5-K393R or the empty construct V5-DEST. 
Amounts of DNA included in the transfection were varied as indicated. Error bars = S.D., N = 3 
internal repeats. V5-β-CAT = V5-β-CATENIN. 
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As such, it was concluded that if an additional construct needed to be added, reducing the 
DNA amounts to keep the total DNA constant would cause adverse effects to the assays, and 
instead it was necessary to increase the total amount of DNA during the transfection. 
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Appendix 5 Optimisation of BiFC 
Interaction of TCF7L2 with both ZIC2 and ZIC5 was chosen for the initial test of the BiFC assay, 
as in addition to ZIC2 already being shown to interact with TCF7L2, these ZICs also represented 
the members of the family that showed the strongest and weakest Wnt/β-catenin signalling 
inhibition in previous assays of Chapter 3. As the BiFC assay had not previously been 
performed in the Arkell Laboratory, this initial test was used as an opportunity to assess how 
slight changes in the protocol would alter the perceived interaction. For example, the 
luciferase assays described so far in this thesis have involved measuring the luciferase level of 
cells in solid white 96-well plates. These plates are designed to reflect all light and therefore 
produce the maximum luminescence signal. BiFC assays on the other hand are typically 
performed in black-sided plates which absorb light therefore reduce background from auto-
fluorescence and cross-talk from wells. The black plates also have clear bottoms, which allows 
the fluorescence levels of adherent cells to be read through the bottom of the plate and thus 
reduces interference from the overlying liquid. While these black-sided plates are usually 
considered better for BiFC assays than solid white plates, it is unclear how much of a 
difference the choice of plate actually makes. As such, both potential plates were assessed in 
side-by-side fluorescence readings. In addition, it was unknown if auto-fluorescence from the 
DMEM media would influence the background fluorescence levels for either of these plates. 
Therefore, in addition to comparing fluorescence levels from solid white plates and clear 
bottomed black plates, in each case the fluorescence levels of cells was also measured when 
either the DMEM was left on the cells or in which the DMEM was replaced with PBS 
immediately before reading.  
 
To test these different conditions, HEK293T cells were co-transfected with V2-TCF7L2 and 
either V1-ZIC2, V1-ZIC5 or the empty construct V1-ORF. In each case, 24 hours after 
transfection, the cells were replated into six well of each of the two types of plates. 48 hours 
after transfection, the DMEM media was removed from half of these wells and replaced with 
PBS, after which the fluorescence levels of all wells was assessed. In each of these different 
conditions, the presence of either both V1-ZIC2 and V2-TCF7L2 or both V1-ZIC5 and V2-TCF7L2 
produced an increase in fluorescence compared to when V2-TCF7L2 was present with the 
empty construct (Figure S5.1a, b), which suggests that the V1 and V2 fragments are reforming 
to produce the fluorescent Venus proteins and thus that the BiFC assay is capable of detecting 
interaction of TCF7L2 with both ZIC2 and ZIC5. 
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Although the different conditions all showed evidence of this interaction, the fold activation 
levels varied. For example, the replacement of DMEM with PBS produced an increase in the 
raw values for both plates, however this difference was much more pronounced for the solid 
white plates than the black sided plates. For the solid white plates the difference was greatly 
but not entirely reduced when the fold activations were calculated As such the DMEM was 
replaced with PBS for further experiments. In each case the black-sided plates produced an 
approximately 2-fold higher activation than the white plates. However, in both cases the 
difference between ZIC and background was reasonably large. Because the interaction was 
visible with both plates and the white plates were readily available they were used for further 
experiments. 
 
S5.1 ZICs alter levels of transfection controls 
When expression constructs are introduced into cells for BiFC assays, a transfection control is 
typically incorporated into the transfection. For these assays the transfection control is a 
plasmid which expresses a protein such as Red Fluorescent Protein (RFP) which emits light at a 
different wavelength than the Venus protein and thus the levels of the two proteins can be 
measured without interference. Although transfection controls for the luciferase assays have 
been avoided so far, due to previous issues with ZICs interacting with such constructs, a RFP 
expression was trialled for the BiFC assays as a transfection control. 
 
Although not mentioned, a RFP based transfection control was trialled in the previous section 
by incorporating a small amount of the plasmid into each transfection. When the Venus 
fluorescence levels were adjusted based on the transfection controls it could be argued that 
the error levels were slightly reduced, as the calculated S.D. of the three internal repeats was 
lowered (Figure S5.1c). However, examination of the RFP levels alone shows that the 
fluorescence levels of RFP are at least halved in the presence of either ZIC2 or ZIC5 (Figure 
S5.1d), which is a much greater difference than would be expected from variation in 
transfection alone. Such a repression was also seen when the assay was repeated by other 
Arkell Laboratory members (Koula Diamand, unpublished observation). The repression of RFP 
expression is likely due to the ZICs interacting with promoter sequences in the RFP plasmid. 
Unfortunately, such a repression is problematic for a transfection control of the BiFC assay as it 
could potential cause the BiFC assay to show a difference in interaction ability, when in 
actuality the difference is due to a change in the ZICs repressing the RFP construct. As such, 
the transfection control was not used in any further assays. 
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Supplementary Figure S5.1: Optimisation of the BiFC assay. HEK293T were transfected with 
V2-TCF7L2 along with either wildtype V1-ZIC2, V1-ZIC5 or the empty construct V1-ORF. The 
resulting levels of fluorescence were measure when the cells were replated into either a white 
sided or a black sided plate and in the absence or presence of DMEM. a) The raw fluorescence 
values. b) The fluorescence values relative to the V1-ORF background. c) The levels after 
adjustment to the transfection control pCherry. d) The raw levels of the transfection control 
pCherry. In all cases the levels of pCherry appear to be repressed by the addition of V1-ZIC. In 
each case the error bars = S.D., N = 3 internal repeats. 
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